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Whose side is your favourite
Rinding an effective treatm ent for intra­
abdom inal infections has becom e much 
easier since the advent o f cephalosporins. 
Their broad spectrum of activity has greatly 
improved the prognosis for many patients 
w ith serious infections.
The trouble is, the cost of cephalosporins has 
been making many hospital pharmacists 
(and cost control staff) see red. It is also now 
increasingly more difficult for many hospital 
formulary committees to be ab le  to strike an 
agreeable ba lance betw een effectiveness 
and cost control.
New Cefizox™ may be the answer everyone' 
been looking for. Not only does it give much 
wider pa thogen coverage* (including B. 
fragilis) than cefoxitin,1,2 but its superior 
dosage schedule (example: ql2h vs q6h) 
m ay make Cefizox™ much less expensive?'4 
It even has packaging designed for easy 
identification.
So if the cost o f effective cephalosporin 
therapy is just too much for your hospital to 
handle, consider new Cefizox™ Its 
com bination o f efficacy and low cost may 
just be w hat everybody ordered.
sCefizox™
ceftizoxime sodium
A  cephalosporin that plays favourites with everybody.
PAAB
CCPP SKSF SMITH KLINE SfRENCH CANADA LTD. 1989
W *
■ ■under licence of
Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
CX:M:189CA
’ Refers to in vitro coverage does not necessarily imply clinical coverage.
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QUILL ON SCALPEL This section provides a medium through which Canadian surgeons can declare themselves, 
briefly and informally, on the day-to-day affairs of surgery.
T reatment of Advanced Cancer of 
Prostate
W.L. Orovan, MD, FRCSC, FACS
Associate Professor o f Surgery (Urology), McMaster University. Chief, Department o f  Surgery, 
St. Joseph's Hospital, Hamilton, Ont.
A fter the pioneering work of Charles Huggins and Clarence 
Hodges in 1941,1 who demonstrat­
ed the efficacy of androgen depriva­
tion in palliative treatment of ad­
vanced prostatic cancer, there were 
few new developments in this field. 
Large studies carried out in the 
United States by the Veterans Ad­
ministration Cooperative Urological 
Research Group (VACURG)2 in the 
1970s did confirm improvement in 
symptom-free intervals, but no 
study has demonstrated conclusive­
ly a survival benefit for patients 
treated with androgen manipula­
tion.3 The two major modalities of
hormone manipulation used during 
this time were bilateral orchiecto­
my and the administration of exoge­
nous estrogens in doses ranging 
from 1 to 5 mg/d. The latter, 
especially at higher dosage, was 
associated with an increased risk of 
cardiovascular complications and 
death. Benefits of treatment were 
not universal; only about 75% of 
patients responded and the median 
duration of response was about 3 
years.4
In the late 1970s and early 
1980s, partly in response to the 
cardiovascular risk factors identified 
with exogenous estrogen and the
reluctance of some patients to un­
dergo surgical orchiectomy, alterna­
tive means of hormone manipula­
tion became available. These agents 
fit broadly into three categories: 
luteinizing hormone-releasing hor­
mone (LHRH) analogues, antiandro­
gens and the synthetic imidazoles.
The LHRH agonists act primarily 
on the central feedback control of 
luteinizing hormone release. An ini­
tial surge of luteinizing hormone 
can precipitate a transient increase 
of the patient’s symptoms (flare 
reaction), but subsequently a reduc­
tion in circulating androgens to 
castrate level occurs. The LHRH
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OROVAN
agents are administered by subcuta­
neous injection, either daily or, 
more recently, monthly in timed- 
release form. Side-effects have been 
less severe than those noted with 
exogenous estrogens and an equiva­
lent treatment benefit has been doc­
umented.5
The antiandrogens, cyproterone 
acetate (Adrocur) and flutamide 
(Euflex), can be administered orally. 
They have proven equivalent in effi­
cacy to exogenous estrogens or 
surgical castration and in addition 
provide benefit by reducing the inci­
dence of treatment complications.6
The duration of response to hor­
mone manipulation is limited and 
virtually all patients will eventually 
relapse and the disease will prog­
ress. Treatment options available 
for this apparently androgen- 
independent or “hormonally es­
caped” treatment group are limited.
Cytotoxic chemotherapy using 
cyclophosphamide, 5-fluorouracil, 
Adriamycin and others, either in­
dividually or in combination regi­
mens, have given mixed results. 
Administration of these toxic 
agents in generally aged and debili­
tated patients, many of whom mani­
fest other cardiovascular or pulmo­
nary diseases, has severely limited 
their effectiveness.
In this issue of the Journal 
(pages 349 to 352), Eichenberger 
and Trachtenberg present their 
early findings with the use of syn­
thetic imidazoles to treat patients 
with androgen-independent prostat­
ic cancer. They note that the imid­
azole ketoconazole, primarily an an­
tifungal agent, when used frequent­
ly at a high dose has been demon­
strated to inhibit the production of 
both adrenal and testicular andro­
gens. Studies in patients with previ­
ously untreated advanced prostatic 
cancer have demonstrated that this 
compound can produce castrate lev­
els of circulating androgens;7 thus, 
it represents an alternative in the
first-line treatment of advanced 
prostatic cancer. Moreover, the au­
thors suggest that these com­
pounds may also have a role in the 
treatment of androgen-independent 
or “hormonally escaped” patients. 
The data from this uncontrolled 
study suggest subjective improve­
ment in symptoms as reflected by 
the patients’ reduced need for anal­
gesics and a trend toward halting 
the progression of disease in some 
patients. The latter finding must be 
treated with some skepticism in 
view of the variable rate at which 
the disease progresses.
Of interest is the authors’ asser­
tion that no significant difference in 
duration of response could be dem­
onstrated between the patients who 
had been treated with conventional 
forms of androgen ablation and the 
14 patients who failed total andro­
gen ablation. The concept of total 
androgen ablation was introduced 
by Labrie and associates,8 who con­
tended that simple ablation of tes­
ticular androgens is insufficient 
for adequate hormonal treatment 
and that total androgen deprivation, 
including adrenal sources, must be 
effected before an adequate re­
sponse of hormone-dependent pros­
tatic cancer can be achieved. This 
controversial theory is at present 
being evaluated by a randomized 
prospective trial in the United 
States. The finding of Eichenberger 
and Trachtenberg that ketocona­
zole seems to affect both groups 
equally suggests that ketoconazole 
may, in fact, have a non-androgen- 
based effect on prostatic cancer. 
The authors quote one in-vitro 
study9 to support this contention 
and speculate about the site of 
action of direct cytotoxic effects of 
ketoconazole on androgen-independ­
ent human prostatic cancer cells.
With the rapid evolution of alter­
native hormonal treatment options 
for advanced prostatic cancer, the 
most difficult clinical problem re­
mains that of androgen-independent 
late-stage disease. The usefulness of 
ketoconazole in this context re­
mains to be defined but the early 
results quoted by Eichenberger and 
Trachtenberg give some reason for 
optimism.
If the authors’ contentions are 
borne out through further in-vitro 
and prospective randomized con­
trolled clinical trials, this will repre­
sent an important advance in the 
treatment of this difficult and com­
mon malignant condition.
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QUILL ON SCALPEL
Monoclonal Antibodies — Gazing Into 
the Submicroscopic
Nis Schmidt, MD, MSc, FRCSC
Member. Editorial Board. Canadian Journal o f  Surgery. Clinical Professor, Department o f  
Surgery. University o f  British Columbia, St. Pau l’s Hospital, Vancouver, BC
Humans have always been dis­satisfied with their limitations. 
Climbing onto horseback extended 
their ability to travel; harnessing 
steam increased muscle power out 
of all proportion; computerization 
expanded the capacity to store and 
sort data beyond expectation. Rais­
ing antibodies to protein antigenic 
material is going beyond the micro­
scope when appropriate labelling 
and manipulation of these complex 
biologic substances are carried out. 
Monoclonal antibodies, developed in 
1975 by Kohler and Milstein,1 
opened a new era in immunobiology 
which continues to expand in expo­
nential shock waves, touching all 
aspects of medicine and surgery in 
areas of diagnosis, prophylaxis, 
treatment and research.
The July issue of the Canadian 
Journal o f  Surgery (pages 279 to 
282) contained an article entitled 
“Immunohistologic diagnosis of 
multiple carcinomas. The role of 
monoclonal antibodies against car- 
cinoembryonic antigen” by Guiot 
and associates, in which they pres­
ent a whole new world of diagnostic 
possibilities by using anti-carcino- 
embryonic antigen (CEA) monoclon­
al antibodies to differentiate and 
clarify the relationship between 
multiple adenocarcinomas in indi­
vidual patients. Five cases were pre­
sented in which the monoclonal 
antibodies helped to differentiate 
the multiple carcinomas and to ar­
rive at an appropriate plan of man­
agement. In each case, the diagnos­
tic problem was ascertaining the 
nature of a second tumour in pa­
tients with a history of colonic 
cancer. The question concerned the 
treatment of a second tumour as a 
separate entity or as a metastasis 
from the colonic cancer.
The application of this new bio­
logic science to diagnosis is far 
from simple. Initially, the antibodies 
developed were mouse and rodent 
xenoantibodies, and they were asso­
ciated with the expectant problems 
of foreign proteins. For diagnostic 
and therapeutic application, human 
antibodies are obviously more desir­
able. The antibody used by Guiot 
and colleagues was a mouse anti- 
CEA antibody (D14), which has 
been shown to be quite specific and 
sensitive to CEA, hence the success 
in their investigation. Human mo­
noclonal antibodies for routine use 
in diagnosis and investigation are 
yet to come.
Monoclonal antibodies were the 
result, initially, of sensitizing labo­
ratory animals with viable lymphoid 
and myeloma cell lines, resulting in 
antibodies with detectable sensitivi­
ty but poor specificity. The evolu­
tion of clones of cells has allowed 
greater sensitivity and specificity of 
the antibodies, and research is now 
at the point where the established 
names and catalogued antibodies 
are available for diagnostic, thera­
peutic and research activities the 
world over. Refinements of the 
process now identify not only cell 
lines but cell surface receptor anti­
gens, even protein molecules and 
genetically manipulated material, all 
of which have become feasible as 
specific antigenic material to raise 
antibodies of high sensitivity and 
specificity. In addition to raising 
and purifying the antibodies, label­
ling procedures add immunofluores- 
cent, immunoenzymatic and im- 
munonucleotide tags, greatly add­
ing to the scope and use in practical 
and research procedures. For exam­
ple, immunofluorescence has facili­
tated the development of practical 
cell sorters and cell counters for 
laboratory use in hematology.
Besides the use of monoclonal 
antibodies for imaging and investi­
gational purposes, monoclonal anti­
body toxin conjugates open up pos­
sibilities of aiming ‘‘magic bullets” . 
Antibody toxin conjugates will find 
extensive application in im­
munosuppression. Antibody phar­
maceutical conjugates conceivably 
will find use in specific antigen 
selectivity for tumour therapy, anti­
microbial therapy and the suppres­
sion and treatment of diseases for 
which cellular secretion can be sup­
pressed or ablated.
Much of this is still conjectural, 
since the cloning of cell lines, isola­
tion of antigens, purification and 
accumulation of the antibody, re-
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Since ciprofloxacin is eliminated primarily by the kidney, CIPRO* should be used with 
caution and at a reduced dosage in patients with impaired renal function (see DOSAGE AND
ADVERSE REACTIONS
CIPRO* (Ciprofloxacin Hydrochloride Monohydrate) is generally weii tolerated. During worldwide 
clinical investigation, 8,861 courses of ciprofloxacin treatment were evaluated for drag 
safety. (Included in th is evaluation were data from 283 patients who received ciprofloxacin 
oftly intravenously and 169 patients who received sequential i«ravenous7orai ciprofloxacin 
therapy.)
Adverse events, whether drag-related or not. occurred in 10.2% of patients. These adverse 
events occurred in the following frequencies: Gastrointestinal System (5.0%), Central 
Nervous System (1(6%), Skin/Hypersensitivity (1 4%). and Adverse Laboratory Changes 
(5.6%)
The most frequently repotted events, drug-related or not were nausea t t . 6%) and diarrhea 
( 1.2% ) .
Additional events that occurred in less than 1% ot ciprofloxacin courses are listed below
Gastrointestinal: vomiting, dyspepsia abdominal pain anorexia
Central Nervous System: dizziness, light-headedness, headache, nervousness anxiety.
agitation, restlessness, tremor, lethargy, drowsiness, somnolence
Skin/Hypersensitivity: rash, pruritus, local edema, urticaria, increased perspiration,
photosensitivity
Most of the adverse events were described as only mild or moderate in severity.
There have been 9 reports of arthropathy associated with CIPRO' Three of these reports 
involved children. Arthralgia was usually the first symptom which led to rapid assessment 
and withdrawal of the drug. No irreversible arthropathies have been observed 
Adverse Laboratory Changes
Changes in laboratory parameters listed asadverse events without regard todrug relationship (5.6%): 
Hepatic: Elevations of: SGPT (1.3%), SGOT (1 4%),
Alkaline Phosphatase (0.4%), y-giutamyl transpeptidase (0.3%)
LDH (0.3%), Serum bilirubin (511%)
Hematologic: Eosinophilia (0.6%), leukopenia (0.2%)
Renal: Elevations of: Serum creatinine (0.3%), BUN (0.3%)
Other changes occurring in less than 0.1% of courses were: elevated uric acid elevated 
cholesterol, increase in blood platelets, monocytes, and leukocytes 
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® (Ciprofloxacin Hydrochloride Mono­
hydrate). In the event of acute overdosage, the stomach should be emptied by inducing 
vomiting or by gastric lavage. The patient should be carefully observed and qiven sup­
portive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the 
severity and nature of the infection, the susceptibility of the causative organism and the 
status of renal function.
CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) may be taken before ot after meals. 
Absorption is faster on an empty stomach. Patients should be advised to drink fluids liberally 
and not take antacids containing magnesium or aluminum.
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finement of sensitivity and specifici­
ty, understanding of the interaction 
of in-vitro and in-vivo responses still 
depend on untold hours of laborato­
ry time and thought, not to mention 
all the dollars required to finance 
the research.
Practical application is, however, 
well advanced. Testing for carcino- 
embryonic antigen in gastrointesti­
nal carcinoma and breast cancer 
estrogen receptor binding is com­
monplace. Endocrine function 
studies, including parathormone 
and adrenocorticotropic hormone 
levels, are in daily use. “OKT3” 
antibody, which appears to exact 
direct immunosuppressive activity 
and inactivate lymphoid T cells 
from circulation, is currently being 
used in the treatment of acute rejec­
tion in histocompatible renal grafts
and for in-vitro prevention of graft 
versus host disease in recipients of 
bone marrow transplants. Mono­
clonal antibody BB5-M2 causes 
stimulation of parathyroid hormone 
release in human parathyroid cell 
cultures, indicating that a possible 
specific cell-surface macromolecule 
may be operative in the regulation 
of calcium and parathormone, and 
this promises control in calcium 
disorders. Enzyme immunoassay 
has allowed accurate pregnancy 
testing in a simple, across-the-coun- 
ter kit.
The scope of the subject of mo­
noclonal antibodies is overwhelming 
and beyond a simple editorial re­
view. Suffice it to say that this 
subject, which only 15 years ago 
occupied the thought of scientists 
observing mice in cloistered labora­
tories, has now evolved sufficiently 
to influence the everyday clinical 
practice of surgeons, as described in 
the article by Guiot and colleagues 
in their stimulating and imaginative 
report. It is obvious that if we keep 
our eyes open, we will be in store 
for more surprises from the submi- 
croscopic in the area of monoclonal 
antibodies.
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Adult
The recommended dosages of CIPRO *  are:
Location of 
Infection Type/Severity
Unit
Dose
Fre­
quency
Daily
Dose
Urinary Tract Mild/Moderate
Severe/Complicated
250 mg 
500 mg
q 12h 
q 12h
500 mg 
1000 mg
Lower Respiratory 
Tract
Bone & Joint 
Skin S Soft Tissue
Mild/Moderate
Severe/Complicated*
500 mg 
750 mg
q 12h 
q 12h
1000 mg 
1500 mg
Infectious Diarrhea Mild/Moderate/Severe 500 mg q 12h 1000 mg
* e.g. hospital-acquired pneumonia, osteomyelitis.
Depending on the severity of the infections, as well as the clinical and bacteriological 
responses, the average treatment period should be approximately 7 to 14 days. Generally, 
treatment should last 3 days beyond the disappearance of clinical symptoms or until 
cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 
to 8 weeks and up to 3 months. With acute cystitis, a five-day treatment may be sufficient. 
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabo­
lized and partially cleared through fhe biliary system of the liver and through the intestine 
(see Product Monograph: HUMAN PHARMACOLOGY). This alternate pathway of drug 
elimination appears To compensate for the reduced renal excretion of patients with renal 
impairment. Nonetheless, some modification of dosage is recommended, particularly for 
patients with severe renal dysfunction. The following fable provides dosage guidelines for 
use in patients with renal impairment. However, monitoring of serum drug levels provides 
the most reliable basis for dosage adjustment. Only a small amount of ciprofloxacin (< 10%) 
is removed from the body after hemodialysis or peritoneal dialysis.
Creatinine Clearance 
mL/min (m L/s) Dose
> 3 0 (0 .5 ) No dosage adjustment
< 3 0 (0 .5 ) Use recommended dose
and patients on hemodialysis once daily or half
or peritoneal dialysis the dose twice daily
When only the serum creatinine concentration is available, the following formula (based on 
sex, weight and age of the patient) may be used to convert this value into creatinine 
clearance. The serum creatinine should represent a steady state of renal function:
Males: Weight (kg) x (140 -  age)
72 x serum creatinine(mg/1 OOmL)
Females: 0.85 x the above value
To convert to international units, multiply result by 0.01667
CHILDREN
The safety and efficacy of CIPRO® in children have not been established. CIPRO® should not 
be used in prepubertal patients (see WARNINGS).
DOSAGE FORMS
Availability
CIPRO’ 250-each tablet contains ciprofloxacin hydrochloride monohydrate 
equivalent to 250 mg ciprofloxacin,
CIPRO* 500-each tablet contains ciprofloxacin hydrochloride monohydrate 
equivalent to 500 mg ciprofloxacin.
CIPRO® 750-each tablet contains ciprofloxacin hydrochloride monohydrate 
equivalent to 750 mg ciprofloxacin.
STORE BELOW 30° C (86° F).
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Recent federal legislation on drug patents has given phar­
maceutical manufacturers in Cana­
da prolonged terms of patent pro­
tection. In return for this protec­
tion, these companies have commit­
ted a substantial portion of their 
income into drug research. As a 
result, a great deal of “research” 
money has become available to in­
vestigators willing to be involved 
with clinical trials, and drug testing 
and reporting.
This research effort has become a 
major source of funding in many 
areas, providing space, personnel 
and equipment. In effect, the drug 
being evaluated supports the ongo­
ing function of the laboratory and 
the investigation. In some in­
stances, the result of the study 
becomes the property of the phar­
maceutical company and may not be 
presented without the company’s 
approval. This type of financial sup­
port is also being used to fund 
conferences and seminars, the sub­
jects of which are related to the 
pharmaceutical products. Often the 
entire seminar, including invited 
speakers and expenses of the orga­
nization or university division hold­
ing the seminar, is financed by the 
drug company involved.
The ethical problems involved in 
this type of “investigation” and 
reporting are obvious, and just a 
generation ago would not be con­
doned in our universities. There is, 
however, a substantial shortfall of 
available research funding from 
granting agencies, particularly for 
part-time and new researchers and 
agencies. More and more investiga­
tors are turning to industry for 
support and, indeed, universities at 
higher levels are fostering joint in­
dustry-university projects. Our med­
ical professional organizations at 
local, national and international lev­
els depend on industry’s financial 
support through commercial exhib­
its and direct grants to preserve the 
calibre of meetings and maintain a 
reasonable registration fee. These 
companies are providing essential 
and otherwise unavailable support. 
In this respect they need to be 
encouraged.
What is lacking are guidelines 
regarding this type of investigation 
and financial support, particularly 
concerning ethical reporting of this 
work to physicians and the public. 
The current, apparently compro­
mised position of the investigator 
and indeed the profession needs 
immediate and close scrutiny. The 
financial need, no matter how wor­
thy, must not compromise the prin­
ciples of academic investigation and 
reporting in our institutions. If we, 
the profession, do not address this 
subject, other regulating agencies 
representing the public will. ■
SESAP VI Question
Item 245
The statistical five-year survival rates for cancer may be artificially improved by all of the following EXCEPT
(A) detection of disease with a screening test before symptoms develop
(B) a change in the staging of patients due to earlier detection of metastases
(C) treatment prolonging the disease-free interval
(D) loss of patients to follow-up
(E) an improved method of treatment of disease
For the incomplete statement above, select the one completion that is best of the five given.
For the critique of Item 245 see page 339.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6. 
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of 
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Rupture of the Diaphragm
To the editors. I have just finished 
reading the article “Spontaneous 
rupture of the diaphragm in labour: 
a case report” (Can J Surg 1989; 
32: 212-213). I read it with interest 
because I am a general surgeon 
doing obstetrics and gynecology al­
most exclusively.
Looking at the sequence of 
events, I wonder if the authors 
considered that the diaphragm 
might have been ruptured by the 
efforts at cardiopulmonary resusci­
tation made when the patient suf­
fered a cardiac arrest on the way to 
the radiology department.
The possibility of a pulmonary 
embolus or some other catastrophe 
resulting in cardiac arrest would be 
more likely than a ruptured dia­
phragm occurring as a result of 
labour. Since the patient did not die 
for 3 weeks, an autopsy to deter­
mine possible pulmonary embolism 
or other causes of her initial pain 
may not have been helpful.
I would be interested in the au­
thors’ comments.
G.E. Rosenquist, MD, FRCSC
St. Lawrence Medical Clinic,
Morrisburg, Ont.
KOC1X0
To the editors. Dr. Rosenquist’s 
comments are well taken and obvi­
ously it is impossible to exclude 
completely an alternative explana­
tion for the patient’s clinical course.
However, several facts argue 
against a pulmonary embolus or 
other, presumably cardiac, cause. 
The patient’s initial complaints were 
epigastric and left shoulder pain, 
and vomiting. Vomiting and epigas­
tric pain are unusual with pulmo­
nary embolism, yet expected with a 
ruptured diaphragm with stomach 
herniated into the chest. The pa­
tient then gradually deteriorated 
over the next 21 hours before cardi­
ac arrest, a finding compatible with 
cardiorespiratory embarrassment 
from abdominal contents gradually 
herniating into the chest but un­
usual for pulmonary embolism 
where one would expect either reso­
lution or complete cardiovascular 
collapse.
The patient was extremely unsta­
ble until the herniated viscera were 
reduced and the diaphragm was 
repaired, after which she had no 
further problems. This implies that 
it was the presence of the herniated 
viscera that was the underlying 
problem.
Finally, the patient was bedridden 
postoperatively for the 3 weeks 
until life support was terminated 
due to her encephalopathy. During 
this time no further difficulties with 
cardiac rhythm, cardiac output or 
oxygenation were encountered. If 
an underlying venous thrombosis 
was present, we would have expect­
ed further problems.
David B. Ross, MD
405 Poplar Dr.,
Dartmouth, NS 
B2W 4K 8
Doctor or Mister?
To the editors. 1 am indebted to 
Doctors (or is it “Misters”?) Cairns, 
de Gara, Rees-Davies, Fraser and 
Thomas for their interest in my 
article on the correct appellation of 
British surgeons, and why it differs 
from the virtually universal designa­
tion of Doctor.
As I believe I tried to indicate, the 
title Mister has a great deal to do 
with early English history when 
surgery and barbery appear to have 
developed synchronously, often at 
loggerheads with each other as to 
their proper domain.
It was King Henry VIII who 
finally separated the two divisions 
of the cutting process, honouring 
each with the epithet “Master” . In 
time, as the Oxford English and 
Skeat’s dictionaries show, “Master” 
was corrupted into “Mister” .
I doubt that there will ever be a 
change. English surgeons will con­
tinue to shudder to the end of 
foreseeable time at the mere 
thought of giving up the venerable 
title. American surgeons will adhere 
to their incorrect designation, by 
English standards, according to 
some of your correspondents.
Both, however, have much to be 
proud of. English “Misters” pro­
duced a Lister and American “Doc­
tors” a Halsted.
P. Eibel, MD, FRCSC
Ste. 370,
5845 Cote des Neiges,
Montreal, PQ 
H3S 1Z4
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CANADIAN SOCIETY OF CARDIOVASCULAR AND 
THORACIC SURGEONS
D oes the Surgical Trauma of 
“ Exploratory Thoracotomy” Affect 
Survival of Patients With Bronchogenic 
Carcinoma?
A. Paul, MD; D. Marelli, MD; J.A.S. Wilson, MD, FRCS(Edin), FRCSC;
R.C-J. Chiu, MD, PhD; D.S. Mulder, MD, MSc, FACS, FRCSC
A retrospective review was carried out to assess the possible adverse 
immunosuppressive effect of exploratory thoracotomy on the survival of patients 
with non-small cell carcinoma of the lung with N2 nodal metastases.
Between 1960 and 1982, 48 patients with non-small cell bronchogenic carcinoma 
underwent exploratory thoracotomy; lung resection was not done because 
mediastinal lymph nodes were involved. The survival of these patients was compared 
with that of 64 patients in whom N2 disease was established by mediastinoscopy 
alone and who did not undergo thoracotomy.
There were no significant differences with respect to age, sex, tumour type and 
adjunctive radiotherapy. There were slightly more T4 tumours in the thoracotomy 
group (50% versus 30%). The hospital stay was longer in the thoracotomy group 
(2.3 ±  1.1 versus 1.5 ±  0.9 months [mean ± SD]). However, follow-up studies 
showed that, although these patients had a more traumatic procedure, the actuarial 
survival curves for the two groups were virtually identical, and the 12-month 
survival rates were less than 20% for both groups. The median survival was 6.0 
months for the thoracotomy group and 7.0 months for the mediastinoscopy group. 
These findings failed to demonstrate an adverse immunosuppressive effect of 
thoracotomy on lung cancer patients.
Cette etude retrospective a ete faite a evaluer la reaction immunosuppressive 
possible de la thoracotomie exploratrice sur la survie des patients souffrant de 
cancers pulmonaires autres que le cancer a petites cellules, avec metastases 
ganglionnaires au stade N2.
Entre 1960 et 1982, 48 patients souffrant de cancers bronchopulmonaires autres 
que le cancer a petites cellules, ont subi une thoracotomie exploratrice; du a 
l’atteinte des ganglions lymphatiques mediastinaux, il n’y eut pas de resection 
pulmonaire. La survie de ces malades a ete comparee a celle de 64 patients dont le 
stade evolutif N2 fut etabli par mediastinoscopie seule, sans thoracotomie.
II n’y avait aucune difference pour ce qui etait de l’age, du sexe, du type de 
tumeur ou de la radiotherapie adjuvante. II y avait un peu plus de tumeurs au stade 
T4 dans le groupe soumis a la thoracotomie (50% par rapport a 30%). L’hospitalisa- 
tion a ete plus longue dans le groupe de thoracotomie (2.3 ± 1 .1  mois par rapport a 
1.5 ±  0.9 mois [moyenne ±  ecart type]). Toutefois, la surveillance des suites 
therapeutiques a revele que, meme si ce groupe avait subi une intervention plus 
traumatique, les courbes de survie actuarielles etaient virtuellement identiques; la 
survie a 12 mois etait inferieure a 20% pour les deux groupes. La survie mediane fut 
de 6.0 mois pour le groupe de thoracotomie et de 7.0 mois pour le groupe de 
mediastinoscopie. Ces resultats n'ont pas fait la preuve que la thoracotomie produit 
un effet immunosuppressive chez les patients souffrant de cancers pulmonaires.
I t is widely believed that major surgical procedures decrease 
host resistance to cancer.1-5 Several 
experimental reports have shown 
that lymphocyte function is de­
pressed after surgery and accelerat­
ed tumour growth has been demon­
strated in such models.1-5 Survival 
has been shorter for two-stage re­
section of obstructing colonic can­
cer than for primary resection. En­
hanced tumour growth secondary 
to immunosuppression caused by 
surgery itself has been proposed as 
an explanation for this difference.6 
To our knowledge there are no data 
concerning the influence of surgical 
trauma on the clinical outcome in 
lung cancer patients.
To test the hypothesis that major 
surgical trauma may adversely af­
fect the survival of patients with 
unresectable lung cancer, we took
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THORACOTOMY AND BRONCHOGENIC CARCINOMA
advantage of the fact that, in the 
past, N2 nodal involvement was 
established only after exploratory 
thoracotomy (a major surgical inter­
vention) and that, recently, cervical 
mediastinoscopy has replaced thora­
cotomy for this purpose. Currently, 
because of the high sensitivity and 
specificity of mediastinoscopy in de­
tecting N2 disease,7 exploratory 
thoracotomy for lung cancer is car­
ried out only when preoperative 
staging fails to detect unresectable 
stage III disease. It was reasoned 
that if major surgical trauma is 
detrimental to the survival of pa­
tients with terminal cancer, those 
who undergo exploratory thoracot­
omy may have a shorter survival 
than those who do not, provided 
the tumour staging and other risk 
factors are comparable. We, there­
fore, undertook a retrospective re­
view of patients with bronchogenic 
carcinoma determined to be inoper­
able after thoracotomy revealed me­
diastinal lymph-node involvement. 
This historical cohort, consisting 
mainly of patients treated before 
mediastinoscopy was used, was 
compared to a control group who 
had the same nodal involvement 
diagnosed by mediastinoscopy 
alone. The purpose of this study 
was to assess the effect of explor­
atory thoracotomy on survival of 
these patients.
Patients and Methods
All patients admitted to the Mon­
treal Chest Hospital for investiga­
tion of bronchogenic carcinoma are 
clinically staged by history-taking, 
physical examination, chest x-ray, 
tomography, liver function studies 
and bronchoscopy. Liver and bone 
scanning are performed if indicated. 
Since 1965, mediastinoscopy has 
been used with increasing frequency 
so that, now, virtually all patients 
who are candidates for tumour re­
section undergo this procedure.
Between 1960 and 1982, sam­
pling of mediastinal lymph nodes, 
with frozen-section histologic ex­
amination during exploratory thora­
cotomy revealed preoperatively un­
diagnosed N2 disease in 48 patients 
with non-small cell carcinoma 
(group 1). Tumour resection in 
these patients was contraindicated 
because of the nodal involvement. 
As a control group, we selected 64 
consecutive patients evaluated for 
bronchogenic carcinoma between 
1978 and 1982 (group 2). These 
patients had non-small cell carcino­
ma and N2 nodal metastases histo­
logically proven by mediastinoscopy 
alone; they did not undergo explor­
atory thoracotomy. Patients were 
re-staged according to the present 
TNM classification.89 In all cases, 
disease was limited to stage III at
the time of diagnosis. Only patients 
with squamous cell carcinoma or 
adenocarcinoma were included. Fol­
low-up consisted of periodic clinical 
and radiologic evaluation.
If patients had no evidence of 
ongoing infection and were in good 
overall physical condition, they 
were offered radiotherapy (5000 to 
6000 rad). An additional 12 pa­
tients who underwent exploratory 
thoracotomy were not included in 
the study because they received 
nonstandardized chemotherapy.
The x2 test was used to compare 
the patients in each group for age, 
sex, preoperative weight loss and 
primary tumour classification at the 
time of diagnosis. Actuarial survival 
was calculated for both groups of 
patients as well as for those who 
received adjunctive radiotherapy.10 
When autopsy was not available, 
cause of death was established on 
clinical, radiologic and laboratory 
bases.
Results
In group 1 patients, N2 disease 
was discovered and histologically 
proven. Preoperative mediastinos­
copy was equivocal or negative in 
20 of these patients. The other 28 
did not undergo mediastinoscopy. 
Postoperative complications were
Table I. Distribution of Age, Sex, Radiotherapy and Weight Loss
Age, yr Sex Radiotherapy Weight loss
Group No. Mean Range M F Yes No <10% >10%
1: thoracotomy 
(1 9 6 0 - 1982) 48 62 4 2 - 7 7 38 10 26 22 42 6
2: mediastinoscopy 
alone (1 9 7 8 - 1982) 64 61 3 6 - 7 5 48 16 36 28 56 7
Table II. Primary Tumour Classification and Distribution of Cell Type
Primary tumour class Cell type
Group T2 T3 T4 Squamous Adenocarcinoma
1: thoracotomy 
2: mediastinoscopy
12 12 24 30 18
alone 21 24 19 43 21
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limited to pneumonia and atelecta­
sis in seven patients and did not 
prevent hospital discharge in any 
case. One patient had a fatal pulmo­
nary embolism on postoperative day 
7. In group 2 patients the N2 
disease was histologically proven by 
mediastinoscopy alone. There were
no serious complications in this 
group. The use of blood transfu­
sions for replacing intraoperative 
blood loss was comparable in the 
two groups.
Patients in both groups were 
comparable for age and sex (Table 
I). Differences in weight loss and
frequency of adjunctive radiothera­
py were not significant. The TNM 
classification of primary tumours in 
both groups ranged from T2 to T4. 
Although T4 tumours were more 
common in the thoracotomy group, 
differences in overall primary tu­
mour distribution were not statisti­
cally significant (Table II). Similar­
ly, tumour cell types were compara­
ble for both groups.
Eleven patients from group 1 
were lost to follow-up between 1 
and 11 months postoperatively, and 
12 patients in group 2 were lost to 
follow-up between 1 and 8 months 
after the diagnosis was established. 
Thus, follow-up rates were 77% and 
81% respectively.
The median hospital stay was 2.0 
months (range from 0 to 4 months) 
for patients in group 1, compared 
with 1.0 months (range from 0 to 6 
months) for group 2. This was 
found to be statistically significant 
(Student’s t-test, p < 0.05). Figure 
1 shows that actuarial survival 
curves were virtually identical for 
both groups. Median survival for 
group 1 patients was 6.0 months 
(range from 0 to 15 months) and 
for group 2, 7.0 months (range 
from 0 to 50 months). Overall sur­
vival after 1 year was less than 20% 
for both groups. The power of 
these data in detecting a 15% differ­
ence in the 12-month actuarial sur­
vival rate is 0.80. In all cases, death 
was secondary to disease progres­
sion. The cell type and the primary 
tumour classification did not affect 
survival.
All patients who received adjunc­
tive radiotherapy had increased me­
dian survival regardless of whether 
they underwent thoracotomy (9.0 
months versus 5.0 months, p < 
0.005). However, actuarial survival 
curves comparing these patients 
with those not receiving adjunctive 
treatment revealed that radiothera­
py did not change the 1-year surviv­
al rate significantly (Fig. 2).
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Discussion
Surgery has been suspected to 
have an immunosuppressive effect, 
which may promote tumour 
growth. Experimentally, there is a 
correlation between accelerated tu­
mour growth and multiple operative 
procedures.8 Other models have re­
vealed increased pulmonary metas- 
tases and impaired immunity after 
surgical trauma.2 Eggermont and 
colleagues3 have made similar ob­
servations in animals subjected to 
major surgical trauma, but not in 
those subjected to minor proce­
dures. In this model, immune func­
tion was only transiently impaired. 
This would suggest a time-limited 
immunosuppressive effect.
Clinical results have not been as 
conclusive. Perioperative blood 
transfusions have been found to 
exert a negative effect on survival 
in patients with rectal cancer.11 An 
immunosuppressive effect is sus­
pected. Surgery and anesthesia 
have produced a measurable depres­
sion in immune response in normal 
patients.4 The clinical implications 
of this observation are not known. 
Fielding and Wells6 retrospectively 
noted shortened survival in patients 
who underwent two-staged resec­
tion of obstructing colonic cancer 
compared with those who under­
went primary resection. These re­
sults have been used to support the 
hypothesis that surgery itself facili­
tates tumour growth. Alternatively, 
these findings may be explained by 
the decision of the surgeon to select 
more complicated cases for staged 
resection.
This study is concerned exclu­
sively with stage III non-small cell 
lung cancer. The poor prognosis 
associated with this tumour stage is 
widely recognized.12"14 Thus, sur­
vival as an end point to study 
possible accelerated tumour growth 
seems to be appropriate in these 
patients. Patients who underwent
exploratory thoracotomy were re­
trospectively compared with a 
group who had the same disease 
classification but had not been sub­
jected to a major surgical proce­
dure. Both groups of patients were 
comparable with respect to age, 
sex, preoperative weight loss, in­
traoperative use of blood products, 
cell type and use of adjunctive 
radiotherapy.
It should be stressed that al­
though this is a retrospective study, 
there is no selection bias, because 
patients were assigned to the 
groups, not by surgeon’s judge­
ment but by the historical fact that 
mediastinoscopy was not routinely 
practised when the earlier patients 
underwent thoracotomy. These pa­
tients were then compared with 
those who had similar lesions but 
did not require thoracotomy simply 
because they were seen after me­
diastinoscopy became available.
Since the group 1 patients pre­
date group 2, it is possible that 
improvements in postoperative care 
could affect the comparison. How­
ever, if this were the case, it should 
increase rather than reduce the dif­
ference in the survival data. The 
fact that we could not find such a 
difference indicates that even with 
improved postoperative manage­
ment, avoiding exploratory thora­
cotomy did improve prognosis. 
Thus, the use of historical controls 
in this case strengthens rather than 
weakens our conclusions.
Patients who underwent thora­
cotomy were found to have signifi­
cantly increased hospital stay. This 
may be in part related to normal 
postoperative care and to deteriora­
tion of physical condition and quali­
ty of life secondary to exploratory 
thoracotomy.15 The fact that all 
patients but one were eventually 
discharged implies that this effect 
was a transient one attributable to 
operative trauma. Nevertheless, to 
spend 1 month of their limited
expected survival in hospital rather 
than at home with their families, is 
a human cost that cannot be mea­
sured in dollars or in days. There­
fore, the use of mediastinoscopy in 
N2 disease patients, although it 
does not improve survival, has 
benefits beyond avoiding the less 
desirable exploratory thoracotomy, 
which is often more painful in the 
postoperative period.
When patients who received ad­
junctive radiotherapy were com­
pared with all others, regardless of 
thoracotomy, they were found to 
have significantly increased surviv­
al. However, this result was subject 
to a selection bias because only 
patients with good performance 
were offered radiotherapy. From 
these data, we cannot conclude, 
therefore, that radiotherapy has a 
beneficial effect on survival in pa­
tients with stage III non-small cell 
disease. This emphasizes the need 
for a randomized trial of radiothera­
py in these patients so that results 
may be compared to an untreated 
control group.16"19
In conclusion, our data failed to 
demonstrate any adverse effect of 
surgical trauma on the survival of 
patients with bronchogenic carcino­
ma. Any immunosuppressive effect 
an “exploratory thoracotomy’’ may 
cause was not reflected in patient 
survival.
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Omental Pedicle Grafting in the 
Treatment of Poststernotomy Mediastinitis
J. Pierre Bedard, MD, FRCSC; Farid Shamji, MD, FRCSC; Wilbert J. Keon, MD, FRCSC
Mediastinitis after median sternotomy may be life-threatening. It should be managed 
by providing adequate mediastinal drainage, removing all foreign material 
(including infected and dead tissues) and obliterating any dead space.
Obliterating dead space may be difficult using the usual method of creating a 
vacuum with large-bore tubes. Alternative methods consist of muscle or omental 
transpositions. The authors describe the cases of two men who had mediastinitis, 1 
week and 3 months respectively, after coronary artery bypass grafting. In both 
cases, the mediastinitis was treated successfully by omental pedicle grafting.
From their experience, the authors recommend omental grafting as a method of 
obliterating a large mediastinal dead space when the sternal edges can be 
approximated but the space cannot be closed by conventional methods.
La mediastinite consecutive a une sternotomie mediane peut mettre en danger la vie 
du malade. Elle doit etre traitee par un drainage mediastinal adequat, le retrait de 
toute substance etrangere (y compris les tissus infectes ou morts) et Termination de 
Tespace mort.
II peut etre difficile d’eliminer Tespace mort lorsqu’on utilise la methode 
habituelle qui consiste a faire le vide a l’aide d’un tube de gros calibre. Les 
transpositions du muscle ou de T epiploon constituent des alternatives. Les auteurs 
decrivent les cas de deux hommes qui ont souffert d’une mediastinite, respective- 
ment 1 semaine et 3 mois apres pontage aortocoronarien. Dans les deux cas, la 
mediastinite a ete traitee avec succes par greffe d’un pedicule d’epiploon.
D’apres leur experience, les auteurs recommandent la greffe d’epiploon comme 
methode d’eliminer les espaces morts mediastinaux importants, quand les bords du 
sternum peuvent etre rapproches mais que Tespace ne peut etre referme par les 
methodes conventionnelles.
M edian sternotomy is the most common incision used in car­
diac surgery. Although wound in­
fection is rarely associated with this 
incision, its occurrence may lead to 
mediastinitis, which carries signifi­
cant mortality and morbidity.
As for any wound infection, the 
treatment should consist of exten­
sive debridement, adequate irriga-
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tion and drainage and the adminis­
tration of appropriate antibiotics. 
Sometimes the wound is difficult to 
close and alternative methods, such 
as omental pedicle graft or muscle 
transposition, must be considered.
We present two cases of postster­
notomy mediastinitis treated suc­
cessfully with debridement and 
omental pedicle grafting.
Case Reports
Case 1
A 55-year-old man underwent 
four-vessel aortocoronary bypass 
grafting in October 1986. Three 
months later, chest pain, fever and 
hemoptysis developed. A chest film 
revealed an anterior mediastinal 
mass, and an echocardiogram con­
firmed the presence of a large false 
aneurysm of the ascending aorta. 
Cardiopulmonary bypass was estab­
lished with femorofemoral bypass. 
Using profound hypothermia (at 
18°C) and circulatory arrest, the 
median sternotomy incision was 
opened, and the false aneurysm was 
entered, blood clots were evacuated 
and the hole on the ascending aorta 
was identified. The false aneurysm 
was related to an infection and 
dehiscence of a proximal coronary 
artery graft anastomosis. The defect 
on the aorta was controlled with 
interrupted Prolene suture, cardio­
pulmonary bypass was resumed and 
the patient warmed.
After the false aneurysm was re­
paired, we were left with a large 
defect in the mediastinum and ex­
tensive raw surface on the medial 
aspect of the upper lobe of the left 
lung. While the patient was being 
warmed, the sternotomy incision 
was extended down to the umbili­
cus so that a well-vascularized 
omental pedicle could be obtained. 
Once mobilized, the omentum was 
brought up to the anterior mediasti­
num so that it would cover both the 
mediastinal defect and the raw area 
of the lung. The chest wall was 
closed in layers and two rubber 
catheters were left in the mediasti-
From the University o f Ottawa Heart Institute, Ottawa. Ont.
Presented at the 8th annual meeting o f the Canadian Society o f Cardiovascular and Thoracic 
Surgeons, held in conjunction with the 57th annual meeting o f the Royal College o f Physicians 
and Surgeons o f  Canada, Ottawa. Ont., Sept. 24. 1988
Reprint requests to: Dr. J.P. Bedard, University o f  Ottawa Heart Institute, Ottawa Civic Hospital, 
1053 Carling Ave., Ottawa, Ont. K1Y 4E9
328 CJS, VOL. 32, NO. 5, SEPTEMBER 1989
OMENTAL PEDICLE GRAFTING
num for irrigation using 0.5% Pro- 
viodine solution. The patient was 
discharged home 4 weeks after the 
operation. He was free of infection 
2 years later.
Case 2
A 62-year-old man had under­
gone three coronary artery bypass 
grafting operations. Six days after 
the last one, he suffered sternal 
dehiscence, which required debride­
ment and reapproximation. Then, 6 
days after that, the sternal dehis­
cence recurred with severe mediasti- 
nitis. Further management included 
radical debridement of the sternum, 
anterior mediastinal tissue and sub­
cutaneous fat, followed by irriga­
tion with antiseptic solution and 
packing of the mediastinum for 1
FIG. 1. Anatomy and blood supply of 
greater omentum.
FIG. 2. Mobilization of vascularized 
omental pedicle graft.
week. Because there was a large 
dead space in the anterior mediasti­
num due to marked fibrosis from 
previous operations, a laparotomy 
was carried out and an omental 
pedicle graft obtained and moved up 
into the anterior mediastinum to 
close the dead space. The sternum 
was reapproximated as usual. The 
patient was discharged home 3 
weeks later and was free of infec­
tion after 1 year.
Technique for Mobilizing an 
Omental Pedicle Graft
The median sternotomy incision 
is extended interiorly and the peri­
toneal cavity entered through the 
linea alba. A well-vascularized 
omental pedicle graft is then pre­
pared as follows.
The greater omentum hangs 
down from the lower convexity of 
transverse colon in front of the coils 
of small intestine. It is a continua­
tion downwards of the gastrocolic 
omentum from the greater curva­
ture of stomach and it receives its 
blood supply from the epiploic 
branches of the gastroepiploic ar­
cade (Fig. 1). This arcade runs 
along the greater curvature of the 
stomach. The attachment of greater 
omentum to the lower convexity of 
the transverse colon along the avas­
cular plane is exposed by gently 
lifting the greater omentum up­
wards over the costal margin. This 
avascular plane is divided to sepa­
rate a segment of greater omentum 
8 to 10 cm wide from the transverse 
colon. The preparation of this seg­
ment of greater omentum by ligat­
ing and dividing lymphatics and 
blood vessels in the gastrocolic 
omentum is continued as far as 5 to 
6 cm from the greater curvature of 
the stomach. This allows the gas­
troepiploic arterial arcade to be pre­
served and maintains the blood sup­
ply to the omental pedicle graft
through its epiploic branches. 
Hence, the omental pedicle graft 
usually does not need to be de­
tached from the greater curvature 
of the stomach (Fig. 2). The omen­
tal pedicle is then delivered into the 
anterior mediastinum through a re­
trosternal tunnel, making sure that 
gastric outlet obstruction from vol­
vulus is avoided. The omental pedi­
cle graft is anchored in place in the 
anterior mediastinum with absorb­
able sutures.
Discussion
The principles of treatment of 
wound infections apply to postster­
notomy mediastinitis. First, all for­
eign material (including necrotic tis­
sue and dead bone) must be ade­
quately debrided. This is followed 
by irrigation with an antiseptic solu­
tion and immediate direct closure of 
the sternum if possible. Cultures of 
the wound are obtained and cover­
age with broad-spectrum and then 
specific antibiotics is provided.
An important factor contributing 
to failure of treatment for postster­
notomy mediastinitis is the presence 
of a dead space posterior to the 
sternum.1 It may be present in the 
mediastinum because of the rigidity 
of the retrosternal compartment. 
The use of an omental flap is 
helpful in those cases as it will not 
only fill up the dead space, but also 
provide healthy tissue with a pro­
pensity for new blood supply and 
granulation.2
The omentum has a number of 
properties that offer protection 
from infection: it has a rich vascular 
and lymphatic supply which favours 
neovascularization;3 it possesses a 
rich source of macrophages which 
will resist infection and seal areas of 
inflammation;4 because of its double 
layer of peritoneum it offers a large 
absorptive surface which will favour 
absorption of fluids;5 finally, its
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bulkiness will seal areas of inflam­
mation, fill up dead space and cover 
tissue defects.2-3-6 Because of its 
advantages, the omentum is becom­
ing more widely used by the cardio- 
thoracic surgeon.
In our first patient, the omentum 
was used not only to fill up the 
large dead space left behind by the 
false aneurysm but also to seal 
communications with the bronchial 
tree and cover the stitches used to 
close the aorta. In our second pa­
tient, the omentum was used to fill 
up the large dead space provided by 
the rigid wall of the mediastinum
due to the three previous coronary 
artery bypass graft operations.
It is worth re-emphasizing that 
the basic treatment of poststernoto­
my mediastinitis remains adequate 
debridement and drainage. The use 
of an omental flap is not necessary 
in all cases, but is useful under 
certain circumstances.
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BOOK REVIEWS
CARDIOTHORACIC TRAUMA. Pana- 
giotis N. Symbas. 404 pp. Illust. W.B. 
Saunders Company Canada Limited, 
Toronto, 1989. $128.25. ISBN
0-7216-2817-3.
This textbook on chest trauma is writ­
ten by a surgeon with more than two 
decades of experience in a major US 
trauma centre. In addition to his exten­
sive clinical experience, he is also the 
director of an active surgical research 
laboratory where problems associated 
with cardiothoracic trauma have been 
studied. Many of the strengths of this 
book are the result of the author’s 
experience.
The book is well organized, concise 
and clearly written, and the quality of 
the illustrations, particularly the roent­
genograms, is superb. The extensive 
references following each chapter will 
be especially useful for readers who 
wish to obtain source material or de­
tailed information on specific subjects.
In the preface it is stated, “The 
material described in this text is de­
signed to be of benefit to any provider 
of health care to patients with thoracic 
injury either in the early or late postin­
jury period”. The systematic and au­
thoritative essays certainly fulfil this 
objective. For nonthoracic surgeons,
such as emergency room physicians and 
paramedic staff, and for surgical resi­
dents and medical students, the detailed 
description of basic concepts of care for 
chest trauma, including early resuscita­
tion and chest-tube drainage, is particu­
larly useful. However, it is important for 
these readers to keep in mind that this 
text should not be read and used in 
isolation. Many patients who suffer car­
diothoracic trauma also have injury to 
other organs. For example, patients 
with blunt trauma requiring intubation 
and respiratory support may also have 
suffered cervical spine injury, and inap­
propriate manipulation may cause per­
manent paraplegia. Setting priority in 
the management of multiorgan damage 
is not within the scope of this book; 
these aspects are emphasized in the 
ATLS (Advanced Trauma Life Support 
course of the American College of Sur­
geons, Committee on Trauma).
For the cardiothoracic surgeon who 
provides definitive operative care, this 
book can also serve as a useful refer­
ence. Again, its strength is the authori­
tative statements based on the author’s 
experience. Consequently, in the discus­
sion of each subject, particularly the 
controversial areas, one notices person­
al biases. For example, the potentially 
lethal complications of systemic air em­
bolism associated with penetrating inju­
ry of the lung are dealt with in a single 
sentence. Neither its pathophysiology 
nor the diagnosis and management are 
discussed. On the issue of shunting for 
the repair of vascular injuries involving 
the innominate or carotid artery, the 
author relies largely on information 
obtained from carotid endarterectomies. 
There is considerable difference in the 
available collateral circulation for endar­
terectomy if the carotid artery is occlud­
ed at its bifurcation or if the common 
carotid or innominate artery is occluded 
unilaterally. In the former, only intra­
cranial collaterals can perfuse the terri­
tory of the occluded internal carotid 
artery. In the latter, however, extra­
cranial collaterals via the branches of 
the external carotid arteries provide 
much more important and reliable col­
laterals. Likewise, repair of ruptured 
descending thoracic aortas using cen­
trifugal pumps without heparinization 
has given good results in recent years, 
but this approach is not elaborated on 
in the present text.
There are other minor inconsisten­
cies. The references are generally ar­
ranged in the order of their appearance 
in the text, but of the 28 references in
continued on page 372
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of the Pericardium: ItsCatheter Drainage 
Safety and Efficacy
C.D. Morgan. MD, FRCPC; S.A. Marshall, MD, FRCPC; J.R. Ross, MD, FRCPC
A retrospective chart review identified 46 consecutive patients who underwent 
catheter drainage of the pericardium over 3 years. Cardiac tamponade was present in 
the majority of patients, and the underlying cause was tumour metastasis in 72%. 
Pericardial catheterization was accomplished by the Seldinger technique using the 
subxiphoid approach. Catheter insertion was successful in 42 of the 46 patients, and 
in only 1 was there a serious complication. The mean duration of catheter drainage 
was 3 days. The pericardial space was successfully drained in all but one patient, 
who subsequently required surgery. Intrapericardial chemotherapy was administered 
in 27 patients. There was no instance of catheter-associated sepsis. Supraventricular 
arrhythmias occurred in 19% of patients, but all were managed medically. There 
were no late complications attributable to the period of drainage. The authors 
conclude that catheter drainage of the pericardium is a safe and effective means of 
providing definitive drainage of the pericardial space.
Une etude retrospective des dossiers medicaux a permis d’identifier 46 patients qui, 
au cours d’une periode de 3 ans, ont subi un drainage par catheter du pericarde. 
Dans la majorite des cas, une tamponade etait presente et la cause sous-jacente, dans 
72% des cas, etait des metastases tumorales. Le catheterisme pericardique fut realise 
grace a la technique de Seldinger en utilisant un abord sous-xiphoi'de. L’insertion 
du catheter fut reussi chez 42 des 46 patients et on n’a rencontre qu’une seule 
complication serieuse. La duree moyenne du drainage fut de 3 jours. L’espace 
pericardique fut draine avec succes dans tous les cas, sauf un qui necessita une 
intervention chirurgicale subsequente. Une chimiotherapie intrapericardique fut 
administree a 27 patients. On n’a enregistre aucun cas de sepsie due au catheter.
Des arythmies supraventriculaires sont apparues chez 19% des patients, mais elles 
purent etre traitees medicalement dans tous les cas. II n’y eut aucune complication 
retardee attribuable a la periode de drainage. Les auteurs concluent que le drainage 
pericardique par catheter est un moyen sur et efficace d’offrir un drainage definitif 
de l’espace pericardique.
The approach to drainage of hemodynamically important 
pericardial effusions remains con-
Accepted for publication Nov. 11. 1988
troversial. Although there is no 
question about the role of a defini­
tive surgical procedure in cases of
traumatic cardiac tamponade, pa­
tients with nontraumatic cardiac 
tamponade have traditionally been 
managed by needle pericardiocente­
sis. Unfortunately, this procedure is 
associated with serious complica­
tions, and frequently a single peri­
cardial tap is unsuccessful in prov­
iding long-term relief.1-3 Although 
there are some4-1’ who advocate 
open surgical drainage in this set­
ting, these patients may tolerate 
surgery poorly due to advanced 
systemic disease. Our institution is 
allied to a major regional cancer 
institute and we have, of necessity, 
been required to manage a large 
number of patients with cardiac 
tamponade due to malignant dis­
ease. Concerns over the safety and 
efficacy of traditional medical and 
surgical management led us to ex­
plore the role of pericardial cathe­
terization in this clinical setting.
Methods
A retrospective chart review iden­
tified 46 consecutive patients who 
underwent catheter drainage of the 
pericardium between May 1982 and 
May 1985. There were 36 women 
and 10 men (mean age 55 years). 
The procedure was performed for 
clinically suspected cardiac tampon­
ade in all but three patients in 
whom the procedure was performed 
for diagnostic purposes. All patients 
had a moderate to large pericardial 
effusion (Table I) documented by 
preceding two-dimensional echocar-
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diography. All procedures were per­
formed in the intensive care unit by 
a staff cardiologist or by a cardiolo­
gy subspecialty trainee under the 
direct supervision of an attending 
cardiologist. Pericardial catheteriza­
tion was performed by the Seldinger 
technique using the subxiphoid ap­
proach.7-8 The patients were awake 
and supine. When necessary for 
patient comfort the head of the bed 
was elevated to 30°. After infiltra­
tion of the skin and subcutaneous 
tissues with 1% lidocaine without 
epinephrine, a small incision was 
made to the left of the xiphisternum 
to ease subsequent passage of the 
catheter. A 17-gauge 20-cm spinal 
needle with trocar was then inserted 
beneath the costal margin at ap­
proximately 30° to the horizontal 
plane and directed towards the mid­
point of the left clavicle. The needle 
was advanced under continuous 
electrocardiographic guidance with 
the trocar frequently withdrawn 
until the pericardial sac was en­
tered, as documented by free aspira­
tion of pericardial fluid without ST- 
segment elevation or dysrhythmias. 
A J-tipped guide wire measuring 
0.025 inches (0.064 cm) in diame­
ter was inserted through the nee­
dle into the pericardial space under 
fluoroscopic guidance. No special 
effort was made to direct the guide 
wire posteriorly within the pericar­
dial sac. That the wire had indeed 
entered the pericardial space and 
not a cardiac chamber was con­
firmed by (a) the observation that 
the guide wire could be advanced 
well into the known pericardial re­
flections off the great vessels, and
T a b le  1. C auses o f P e r ica rd ia l E ffu s io n s  in 
46  P a tie n ts
C ause No. %
M a lig n a n t d isease 33 72
U re m ia 6 13
C o n n e c tiv e  tis su e  d isease 3 6 .5
V iru s 3 6 .5
H y p o th y ro id is m 1 2
(b) the absence of dysrhythmias 
with guide wire manipulation. The 
subcutaneous tissues were then 
carefully dilated using a no. 7F 
standard vein dilator. Under fluoro­
scopic guidance, a 25-cm long 6.5F 
polyethylene catheter (Vas Cath of 
Canada, Ltd., Mississauga, Ont.) 
with six 0.035-inch (0.089-cm) di­
ameter side-holes, spirally arranged 
between 1 and 3 cm from the tip, 
was advanced into pericardial space 
so that its tip was no more superior 
than the centre of the cardiac sil­
houette (Fig. 1). The catheter was 
sutured to the skin and covered by 
a sterile occlusive dressing.
The pericardial effusion was 
drained continuously by gravity 
using a closed system. A stopcock 
was included to permit sampling of 
the pericardial fluid and instillation 
of chemotherapeutic agents. Open­
ing of the system was kept to a 
minimum and strict aseptic tech­
nique was emphasized. Heparin was
not used to maintain catheter pat­
ency. Fluid was sent for cytologic 
examination, cell counts and 
Gram's staining and, in addition, 
was cultured daily. A chest x-ray 
film was obtained after the proce­
dure to document catheter location. 
All patients underwent continuous 
electrocardiographic monitoring 
while the catheter was in situ.
Results
Percutaneous catheter insertion 
was successful in 42 of the 46 
patients. In two of these, the cathe­
ter entered the right atrium, result­
ing in a nonfatal cardiac arrest in 
one and no sequelae in the other. In 
both instances, immediate repeat 
catheterization was successful. 
Both these cases occurred early in 
our experience when a straight 
guide wire was being used. Since 
switching to a J-tipped guide wire,
FIG. 1. Diagram showing technique of catheter insertion.
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we have not seen this complica­
tion. In two patients, no fluid was 
obtained through the needle despite 
adequate fluid demonstrated by 
echocardiography. In two other pa­
tients, the catheter could not be 
passed over the guide wire despite 
apparently adequate subcutaneous 
dilatation. In 41 of the 42 patients 
successfully cannulated, the effu­
sion was adequately drained. One 
patient suffered recurrent tampon­
ade, despite initial successful drain­
age and a patent catheter. In this 
patient, the catheter tip travelled 
anterior to the right ventricle and 
was likely too far superior for ade­
quate drainage. The catheter was 
repositioned and tamponade was re­
lieved. The patient ultimately re­
quired a pericardial window. Of the 
entire group, this was the only 
patient who required surgical inter­
vention.
The mean duration of catheter 
drainage was 3 days (ranging from 
1 to 5 days) and during this time 27 
patients received intrapericardial 
tetracycline and 3 intrapericardial 
steroids. When indicated, tetracy­
cline poudrage was performed as 
described previously.9 Briefly, this 
involved the daily intrapericardial 
instillation of 500 mg of tetracy­
cline to a maximum total of 2.0 g. 
Daily cultures from all pericardial 
effusions were sterile. Eleven (26%) 
of 42 patients had a fever with a 
temperature greater than 38.5°C. 
Two (5%) of 42 catheter tips cul­
tured positive for Staphylococcus 
epidermidis upon removal. This was 
most likely due to skin contamina­
tion; no subsequent local infections 
developed. In the majority of febrile 
patients, a potential alternative 
cause of fever could be identified. 
There were no sustained dysr­
hythmias during the insertion pro­
cedure. Subsequently, a new su­
praventricular tachycardia devel­
oped in 8 (19%) of 42 patients 
during the period of drainage. All of
these patients had also received 
intrapericardial tetracycline. No pa­
tient suffered hemodynamic com­
promise and the dysrhythmias were 
successfully treated medically. One 
(2%) of 42 patients required cathe­
ter removal due to refractory peri­
cardial pain. Even though we did 
not use heparin or vacuum-assisted 
drainage, there were no instances in 
which, because of clotting, the 
catheter had to be removed before 
the drainage or planned course of 
treatment was completed. There 
were no late complications attribut­
able to catheter drainage.
Discussion
Malignant disease and uremia are 
common causes of hemodynamical- 
ly important nontraumatic pericar­
dial effusion. Primary malignant tu­
mours of the pericardium are ex­
ceedingly rare. Secondary involve­
ment is most frequently encoun­
tered with carcinomas of the lung 
and breast. Large pericardial effu­
sions are reported to occur in up to 
7% of patients on long-term dialy­
sis,10 and when cardiac tamponade 
occurs, it cannot be managed by 
dialysis alone. Needle pericardi­
ocentesis will relieve nontraumatic 
tamponade in 60% to 90% of 
cases.1-2 Although useful in the 
acutely deteriorating patient with 
tamponade, it is less effective for 
long-term management. Krikorian 
and Hancock1 reported that 76% of 
patients required multiple taps, 
placement of indwelling catheters 
or definitive surgical drainage. Gub- 
erman and associates2 noted that 
20% of patients with nontraumatic 
tamponade ultimately required peri­
cardial resection for recurrent accu­
mulation of fluid.
Our results indicate that when an 
indwelling catheter is used routinely 
as part of the initial drainage proce­
dure, the need for subsequent sur­
gical te rv en tio n  or repeat drain­
age pbcedures falls to less than  
10%. !his m ay, in part, be because 
the indwelling catheter permits r e ­
peated administration of intraperi­
cardia chemotherapy. The compli­
cation ra te  in this series is lower 
than that reported with needle peri­
cardiocentesis.1 10 Only one of o u r  
patients had  a life-threatening com­
plication. In comparison with previ­
ous studies, all had a t least a mod­
erate pericardial effusion as demon­
strated by two-dimensional echocar­
diography. Failure to  obtain peri­
cardial fluid in two - patients may 
have been due to the presence of 
intrapericardial clot, loculations, fi­
brous tissue or tumour masses.11 
The fact that previous studies in­
cluded patients who had not under­
gone echocardiography may have 
contributed to the higher complica­
tion rates in some earlier reports.3
The incidence of supraventricular 
dysrhythmias (19%) in this series is 
higher than that reported previous­
ly. This may be the result of either 
the continued dysrhythmogenic po­
tential of a foreign body in the 
pericardial space over a prolonged 
period or the intense inflammatory 
reaction seen after intrapericardial 
instillation of tetracycline. The lat­
ter mechanism is supported by the 
observation that all patients who 
had supraventricular dysrhythmias 
also received intrapericardial tetra­
cycline.
There has been concern that the 
presence of an indwelling catheter 
could lead to septic pericarditis. In 
our series, 26% of patients had a 
temperature greater than 38.5°C 
recorded while the catheter was in 
situ. Many patients had clinically 
apparent foci of infection elsewhere, 
and pericardial fluid cultures were 
uniformly negative. The occurrence 
of fever did not bear any relation to 
the concurrent intrapericardial use 
of tetracycline. These results con­
firm that the risk of infection is
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negligible when appropriate aseptic 
technique is used both at the time 
of catheter insertion and during 
subsequent manipulations of the 
system such as fluid aspiration for 
culture and instillation of chemo­
therapeutic agents.
In this series, catheter blockage, 
when it occurred, could always be 
managed by manual flushing of the 
catheter with a small volume of 
physiologic saline solution. Elabo­
rate precautions against catheter 
clotting do not appear necessary.12 
The size and arrangement of the 
side-holes near the catheter tip may 
be important in preventing catheter 
blockage,13 but with the data from 
this series we cannot directly ad­
dress this issue.
Conclusions
We recommend that catheter 
drainage of the pericardium be un­
dertaken in the cardiac care unit, 
intensive care unit or cardiac cathe­
terization laboratory, where appro­
priate resuscitation equipment is 
immediately available. In our experi­
ence. the keys to safe and success­
ful pericardial catheterization in­
clude the following: (a) the use of a 
J-tipped guide wire, (b) continuous 
electrocardiographic and fluoro­
scopic monitoring and (c) adequate 
dilatation of all tissues from skin to 
pericardium before the catheter is 
introduced. Percutaneous catheter 
drainage of hemodynamically sig­
nificant nontraumatic pericardial ef­
fusions is a safe and effective alter­
native to conventional surgical in­
tervention. The technique may be of 
particular value in critically ill pa­
tients who may be poor candidates 
for surgery. The ability to adminis­
ter intrapericardial chemotherapy 
through the catheter is an impor­
tant adjunctive measure in the con­
trol of malignant pericardial tam­
ponade.9
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Current Operative Morbidity Associated 
With Elective Surgical Resection for Lung 
Cancer
Jean Deslauriers, MD, FRCSC;* Robert J. Ginsberg, MD, FRCSC;t Pierre Dubois, MD, FRCSC;t 
Maurice Beaulieu, MD, FRCSC;§ Melvyn Goldberg, MD, FRCSC;|| Michel Piraux, MD, FRCSC§
To determine the current operative morbidity for elective surgery of lung cancer, 
the authors reviewed the charts of 1076 consecutive patients who underwent 
pulmonary resection between 1978 and 1984 at two major Canadian teaching 
hospitals.
Of these patients, 731 (68%) had a normal course. Minor complications occurred 
in 206 patients (19%); the majority were supraventricular arrhythmias (100 events) 
and atelectasis (41 events). Nonfatal major complications occurred in 105 patients 
(9.8%). The overall operative death rate was 3.2%. If supraventricular arrhythmias 
are excluded, nearly 80% of patients had a smooth postoperative course.
In order to correlate the occurrence of complications with pre- and perioperative 
data, several possible risk factors were analysed. For major complications and death, 
the age, the forced expiratory volume, weight loss, coexisting disease, stage of 
cancer and extent of resection were significant risk factors (p < 0.05).
The data show that elective pulmonary surgery can be done safely and 
complications prevented. The necessary requirements are: proper selection of 
patients, a well-performed operation and prompt treatment of potential problems.
Pour determiner la morbidite associee a la chirurgie elective d’un cancer du 
poumon, les auteurs ont revu les dossiers de 1076 malades ayant subi une resection 
pulmonaire entre 1978 et 1984 dans deux hopitaux universitaires canadiens.
Sept cent trente et un malades (68%) ont eu des suites postoperatoires 
entierement normales. Deux cent six malades (19%) ont present des complications 
d’ordre mineur, ces dernieres etant surtout des arrythmies supra-ventriculaires (100 
malades) ou des atelectasies (41 malades). Des complications majeures mais non 
fatales sont survenues chez 105 malades (9.8%) et la mortality operatoire a ete de 
3.2%. En excluant les arrythmies supra-ventriculaires, quelques 80% des malades 
ont eu des suites operatoires normales.
Dans le but d’etablir une correlation entre morbidite et donnees pre- ou 
perioperatoires, plusieurs variables ont ete etudiees. Pour les complications 
majeures et deces operatoires, l’age, la fonction respiratoire, la perte de poids, les 
maladies co-existantes, le stade de la tumeur et l’etendue de la resection ont ete 
identifies comme facteurs de risque statistiquement significatifs (p < 0.05).
Ces resultats demontrent que la chirurgie pulmonaire peut etre pratiquee de fa?on 
securitaire, la plupart des complications pouvant etre prevenues. Un effort doit 
cependant etre fait pour bien selectionner les malades, bien faire la chirurgie et 
traiter sans delai les problemes potentiels.
A lthough pulmonary resection is recognized as the best treat­
ment for lung cancer, there is little 
published information on the 
30-day morbidity associated with 
such operations. Nagasaki and col­
leagues1 from the Memoral Sloan- 
Kettering Cancer Center reported a 
19% operative morbidity, but their 
series included 202 patients with 
either biopsy only or with intersti­
tial implantation of radioisotopes. 
Keagy and associates2 analysed
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morbidity and mortality in 369 con­
secutive pulmonary lobectomies 
performed between 1970 and 1983 
and found that 41% of patients had 
postoperative management prob­
lems. Much of the remaining litera­
ture is limited to the reporting of 
specific postoperative problems or 
to collective reviews of potential 
complications after elective resec­
tions.3
This analysis of 1076 consecutive 
resections done during the years 
1978 and 1984 at two major Cana­
dian hospitals was undertaken to 
determine the current complication 
rate for operative treatment of lung 
cancer. In addition, possible risk 
factors were analysed in the hope of 
correlating the occurrence of com­
plications to pre- and perioperative 
data.
Study Population
We reviewed the records of 1076 
consecutive patients (907 men, 169 
women) who underwent elective re­
section for lung cancer between 
1978 and 1984. The patients 
ranged in age from 29 to 86 years.
For all cases, preoperative work­
up included posteroanterior and lat­
eral chest roentgenography, bron­
choscopy, electrocardiography, 
basic biochemical tests, and liver 
function studies; 62% (672 patients) 
had pulmonary function studies. 
These tests were usually limited to 
measurement of forced expiratory 
volume (FEV,), forced vital capacity 
(FVC) and diffusing capacity of the 
lung for carbon monoxide (DLCO). 
Arterial blood-gas determinations, 
exercise tolerance tests and isotopic 
regional function studies were also 
performed in selected patients with 
compromised function. Mediastinos­
copy was done in 92% of cases, 
with random node sampling at three 
different levels. Very few patients 
were subjected to thoracotomy
when nodal metastases were identi­
fied by mediastinoscopy.
All tumours were staged accord­
ing to the TNM classification.4 
Staging was based on complete clin­
ical and pathological assessment of 
the primary tumour (T status) and 
surgical sampling of at least the 
bronchopulmonary, hilar and medi­
astinal nodes (N status).
The types of procedures per­
formed at thoracotomy are listed in 
Table I. Limited resections (segmen- 
tal/wedge) were carried out only 
when the patient’s pulmonary re­
serve was thought to be compro­
mised; these were done infrequent­
ly. Lobectomies included all simple 
lobectomies, bilobectomies, sleeve 
lobectomies or extended lobecto­
mies. Similarly, standard, intraperi- 
cardial or extended pneumonecto­
mies were all included in the pneu­
monectomy group. A complete re­
section was defined as removal of 
all gross carcinoma, disease-free re­
section margins and the highest 
mediastinal node free of tumour. 
According to these criteria, 89% of 
procedures were considered com­
plete.
Operative death was defined as 
death occurring within 30 days of 
the surgery or directly related to 
the operation if it occurred after 30 
days. For example, a patient who 
died on the 40th postoperative day 
of a bronchopleural fistula would 
fall into the operative death group.
Nonfatal postoperative complica­
tions were classified as minor or 
major. Minor complications were 
defined as events that had no im­
portant impact on the patient’s 
postoperative course; in contrast, 
major complications were events 
considered to be life-threatening. 
When a given patient had both 
minor and major postoperative com­
plications, he was coded as having 
major complications only, although 
the nature of the minor complica­
tion was also recorded.
The influence of each selected 
pre- or perioperative risk factor on 
the development of postoperative 
complications was examined by x 2 
analysis. For this purpose, patients
T a b le  1. Type of Procedure in Patients Who 
Underwent Thoracotomy
P ro c e d u re
N o . of 
p a tie n ts
(%)
Limited resection (wedge or
segmental) 58 (5)
Lobectomy 616(57)
Pneumonectomy 402 (38)
T a b le  I I .  Minor Complications After Elective 
Pulmonary Surgery
C o m p lic a tio n
N o . of 
e v e n ts
Respiratory
Atelectasis requiring no or 
only one bronchoscopy 41
Air leak for > 14 d 25
Cardiovascular 
Atrial or ventricular 
arrhythmias responding to 
drug treatment 100
Pleural
Pneumothorax requiring tube 
drainage 25
Pleural effusion requiring 
thoracentesis or tube 
drainage 9
Miscellaneous 39
Total 239
T a b le  I I I .  Major Complications After 
Elective Pulmonary Surgery
C o m p lic a tio n
N o . of 
e v e n ts
Respiratory
Atelectasis requiring two or 
more bronchoscopies 21
Pneumonia/lung abscess 20
Respiratory failure 15
Cardiovascular 
Myocardial infarction 2
Pulmonary embolism 2
Congestive heart failure 4
Cerebral thrombosis 6
Pleural
Empyema and/or 
bronchopleural fistula 29
Miscellaneous 
Hemorrhage requiring 
reoperation 9
Wound dehiscence 2
Chylothorax 2
Cardiac herniation 1
Other 20
Total 133
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were included in one of two catego­
ries for each factor as follows: (a) 
older or younger than 60 years, (b)
Table IV. Deaths After Elective Pulmonary 
Resection
Primary cause of death No.
Respiratory
Respiratory failure 13
Cardiovascular
Cerebral thrombosis 4
Pulmonary embolism 2
Pleural
Empyema and/or
bronchopleural fistula 8
Miscellaneous
Hemorrhage 1
Esophagopleural fistula 2
Tumour embolism 2
Other 2
Total 34
FIG. 1. (Top) Preoperative chest x-ray 
film of 68-year-old man who underwent 
left pneumonectomy for large necrotic 
tumour of upper lobe. (Bottom) Angio­
gram done 24 hours postoperatively, 
showing occlusion of both femoral ar­
teries by tumour embolism.
FEVi greater or smaller than 2.0 L, 
(c) weight loss greater or smaller 
than 10% of ideal body weight, (d) 
presence or absence of coexisting 
diseases, (e) carcinoma stage I or 
stages II and III, and (f) limited 
resection and lobectomy or extend­
ed resection and pneumonectomy.
Results
Of the 1076 patients, 731 (68%) 
had a normal course, whereas 206 
patients (19%) had 239 minor com­
plications (Table II). These included 
atelectasis (41 patients), prolonged 
bronchoalveolar air leaks (25), su­
praventricular arrhythmias (100) 
and simple pneumothorax requiring 
tube drainage (25 patients). If su­
praventricular arrhythmias are ex­
cluded, nearly 80% of patients had 
an uncomplicated postoperative 
course.
One hundred and thirty-three 
nonfatal major complications oc­
curred in 105 patients (9.8%), most 
of these being pleural or respiratory 
in nature (Table III). Major atelecta­
sis requiring two or more broncho­
scopies was noted in 21 patients, 
pneumonia in 20 and respiratory 
failure requiring mechanical assis­
tance in 15 patients. Only two pa­
tients had a myocardial infarction,
FIG. 2. Barium swallow showing ex­
travasation at site of esophagopleural 
fistula following right pneumonecto­
my.
which in both cases was not fatal. 
Wound complications were also un­
common since only two individuals 
had a wound dehiscence and none a 
wound infection. Unusual complica­
tions included chylothorax (two pa­
tients) and postpneumonectomy 
cardiac herniation (one).
Thirty-four (3.2%) of the 1076 
patients died postoperatively (Table 
IV). The commonest primary causes 
of death were respiratory failure (13 
patients), bronchopleural fistula (8) 
and cerebral thrombosis (4). Fatal 
esophagopleural fistulas occurred in 
two patients (Fig. 1) and tumour 
embolism in two others (Fig. 2).
Comparison by x 2 analysis of the 
group with major complications or 
death and those without, or with 
only minor complications, showed 
that all six variables were signifi­
cant risk factors. Complications 
were more common in patients 
older than 60 years of age, in 
patients with an FEVj smaller than 
2 L, in patients with weight loss 
greater than 10% of normal body 
weight, in patients with coexisting 
diseases, in patients with lung can­
cer stages II and III, and in patients 
who had an extended resection or 
pneumonectomy.
Discussion
In general, the reported morbidi­
ty after operative treatment of lung 
cancer is high because the majority 
of patients are elderly and most 
have chronic obstructive lung dis­
ease. Breyer and associates5 have 
shown, however, that advanced age 
is not necessarily associated with 
high morbidity. They reported an 
overall death rate of 3% among 218 
thoracotomies performed in patients 
older than 70 years and concluded 
that no patient should be denied 
thoracotomy because of age. Simi­
larly, the Lung Cancer Study 
Group6 retrospectively looked at the
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operative death rate among patients 
in the various participating institu­
tions during the years 1979 to 
1981. There were 81 deaths among 
2220 resections, an incidence of 
3.7%. Although the death rate was 
significantly higher for pneumonec­
tomy patients (6.2%) and for pa­
tients 70 years or older (7.1%), it 
was concluded that major resec­
tions could be done with acceptable 
mortality even in elderly patients.
Preoperative pulmonary function 
is regarded by many as the most 
important predictor of operative 
morbidity. Keagy and colleagues7 
have shown, however, that the re­
sults of three spirometric tests 
(FEV1; FVC and FEVi/FVC) did 
not correlate with postoperative 
morbidity or mortality in patients 
who underwent pneumonectomy for 
carcinoma of the lung. In a similar 
study on lobectomy patients, Keagy 
and colleagues2 showed an in­
creased number of complications 
among male patients and those 
older than 60 years. Stepwise dis­
criminant analysis included FEVi as 
a significant predictor of postopera­
tive complications.
In this series, the variables con­
sidered to be significant for the 
development of major complications 
or death were old age, compromised 
pulmonary function, coexisting dis­
eases, weight loss, extent of resec­
tion and stage of disease.
The analysis of age as a risk 
factor (Table V) shows a substantial 
increase in the number of complica­
tions after the fifth decade. This 
difference is greater in the seventh 
decade being 13% in the 60 to 69
Table V. Age-adjusted Morbidity According 
to Decade (1076 Patients)
Major complications
Age, yr and death, %
< 50 
50 - 59
3.0—  
10.7-—
60 - 69 13.0—
70 - 79 24.5
> 80 20.0—
years age group and 24.5% in the 
70 to 79 years age group. The 
lower morbidity seen in older pa­
tients (80 years or older) reflects 
more rigorous preoperative selec­
tion.
Morbidity was also found to be 
significantly higher in patients with 
compromised pulmonary function 
(Table VI), this being most signifi­
cant (p < 0.005) in patients with an 
FEVj smaller than 1.2 L. Prolonged 
air leaks, atelectasis and respiratory 
failure were the commonest man­
agement problems seen in this 
group.
Among all variables analysed, one 
of the most important was the ex­
tent of weight loss suffered preoper- 
atively (Table VII). Major complica­
tions occurred about twice as often
in patients with a weight loss great­
er than 10%.
The stage of disease and, most 
importantly, the extent of operation 
(Table VIII) were important predic­
tors of morbidity. With simple re­
sections, the incidence of complica­
tions was around 10%, no matter 
how much lung was removed. In 
contrast, there was a significant 
increase in the number of complica­
tions among patients who needed 
more extended procedures such as 
the removal of the chest wall, peri­
cardium or trachea.
There are several reasons why 
the morbidity observed in this series 
is relatively low and in keeping with 
recently published information (Ta­
ble IX). Medical operability requires 
consideration of age, weight loss,
Table VI. Pulmonary Function: Adjusted Morbidity According to Forced Expiratory Volume/s
(FEV,) (672 Patients)
FEV,, L No. of resections
Major complications 
and death, %
< 1.2 100 22—
1.2 -2 .0 297 14 — p < 0.005
> 2.0 275 14—
Table VII. Weight Loss: Adjusted Morbidity According to Percentage Weight Loss (1015 Patients)
Weight loss, % No. of resections
Major complications 
and death, %
None 681 9—
< 10 208 12 — p < 0.001
> 10 126 20—
Table VIII. Extent of Resection: Adjusted Morbidity According to Type of Operation (1076
Patients)
No. of Major complications
Type of operation resections and death, %
Lesser resection 58 10.4—
Simple lobectomy 495 11.2—
Simple pneumonectomy 121 10.0—
Extended lobectomy 231 20.0— i
Extended pneumonectomy 171 17.0—
Table IX. Literature on Operative Morbidity and Mortality for Pulmonary Resection
Series
Years
analysed
No. of
cases
Complications, Operative 
% mortality, %
Nagasaki and colleagues, 19821 1973-1980 961* 21 2
Ginsberg and colleagues, 1983® 1979-1981 2200 3.7
Keagy and colleagues, 19852 1970-1983 369t 41 2.2
‘ Includes 202 nonresected patients. 
tLobectomies only.
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coexisting diseases and cardiopul­
monary function. Similarly, the as­
sessment of technical resectability 
requires consideration of the clinical 
stage of disease and possible extent 
of resection. Patients in their sev­
enth or eight decade, those with 
compromised pulmonary function 
or with locally advanced disease 
may be operated on with reasonably 
low levels of morbidity and mortali­
ty, but they must be carefully se­
lected.89 Golebiowski10 has empha­
sized the hazards of coexisting dis­
eases in elderly patients.
Patients should be optimally pre­
pared preoperatively by learning the 
methods for coughing, deep breath­
ing, incentive spirometry and chest 
physiotherapy. In addition, all pa­
tients should receive proper expla­
nations about the nature of the 
surgery and its possible hazards. 
The procedure itself should be well 
and rapidly performed; the anesthe­
tist must know about all modern 
techniques of intubation, one-lung 
anesthesia and perioperative moni­
toring. Postoperatively, new meth­
ods of analgesia such as epidural or
cryoanalgesia should be routinely 
used and finally, but most impor­
tant, potential problems must be 
recognized and treated at the earli­
est stage possible.
Conclusions
The morbidity rates for elective 
surgery of lung cancer, collected 
from consecutive cases at two 
major teaching units for thoracic 
surgery, show that pulmonary sur­
gery can be done safely and compli­
cations prevented if an effort is 
made to select patients properly, 
perform the operation well and treat 
any potential problem promptly. 
During the presurgical work-up, 
special consideration must be given 
to age, pulmonary function and 
extent of resection that may be 
required.
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SESAP VI Critique
Item 245
Physicians must regularly read and interpret data regarding improved methods of treatment of disease. Recently, 
several questions have been raised as to the actual or artifactual improvement of survival rates. If new detection 
methods pick up disease earlier, the survival may seem longer simply because the patient has had the disease 
longer, rather than because the cure rate is better. For example, liver-spleen or bone scans can now reveal 
previously undetectable metastases, thus shifting a tumor, formerly diagnosed as “favorable,” to a higher stage. 
This shift artifactually improves the survival of both groups. Such considerations mandate caution in 
recommending different treatment without careful consideration whether the method of treatment is truly better 
than the previous method.
¥
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SPRIMAXIN®
(imipenem and cilastatin sodium 
for injection)
Antibiotic
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN® especially when 
recommended dosages based on renal function 
and body weight were exceeded. These expe­
riences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known 
factors that predispose to seizures.
ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
PRIMAXIN® consists of tw o com ponents: 
(1) imipenem, a derivative of thienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme w hich m etabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E sch e rich ia  c o li and se lec ted  s tra in s  of 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
is removed prior to complete killing of gram­
negative species, the remaining viable cells show a 
measurable lag, termed a “ post-antibiotic effect’’ 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria. Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient's clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN® 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by Staphylococcus 
aureus
7. Bone and Joint Infections
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
•  Nocardia asteroides
•  Staphylococcus (excluding many strains 
which are methicillin resistant)
•  Streptococcus (excluding S. faecium)
Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
•  Enterobacter
•  Escherichia coli
•  Haemophilus influenzae
•  Haemophilus parainfluenzae
•  Klebsiella
•  Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium for 
in jection) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN® OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SEN SITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN®. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
severe cases, m anagem ent may in c lu d e  
sigm oidoscopy, appropriate bacterio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and 
cilastatin sodium for in jection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient's condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have been 
reported with PRIMAXIN® especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS TR A TIO N ). A n ti­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN® 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pairm ent (see DOSAGE AND ADM INIS­
TRATION - Dosage in Patients w ith Renal 
Insufficiency).
Use In Pregnancy
The use of PRIMAXIN® in pregnant women has not 
been studied, therefore, PRIMAXIN® should be 
used during pregnancy only if clearly needed. Use 
of this drug in women of childbearing potential 
requires that the anticipated benefits be weighed 
against possible hazards.
Reproduction studies with bolus I V. doses suggest 
an apparent intolerance to PRIMAXIN® (including
emesis, inappetence, body weight loss, diarrhea 
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. Inother studies, PRIMAXIN® 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in 
milk. If the use of PRIMAXIN® is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN® is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN® and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically 
added to other antibiotics. PRIMAXIN® has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN® with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determine causal relationship of adverse ex­
periences to therapy with PRIMAXIN®.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN® were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly, probably, o r de fin ite ly  related to 
PRIMAXIN® were:
Gastrointestinal
Incidence (%)
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 
pseudomembranous colitis
0.2
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures
(see PRECAUTIONS)
0.2
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia 
Special Senses
transient hearing loss in
<0.1
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN® 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined 
by the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN® 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73m2 «0 .08 mL/s/1.73m2) should 
not receive PRIMAXIN® unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
h e m od ia lys is . The p a tien t shou ld  rece ive 
PRIMAXIN® after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r  pa tien ts  on h e m od ia lys is , 
PRIMAXIN® is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN® in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION
R E N A L
F U N C T IO N
C R E A T IN IN E  
C L E A R A N C E  
m L /m in /1 .7 3  m * 
(m L /s /1 .7 3  m2)
D O S E
(g)
D O S A G E
IN T E R V A L
(h)
M A X IM U M
T O T A L
D A IL Y
D O S A G E
(g)
M ild
im p a irm e n t 3 1 - 7 0
(0 .5 2 -1 .1 7 )
0.5 6 - 8 1 . 5 - 2
M o d e ra te
im p a irm e n t 2 1 - 3 0  
(0 .3 5  -  0 .50)
0 .5 8 - 1 2 1 - 1 . 5
S e v e re *
im p a irm e n t 0 - 2 0  
(0  -  0 .3 3 )
0 .2 5  -  0 .5 12 0 . 5 - 1 . 0 * *
Patients w ith  c reatin ine  clearance o f 6 to 
20 mL/min/1.73 m* (0.1 - 0.3 mL/s/1.73 rrp) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lower) every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
xx The highest dose is only recommended fo r 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 -age, years) x 1.4736 
(72) x (serum creatinine concentration, /zmol/L)
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
TABLE 1
ADULT DOSAGE OF PRIMAXIN®
I.V . Administration
Severity  
of infection
Dose
(m g of im ipenem )
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections
due to less
susceptible
organisms
or life threatening
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
x Primarily some strains of Ps. aeruginosa.
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, /zmol/L)
PRIMAXIN® is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Dosage in Infants and Children
The recom m ended to ta l da ily  dosage of 
PRIMAXIN® in children and infants 3 months of age 
and older is 60 to 100 mg/kg of body weight divided 
into 4 equal doses given at six hour intervals. The 
higher dosages should be used for infants and 
young children. The total daily dosage should not 
exceed 2 grams. Clinical data are insufficient to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
Contents of the vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION; CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium C h lo ride  
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN® range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN® has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture 
in vials containing imipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
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CANADIAN SOCIETY OF CARDIOVASCULAR AND THORACIC SURGEONS
Prolonged Ventricular Support Using a 
Centrifugal Pump
Fredrick B.Y. Hoy, MD; Carol Stables, RN; Robert C. Gomez, MD;
James R. Munns, MD; Dale M. Geiss, MD; Dennis Flack, CCP;
David Filko, CCP; James Zischler, CCP, Dean Schmidt, RN
The Biomedicus centrifugal pump was required to provide prolonged ventricular 
support to 13 patients with hemodynamic instability: 11 after cardiovascular 
surgical procedures, 1 after myocardial infarction and 1 after failure of a heart 
transplant.
The duration of support ranged from 3.5 hours to 9 days (mean 72 hours). 
Complications included bleeding in six patients, renal insufficiency in three and 
central nervous system deficit in three. Six patients (46%) were successfully weaned 
from the pump. The patient with graft failure had hyperacute rejection of a second 
heart. Five patients were discharged from the hospital. There was one death 8 
months postoperatively.
Prolonged ventricular support with the centrifugal pump may allow recovery of 
potentially reversible ventricular dysfunction in selected patients after cardiac 
surgical procedures.
L’usage de la pompe centrifuge Biomedicus fut necessaire pour assurer un soutien 
ventriculaire de longue duree chez 13 patients souffrant d’instabilite hemodynami- 
que: 11 apres chirurgie cardiovasculaire, 1 apres infarctus du myocarde et 1 apres 
echec d’une greffe cardiaque.
La duree de l’intervention de soutien a varie de 3.5 heures a 9 jours (moyenne de 
72 heures). Les complications rencontrees comprennent: saignement chez six 
patients, insuffisance renale chez trois et deficit neurologique chez trois. Six 
patients ont pu etre sevre de la pompe avec succes (46%). Le patient greffe a subi le 
rejet aigu d’un second coeur. Cinq patients ont pu recevoir leur conge de l’hopital. II 
y eut une mortalite, 8 mois apres l’intervention.
Chez des patients choisis qui ont subi diverses chirurgies cardiaques, un soutien 
ventriculaire prolonge peut permettre la guerison de dysfonctionnements potentiel- 
lement reversibles.
D espite advances in surgical technique, myocardial preser­
vation, anesthesia and pharmacolo­
gy, some patients cannot be weaned
Accepted fo r publication Oct. 13. 1988
from cardiopulmonary bypass after 
cardiovascular surgical procedures. 
Several devices are currently avail­
able for temporary support of the
heart until it recovers sufficiently to 
sustain adequate cardiac output. 
This article outlines our experience 
with the use of the centrifugal 
pump for prolonged ventricular 
support.
Patients and Methods
Between July 1986 and July 
1988, 13 patients, who ranged in 
age from 6 weeks to 69 years, 
required prolonged ventricular sup­
port with a centrifugal pump (Bi­
omedicus Pump, Biomedicus, Min­
neapolis, Minn.). Use of the device 
was indicated in 11 patients who 
could not be weaned from cardi­
opulmonary bypass after open-heart 
surgical procedures, in 1 patient 
because of graft failure after or­
thotopic cardiac transplantation and 
in 1 patient because of cardiogenic 
shock after acute myocardial infarc­
tion.
All patients had refractory cardio­
genic shock before mechanical as­
sistance was instituted. This was 
defined as a cardiac index of less 
than 2.0 L/min-m~2 with a left or 
right atrial pressure, or both, great­
er than 20 mm Hg, a mean arterial 
pressure less than 60 mm Hg and 
urine output less than 20 m l/h 
despite maximal inotropic support, 
intra-aortic balloon counterpulsa­
tion, optimal pre-load and after-load 
and correction of metabolic abnor­
malities. In the pediatric population, 
refractory cardiogenic shock was 
characterized by persistent hypoten-
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sion, anuria or oliguria, poor pe­
ripheral perfusion and metabolic ac­
idosis despite elevated filling pres­
sures and maximal inotropic and 
vasodilator support.
In 10 patients, left ventricular 
support was used, with venous out­
flow from the left atrium and arteri­
al inflow into the aorta. In one 
patient, right ventricular support 
was used, with right atrial venous 
outflow and pulmonary arterial in­
flow. Two patients were essentially 
on cardiopulmonary bypass with ve­
nous outflow from the right atrium 
and arterial inflow into the aorta 
and with the use of a Biomedicus 
pump and membrane oxygenator.
The duration of support ranged 
from 3.5 hours to 9 days (mean 72 
hours). Flow rates were maintained 
at the highest rate afforded by the 
venous return. This ranged from 
1.0 to 5.0 L/min in adults (mean 3 
L/min) and 0.35 to 0.8 L/min for 
the two children. When hemostasis 
was secure after the surgical proce­
dure, activated coagulation times 
were maintained in the range of 
150 to 200 seconds using heparin. 
In eight patients, intra-aortic bal­
loon counterpulsation had been in­
stituted before the Biomedicus 
pump was inserted.
Attempts to wean the patient 
from ventricular support were 
begun when the patient’s cardiac 
index was greater than 2 
L/min*m~2 during temporary with­
drawal of the support.
Results
Six (46%) of the 13 patients 
could be weaned from ventricular 
assistance. All of them had left 
ventricular support — after coro­
nary artery bypass grafting in five 
and after extensive myocardial in­
farction in one. Five of the six 
patients also had an intra-aortic 
balloon pump in place.
Of the seven patients who could 
not be weaned from the ventricular 
support, one patient required right 
ventricular assistance after a repeat 
aortic valve replacement and coro­
nary artery bypass grafting; this 
patient died of right ventricular fail­
ure. One patient on cardiopulmo­
nary bypass after repair of the trun- 
cus arteriosus died of a cerebrovas­
cular accident. One patient was on 
cardiopulmonary bypass after or­
thotopic transplantation and had 
acute rejection of a second heart. 
One patient, who was on left ven­
tricular support after coronary ar­
tery bypass grafting, died of right 
ventricular failure. Another, on left 
ventricular support after repair of a 
double outlet right ventricle, also 
died of right ventricular failure. Of 
two others on left ventricular sup­
port after mitral valve replacement, 
one died of a cerebrovascular acci­
dent and the other of biventricular 
failure.
Complications were frequent. 
Bleeding occurred in six patients 
(46%). Renal failure occurred in 
three (23%); none survived. A docu­
mented cerebrovascular accident oc­
curred in three patients (23%); only 
one survived.
Five patients were discharged 
from the hospital. One patient, al­
though weaned from the device, 
died of low cardiac output 3 weeks 
later. This was the patient who 
suffered a large myocardial infarc­
tion and was considered too old for 
a heart transplant. One other pa­
tient died 8 months postoperatively 
of unknown cause.
Discussion
Much progress has been made in 
the field of mechanical ventricular 
assistance, ranging from intra-aort­
ic balloon pumping, prolonged car­
diopulmonary bypass and centrifu­
gal pumping to pneumatically driv­
en ventricles and use of artificial 
hearts.
The Biomedicus centrifugal 
pump uses the rotating motion of 
cones to accelerate the blood during 
its course between inlet and outlet 
ports of the pump, where rotational 
energy is recovered in the form of 
pressure-flow work. The pressure 
head created by the pump generates 
movement of blood. While operat­
ing at a given constant speed, the 
pump generates a nearly constant 
pressure over a wide range of flow 
rates. Power for the pumping action 
is transmitted via magnetic cou­
pling to the mated drive magnet 
which is fixed to the motor drive.1 
The Biomedicus pump can be used 
with little or no heparinization; it 
will not pump or suck air and will 
not pump against increased resist­
ance. The Biomedicus pump is also 
readily available, the cost is low and 
it is user friendly.
To be effective, a ventricular as­
sist device must aid the ventricle in 
maintaining a reasonable perfusion 
pressure and cardiac output for 
vital organ perfusion. It must in­
crease the myocardial oxygen sup­
ply or decrease myocardial oxygen 
consumption to make oxygen avail­
able to injured cells and reduce 
magnitude of myocardial injury. It 
must reduce pre-load to allow time 
to restore high-energy substrates, 
decrease edema and restore ade­
quate function.
Cardiogenic shock refractory to 
medical management carries an 
85% to 100% mortality.2 Intra-aort­
ic balloon pumping produces im­
provement in up to 75% of patients 
but can only be used if there is a 
reasonable amount of ventricular 
function remaining. Improvements 
in anesthesia, intraoperative myo­
cardial protection, pharmacology 
and surgical techniques have left 
only a small number of patients 
who cannot be weaned from cardi­
opulmonary bypass. In these pa-
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tients, optimal results may be ob­
tained if ventricular assistance is 
instituted when the period of isch­
emia is short. The recognition of 
cardiogenic shock, as previously de­
fined, should lead to the consider­
ation of ventricular assistance in 
patients considered to have revers­
ible ventricular dysfunction.
Problems associated with the use 
of ventricular assist devices include 
bleeding, inflow obstruction, renal 
insufficiency, infection and biven­
tricular failure.
Heparin may be reversed postop- 
eratively until hemostasis is se­
cured. Activated coagulation times 
may then be maintained in the 
range of 150 to 200 seconds with­
out thrombus forming in the cen­
trifugal pump. The role of antiplate­
let agents is still undetermined. In­
flow obstruction may be minimized 
by using a large cannula in the left 
atrium or left ventricle via the mi­
tral valve. A patent foramen ovale 
must be ruled out. The early use of 
arteriovenous ultrafiltration is im­
portant because of the frequency of 
renal insufficiency. Infection is also 
a potential problem because the 
cannulas must traverse the skin to 
the outside power supply. Right 
ventricular failure may not be rec­
ognized until left ventricular assis­
tance has been instituted. Biven­
tricular assistance should be consid­
ered if volume loading and adminis­
tration of Isuprel do not maintain 
adequate cardiac output.
Our results are similar to those 
reported in other series. Zumbro 
and colleagues3 reported a series of 
33 patients, in which 25 were sup­
ported by the Biomedicus pump and 
8 by the Pierce Donahey pump. Ten 
patients (30%) were discharged 
from the hospital. Complications 
were frequent; they included bleed­
ing in 36%, central nervous system 
deficits in 18%, sepsis in 30%, renal
failure in 61% and respiratory fail­
ure in 61%. There was a 30% 
incidence of biventricular failure.
Park and associates4 reported on 
41 patients supported by the Bi­
omedicus pump for periods ranging 
from 2 to 186 hours. Twenty-one 
patients (51%) were weaned from 
the pump and 13 (32%) were dis­
charged from the hospital. Death in 
most cases was the result of pro­
gressively decreasing cardiac func­
tion and multiorgan failure. Right 
ventricular support was used if the 
left ventricular assist device was 
incapable of producing a cardiac 
output greater than 1.8 L/min. 
Park and associates believed that 
nonpulsatile flow provided adequate 
support to preserve vital organ 
function.4 Schoen and associates5 
reported on 41 patients supported 
with a pulsatile pump. Eleven pa­
tients (27%) were weaned and 6 
patients (15%) were discharged 
from the hospital. The mean dura­
tion of ventricular assistance was 
62 hours. Most patients who died 
survived less than 30 hours on 
ventricular assistance. The presence 
of established myocardial necrosis 
itself did not preclude a favourable 
hemodynamic response or survival. 
Pae and colleagues6 reported that 
12 (48%) of 25 patients were 
weaned from the Penn State device 
and 9 (36%) were discharged from 
the hospital. Long-term survivors 
had an excellent quality of life with 
minimal cardiac disability. Kanter 
and colleagues7 reported 14 survi­
vors (23%) of 62 patients supported 
by the Pierce Donahey or Bi­
omedicus pump. There was a 67% 
rate of major complications in the 
survivors. Crippling cardiac disabili­
ty in survivors was unusual.
In summary, a number of pa­
tients who have undergone techni­
cally satisfactory open-heart proce­
dures experience cardiogenic shock.
Those with potentially reversible 
ventricular dysfunction may benefit 
from the use of temporary ventricu­
lar support with a mechanical de­
vice. The most effective and cost- 
efficient device and the indications 
and contraindications to the use of 
these devices have yet to be defined 
and require further study.
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium) 
a semi synthetic cephalosporin antibiotic, results from inhibition of cell wall 
synthesis.
Indications and Clinical Uses
Treatment: CLAFORAN (cefotaxime sodium) may be indicated for the treatment 
of infections caused by susceptible strains of the designated micro organisms 
in the diseases listed below.
Lower respiratory tract in fec tions : pneumonia and lung abscess caused by 
Streptococcus pneumoniae (formerly Diplococcus pneumoniae), other streptococci 
(excluding enterocci, e.g. S. taecalis), Straphylococcus aureus (penicillinase and 
non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella 
species (including K. pneumoniae), Proteus mirabilis, indole positive Proteus, Ser- 
ratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor­
rhea caused by N. gonorrhoeae including penicillin resistant strains 
B acterem ia /S e pticem ia : caused by Escherichia coli, unspecified Klebsiella 
strains and Serratia marcescens.
Skin in fec tions : caused by Staphylococcus aureus (penicillinase and non­
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli, 
Proteus mirabilis and indole positive Proteus.
Intra-abdominal in fec tions: caused by Escherichia coli, and unspecified Kleb­
siella species.
Gynecological in fec tions: including pelvic inflammatory disease, endometritis 
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus 
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostrep- 
tococcus strains and some strains of Bacteroides fragilis. In several cases, although 
clinical cures were achieved, bacteriological follow-up was not available. 
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN 
has been used with some success in wound and intra-abdominal infections against 
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas. 
In the treatment of infections encountered in immunosuppressed and granulo­
cytopenic patients, results of therapy with CLAFORAN have not been impressive. 
CLAFORAN should not be considered in the treatment of enterococcal infections, 
i.e. Streptococcus taecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order 
to isolate and identify the causative organisms and to determine their suscep­
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re-evaluated once these results 
become available.
Prophylactic U se : The administration of CLAFORAN perioperativety (preoperative 
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec­
tions in patients undergoing elective surgical procedures (eg. abdominal or vaginal 
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified 
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased 
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative 
use of CLAFORAN may also reduce the incidence of certain postoperative infections 
Effective use for elective surgery depends on the time of administration (see Dosage 
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation 
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin) 
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden­
tification of the causative organism so that appropriate therapy may be instituted. 
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to 
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics. 
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether 
the patient has had previous hypersensitivity reactions to cefotaxime, 
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution 
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including 
CLAFORAN should be administered with caution to any patient who has 
demonstrated some form of allergy, particularly to drugs. If an allergic reaction 
to CLAFORAN occurs, the drug should be discontinued and the patient treated 
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or 
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins 
(and other broad spectrum antibiotics); therefore, it is important to consider its 
diagnosis in patients who develop diarrhea during the administration of CLAFORAN. 
This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor­
mal flora of the colon and may permit overgrowth of Clostridium difficile or other 
Clostridia. It has been established that a toxin produced by Clostridium difficile 
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace­
ment with a suitable specific antibiotic. Moderate to severe cases should be manag­
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis 
is not relieved by discontinuance of CLAFORAN administration or when it is severe, 
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis 
(eg. vancomycin) or other suitable therapy may be indicated. Other possible causes 
of colitis should also be considered (see Averse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals 
with a history of lower gastrointestinal disease, particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently, 
use of the drug in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child-bearing potential requires that the anticipated 
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be 
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible 
organisms. Constant evaluation of the patient's condition is essential. If super­
infection occurs, therapy should be discontinued and appropriate measures taken. 
Although CLAFORAN rarely produces alterations in kidney function, evaluation 
of renal status is recommended, especially in severely ill patients receiving high 
doses.
Patients with markedly impaired renal function should be placed on the special 
dosage schedule recommended under Dosage and Administration, because nor­
mal dosage in these individuals is likely to produce excessive and prolonged serum 
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment 
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing 
substances but not with the use of specific glucose oxidase methods. 
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are: 
Hypersensitivity (1.8%); Rash, pruritus, fever. Local (5%): Injection site inflam­
mation with intravenous administration. Pain, induration and tenderness after in­
tramuscular injection. Gastrointestinal (1.7%): Colitis, diarrhea, nausea and 
vomiting. Symptoms of pseudomembranous colitis can appear during or after 
CLAFORAN treatment. Hem ic and Lymphatic System ( <  1%). Mild, reversi­
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some 
patients developed positive direct Coomb's test during treatment with CLAFORAN. 
Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient 
elevations in SGOT, SGFT, serum LDH and serum alkaline phosphatase levels 
have been reported. Kidney ( <  1%): Increased serum creatinine and BUN have 
occasionally been observed. Central Nervous System (0.2%): Headache. 
Symptoms and Treatment of Overdosage 
Since no case of overdosage has been reported to date with CLAFORAN, no 
specific information on symptoms or treatment is available. Treatment of over­
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in­
travenously after reconstitution (see Table with recommended mode of reconstitution 
according to route of administration).
Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative 
organisms, severity of the infection and condition of the patient.
Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated
Gonorrhea
1 1 g IM (single dose)
Uncomplicated
infections
2 1 g every 12 hours 
IM or IV
Moderately 
severe to severe 
infections
3-6 1-2 g every 
8 hours IM or IV
Very severe 
infections (e.g. 
septicemia)
6-8 2g  every 
6-8 hours IV
Life-threatening
infections
up to 12 2g  every 
4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated 
surgery, recommended doses are as follows.
(a) 1g IM or IV administered 1/2  to IV 2 hours prior to the initial surgical incision 
to ensure that adequate antibiotic levels are present in the serum and tissues 
at the start of surgery
(b) 1 g IM or IV administered 1V2 to 2 hours following the first dose; for lengthy 
operative procedures, additional intraoperative doses may be administered, if 
necessary, at appropriate intervals (IV2  to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period. 
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. 
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours 
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 m g/kg IV q 12 h
1-4 weeks of age 50 m g/kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, 
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid­
ed into 4 to 6 equal doses, or up to 180 m g /k g / day for severe infections. 
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72 
hours after the patient defervesces or after evidence of bacterial eradication has 
been obtained; a minimum of 10 days of treatment is recommended for infec­
tions caused by Group A beta-hemolytic streptococci in order to guard against 
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical 
appraisal is necessary during therapy of chronic urinary tract infections and may 
be required for several months after therapy has been completed; persistent in­
fections may require prolonged treatment. Doses less than those recommended 
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on 
sex, weight, and age of the patient) may be used to convert these values into 
creatinine clearance.
Males: Weight (kg) x  (140 -  age) Females: 0.85 x above value 
72 x  serum creatinine
Administration
Intramuscular: CLAFORAN should be injected well within the body of a relatively
large muscle such as the upper outer quadrant of the buttock (i.e. gluteus max- 
imus); aspiration is necessary to avoid inadvertent injection into a blood vessel. 
Intravenous: The intravenous route is preferable for patients with bacteremia, 
bacterial septicemia, or other severe or life-threatening infections, or for patients 
who may be poor risks because of lowered resistance resulting from such 
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, 
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be 
injected over a period of 3 to 5 minutes. Using an infusion system, it may also 
be given over a longer period of time through the tubing system by which the 
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type 
needles are preferred for this type of infusion. However, during infusion of the 
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad­
ministration of other solutions at the same site.
Reg’d TM of Abbott Laboratories.
Reconstitution
For Intramuscular U se : CLAFORAN should be reconstituted with Sterile Water 
for Injection or Bacteriostatic Water for Injection in accordance with the volumes 
recommended in the following table.
Reconstitution Table
Intramuscular
Volume to be 
Added to 
Vial (mL)*
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial 2 2 .2 230
1 g vial 3 3.4 300
2 g vial 5 6.0 330
’ shake to dissolve.
For direct intravenous injection (bolus) a n d /o r  continuous intravenous 
in fus ion : 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL 
of Sterile Water for Injection, Reconstituted solution may be further diluted with 
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table
Intravenous
Volume to be 
Added to
Vial (mL)*
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 mg vial 10 10.2 50
1 g vial 10 10.4 95
2 g vial 10 11.0 180
’ shake to dissolve.
Solutions for IV In fus ion : CLAFORAN is compatible with the following infu­
sion fluids:
-  Sterile Water for Injection
-  0.9% NaCI injection
-  5% dextrose injection
- 0.9% NaCI and 5% dextrose injection
- 0.45% NaCI and 5% dextrose injection
- 0.2% NaCI and 5% dextrose injection
- Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer's injection
-  Lactated Ringer's solution
- Lactated Ringer’s with 5% dextrose injection 
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic. 
S tability of Solution
S torage: Solutions of CLAFORAN range from light yellow to amber, depending 
on concentration and the diluent used. The solutions tend to darken depending 
on storage conditions and should be protected from elevated temperatures and 
excessive light.
’ ’ Reg’d TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution 
maintains satisfactory potency for 24 hours at room temperature (25°C) and for 
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu­
tions may be further diluted with 50 to 1000 mL of the recommended infusion 
fluids in Viaflex”  intravenous bags. Such solutions maintain satisfactory poten­
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration 
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for 
up to 24 hours at room temperature and 48 hours under refrigeration (reference 
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special Instructions; Parenteral drug products should be inspected visually 
for particulate matter and discoloration prior to administration. Solutions of 
CLAFORAN range from light yellow to amber, depending on concentration and 
diluent used. The dry powder as well as solutions tend to darken, depending 
on storage conditions.
Incom patib ilities; Solutions of CLAFORAN must not be admixed with 
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad­
ministered to the same patient, they must be administered separately and not 
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above 
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, 
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as 
acid on a dry basis).
S torage: CLAFORAN in the dry state should be stored at room temperature, 
protected from light and heat.
Product monograph available on request 
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Lithotripsie des calculs biliaires: 
evaluation de l’ultrasonographie comme 
moyen de diriger le traitement par ondes 
de choc extracorporelles
Yves-Marie Dion, MD, FRCSC;* Jacques Morin, MD, FRCSC;* Bruno Laroche, MD, FRCSC;t 
Gilles Robert, MD, FRCSC;t Michel Thabet, MD, FRCSCt
La lithotripsie des calculs biliaires par ondes de choc extracorporelles est une 
procedure recemment developpee qui serait une alternative au traitement chirurgical 
de la cholelithiase symptomatique. Selon la litterature, 15% a 25% des personnes 
symptomatiques seraient candidates a cette procedure si elle est prouvee efficace. 
Presentement, l’echographie semble un des meilleurs moyens devaluation et de 
suivi durant la procedure de lithotripsie. Les auteurs ont mis au point un modele in 
vitro qui permet de comparer les evenements qui surviennent dans le modele 
experimental et ce qui est en meme temps note a l’echographie. Les caracteristiques 
echographiques des differentes phases de la lithotripsie des calculs biliaires sont 
presentees.
Extracorporeal shock-wave lithotripsy is a procedure recently introduced to treat 
gallstone disease. According to the literature, 15% to 25% of symptomatic persons 
will be candidates for this procedure if it proves effective. Currently, sonography is 
one of the best methods for monitoring the performance of lithotripsy. The authors 
have confirmed this. They have designed an in-vitro model which allows comparison 
between what is actually happening during gallstone lithotripsy and what is being 
seen by real-time sonography. The sonographic characteristics of the different 
phases of gallstone lithotripsy are presented.
L ’idee de la lithotripsie par ondes de choc extracorporelles a evol- 
ue a partir des observations faites 
par un groupe de physiciens qui 
travaillaient sur les effets produits 
par des nuages de pluie a travers 
lesquels passaient des avions super- 
soniques et sur les effets de petits 
meteorites qui frappaient des satel-
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lites.1 Ils ont note que les gouttes 
d’eau et autres petites particules 
generaient des ondes de choc qui 
causaient des dommages, non seule- 
ment a la surface, mais aussi a 
l’interieur de ces vehicules.1 C’est 
ainsi qu’en 1974, le premier projet 
de recherche a visee medicale voyait 
le jour en Allemagne, avec comme
hypothese que les calculs renaux 
pouvaient etre detruits par des 
ondes de choc extracorporelles.1 
Depuis, plus de 60 000 patients ont 
ete traite avec succes, cette tech­
nique etant applicable a 80% de 
tous les patients porteurs de calculs 
renaux.1 En 1983, Brendel et En- 
ders1 etudierent les effets de la 
lithotripsie par ondes de choc ex­
tracorporelles sur les calculs bi­
liaires humains implantes dans les 
vesicules biliaires de chiens. En 
fevrier 1988, les resultats d’une 
etude clinique etaient publies.2 Les 
auteurs rapportent un taux de 
succes de 91%, 18 mois apres la 
lithotripsie qui est combinee a un 
traitement aux acides chenodesoxy- 
choliques et ursodesoxycholiques. 
Recemment, un article faisait le 
point sur les resultats obtenus a ce 
jour et sur les questions sur le 
sujet, qui demeurent sans reponse 
actuellement.3 Cependant, apres 
avoir consulte la litterature, nous 
n’avons note aucun article decrivant 
la procedure de lithotripsie. Nous 
rapportons notre experience suite a 
la fragmentation in vitro de 15 
calculs biliaires.
Materiel et methode
Le lithotripteur utilise est l’appa- 
reil de seconde generation EDAP
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LT-01. Les ondes de choc sont 
emises par des ceramiques qui tapis- 
sent le fond d’une coupelle. Cette 
coupelle est recouverte d’une mem­
brane qui est mise en contact avec 
le modele experimental grace a un 
gel conducteur (fig. 1). Le modele 
experimental consiste en une cuvet­
te dont la base est recouverte d’une 
membrane de meme type que la 
coupelle. Deux litres et demi d’eau 
sont places dans cette cuvette. Par 
la suite, un sac de fine polythene, 
dans lequel ont ete precedemment 
places 75 ml d’eau et le calcul, est
FIG. 1. Coupelle (longues fleches) de 
l’appareil EDAP LT-01, recouverte 
d’une membrane (courtes fleches) sur 
laquelle se trouve le modele experi­
mental.
insere dans la cuvette (fig. 2). La 
cadence des ondes de choc a ete 
etablie a 20 coups/s. Ensuite, le 
calcul est repere echographique- 
ment et les ondes de choc sont 
mises au foyer au niveau du calcul 
grace a un curseur qui apparait sur 
l’appareil echographique (fig. 3). 
Quinze calculs biliaires de taille, de 
forme et de composition differentes 
ont ete soumis a la lithotripsie. Les 
caracteristiques echographiques qui 
seront mentionnees sont le fruit de 
ces experiences. En vue de demon- 
trer la sequence des evenements 
lors de la lithotripsie, les figures 
suivantes proviennent d’une seance
FIG. 2. Modele experimental fait d’une 
cuvette dont la base est recouverte 
d’une membrane permeable aux ondes 
de choc. Le calcul a ete place au fond 
d’un sac dont la dimension se compare 
a celle de la vesicule biliaire normale.
effectuee sur un calcul mixte, a 
facettes, mesurant 1.6 cm dans son 
plus grand diametre et pesant 1.41 
g. Une fois l’image echographique 
jugee satisfaisante en debut de pro­
cedure, les caracteristiques echogra­
phiques n’ont pas ete modifiees.
Resultats
Avant le debut de la lithotripsie, 
le calcul est bien demontre par 
echographie (fig. 4). Les parois du 
petit sac de polythene que nous 
appellerons “vesicule biliaire” sont 
bien visibles; le calcul situe au fond 
de la “vesicule biliaire” est bien 
demontre ainsi que le cone d’ombre 
sus-jacent. Quelques minutes apres 
le debut de la lithotripsie, 1’elargis- 
sement du cone d’ombre est demon­
tre, ce qui temoigne du debut de la 
fragmentation du calcul. En effet, 
les fragments se deposent au pour- 
tour du calcul creant cet elargisse- 
ment du cone. Le calcul est tou- 
jours visible a la base du cone 
d’ombre (fig. 4). Par la suite, a 
l’echographie, la “vesicule biliaire” 
devient de moins en moins echo- 
genique. En effet, elle semble se 
remplir de materiel qui la rend plus
FIG. 3. Elargissement du cone d’ombre (longues fleches), 
temoin du debut de la fragmentation du calcul. Le curseur 
(petites fleches) indique l’endroit ou les ondes de choc 
convergent.
FIG. 4. Echographie du calcul biliaire demontrant le calcul 
(petites fleches) et le cone d’ombre sus-jacent (longues 
fleches). Le calcul se trouve au fond de la “vesicule biliaire” 
(fleches larges).
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opaque sur l’image. Ce phenomene 
correspond au developpement dans 
la “vesicule biliaire” d’un nuage de 
poussiere bilieuse verdatre (fig. 5). 
Plus tard, on note que le cone 
d’ombre s’amenuise (fig. 6) dans 
une “vesicule biliaire” qui devient 
de plus en plus opaque, c’est-a-dire, 
dans laquelle le nuage de poussiere 
est devenu plus dense. Le retrecis- 
sement du cone d’ombre confirme la 
disintegration progressive du cal- 
cul. Dans les dernieres minutes 
precedant la fin de l’intervention, on 
procede a un balayage echographi- 
que de la “vesicule biliaire” a la 
recherche de cones d’ombre resi-
duels (fig. 7). Ces endroits ou Ton 
note de petits cones d’ombre sont 
par la suite soumis a l’effet des 
ondes de choc en vue de desintegrer 
les fragments le plus possible. On 
note simultanement, au niveau du 
modele experimental, que ces frag­
ments de 4 a 6 mm de diametre 
devenus legers par la fragmentation 
vont et viennent dans la zone de 
turbulence creee par les ondes de 
choc. On note parallelement, a l’e- 
chographie, l’apparition et la dispa- 
rition alternative des petits cones 
d’ombre correspondant a ces frag­
ments (fig. 7).
L’indication echographique de la
fin de la procedure nous apparait 
demontree de deux faqons. La pre­
miere consiste en la visualisation 
d’une vesicule biliaire completement 
opacifiee par les fragments en sus­
pension avec absence de cone d’om­
bre (fig. 8). Cette image indique que 
la quantite de matieres en suspen­
sion rend l’echographie inapte a 
visualiser les calculs residuels, s’il 
en demeure. Cependant, comme 
nous l’avons note, cette image, lors- 
qu’elle est combinee a l’effet de 
balayage des ondes de choc, devient 
tres suggestive que les fragments 
restants sont de petite taille.
L’autre image echographique ap-
FIG. 5. “Vesicule biliaire” est plus echogenique (fleches) due 
a une suspension calculeuse qui la remplie peu a peu.
FIG. 6. Le cone d’ombre s’amenuise (fleches) dans “vesicule 
biliaire” de plus en plus echogenique.
FIG. 7. Balayage de la vesicule biliaire a la recherche d’un 
petit cone d’ombre (fleches). Ces cones d’ombre apparaissent 
et disparaissent, etant projetes sous l’effet des ondes de choc.
FIG. 8. Aspect final de la “vesicule biliaire” et de son contenu 
(fleches) a la fin de la lithotripsie. Elle est completement 
impermeable aux ultrasons sans evidence de cone d’ombre.
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paraissant demontrer la fin de la 
procedure se voit le plus souvent 
dans le cas de calculs de plus grand 
diametre, c’est-a-dire au-dela de 1 
cm. En effet, la quantite de debris 
non en suspension demeurant au 
fond de la “vesicule biliaire” est 
plus grande et ceux-ci s’etalent a 
l’endroit le plus declive, ce qui 
cause l’elargissement du cone d’om- 
bre (fig. 9). Cependant sous le cone 
d’ombre, il n’y a pas de calcul 
identifiable. Lorsque les ondes de 
choc sont dirigees a ce niveau, on 
peut noter a l’echographie la pous- 
siere et les petits fragments qui 
s’elevent dans le cone d’ombre 
temoignant de leur petite taille.
Discussion
La lithotripsie des calculs biliaires 
est presentement le sujet de beau- 
coup d’interet. Plusieurs etudes ont
demontre la possibilite de desinte- 
grer les calculs par cette techni­
que.4-8 D’autres articles ont fait etat 
de la fragmentation de calculs biliai­
res situes non seulement au niveau 
de la vesicule biliaire mais aussi 
dans le choledoque et en position 
intra-hepatique.910 Quinze pourcent 
a 20% des patients presentant des 
crises de coliques hepatiques se- 
raient candidats a cette procedure si 
elle est prouvee efficace.4
A notre connaissance, la literatu­
re actuelle n’indique pas de fagon 
claire comment suivre la progres­
sion de la lithotripsie des calculs 
biliaires. Notre etude in vitro nous a 
permis de mettre en correlation les 
evenements survenant au niveau du 
modele experimental et leur trans­
position echographique. Nous 
avons constate que l’echographie 
permet de determiner avec justesse 
les phases de la disintegration des 
calculs. Etant donne que l’echogra-
phie donne les informations en deux 
plans, ils revient a l’operateur de 
manipuler l’appareil dans le troi- 
sieme plan (profondeur) de fagon a 
visualiser tout le contenu de la 
vesicule biliaire. Une fois l’image 
echographique du calcul ou du 
fragment obtenue, les ondes de 
choc sont dirigees vers la cible 
grace a un curseur qui apparait sur 
l’image echographique.
En resume, l’echographie s’est 
revelee un moyen efficace de suivre 
la procedure de lithotripsie au ni­
veau de notre modele experimental.
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Effects of High-Dose Ketoconazole on 
Patients Who Have Androgen-Independent 
Prostatic Cancer
T. Eichenberger, MD;* J. Trachtenberg, MD, FRCSCt
Forty-four patients who had metastatic cancer of the prostate that had not responded 
to conventional hormonal manipulation were treated with high-dose ketoconazole 
(600 to 1200 m g/d). All had castrate serum concentrations of testosterone prior to 
therapy. All patients had been categorized as having progressive cancer on 
assessment by the criteria of the National Prostatic Cancer Project. After treatment 
with ketoconazole, 57% were recategorized as having stable disease. The majority 
showed marked subjective lessening of pain on this therapy. Objective responses 
were noted but were not consistent. Side-effects were common but tolerable. The 
mean survival time was 73.3 weeks. Ketoconazole may be a useful palliative adjunct 
in the treatment of hormone-refractory prostatic cancer.
Quarante-quatre patients porteurs de cancers metastatiques de la prostate qui 
n’avaient pas repondu aux manipulations hormonales habituelles, ont ete traites 
avec de fortes doses de ketoconazole (600 a 1200 mg/j). Tous avaient des taux de 
testosterone serique nuls avant le traitement. Tous les patients avaient ete classifies 
selon les criteres du Projet national sur le cancer de la prostate comme ayant un 
cancer en evolutif. Apres traitement au ketoconazole, 57% des patients ont ete 
reclassifies comme ayant une maladie stable. La majorite a manifesto une attenuation 
subjective marquee de la douleur grace a cette therapie. Des reponses objectives ont 
ete observees, mais elles n’etaient pas constantes. Les reactions adverses ont ete 
frequentes mais tolerables. Le temps de survie moyen a ete de 73.3 semaines. Le 
ketoconazole peut etre un traitement palliatif d'appoint utile dans les cas de cancers 
de la prostate hormono-resistants.
P rostatic cancer is the second most common cause of death 
due to malignant disease in North 
American men and in the majority 
the disease is advanced at the time 
it is discovered.1’2 Although the
disease is considered to be andro­
gen-dependent, only about two- 
thirds of patients who receive thera­
py designed to lower concentrations 
of androgen (castration or the ad­
ministration of estrogens) obtain a
remission of notable duration. In 
spite of an initial response, most 
patients relapse and die. No single 
agent or combination of agents has 
so far provided substantial benefit 
to patients with advanced prostatic 
cancer.3
Ketoconazole, a synthetic imida­
zole dioxolane, is widely used to 
treat superficial and deep fungal 
infections. In man the action of 
ketoconazole is poorly understood. 
The drug appears to interfere with a 
wide variety of cytochrome P450- 
linked enzyme systems. Recent 
studies4 5 have demonstrated that at 
high doses ketoconazole can rapidly 
and profoundly inhibit both adrenal 
and testicular androgen production 
by inhibiting 17,20-desmolase, an 
enzyme that is P450-dependent. 
These changes in steroidogenesis 
are reversible by withdrawal of ther­
apy.6 Reports of patients with previ­
ously untreated advanced prostatic 
cancer who are given ketoconazole 
describe a rapidly induced and sus­
tained clinical remission accompa­
nied with a sustained decrease in 
serum testosterone and adrenal an­
drogen levels.7 In the course of 
treating such patients we have also 
noted a marked salutary effect of 
ketoconazole on patients who had 
relapsed while receiving a variety of 
forms of hormonal therapy.8 Indeed, 
other investigators have noted simi­
lar effects and suggested that keto­
conazole may have a role to play in 
the treatm ent of androgen-
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independent prostatic cancer.9 In 
this study we attempted to define 
more precisely the role of ketocona- 
zole in the treatment of patients 
who have this disease.
Patients and Methods
Forty-four patients who had biop­
sy proven metastatic prostatic can­
cer were treated at eight centres 
across Canada. The average age 
was 69.9 ±  9.1 years (mean ± 
SEM) (range from 48 to 84 years). 
All had failed to respond to hor­
monal therapy which had reduced 
their serum testosterone concentra­
tion to the castrate level. The previ­
ous treatments are shown in Table 
I .
All patients gave their informed 
consent and were administered ke- 
toconazole in 200-mg tablets at a 
recommended dosage of 200 to 400 
mg every 8 hours (to maintain a 
maximum concentration of 5 to 10 
jig/ml). The dose was adjusted by 
serum ketoconazole levels and the 
occurrence of side-effects. The pa­
tients continued on their original 
hormonal therapy. No patient re­
ceived supplemental glucocor­
ticoids. Patients were allowed to 
continue taking additional medica­
tion needed to control pain or con­
current illnesses. They were seen 
weekly for the first month and 
monthly thereafter. At each visit a 
complete history was obtained, and 
they underwent physical examina­
tion and extensive biochemical 
work-up; all adverse experiences 
were reported and each patient was 
rated on a five-point abbreviated 
Karnofsky performance scale (0 to 
4), where 4 represents maximum 
performance, and a six-point pain 
scale (0 to 5), where 0 represents 
no pain. At 3-month intervals bone 
scanning was repeated.
The patient’s response to therapy 
was assessed using the criteria of
the National Prostatic Cancer Pro­
ject (complete regression, partial 
regression, stable or progression). 
Each patient’s duration of “benefit” 
was calculated as the time from the 
initiation of benefit to the first 
evidence of recurrent progression. 
The time during which the group 
benefited from ketoconazole was 
subjected to a “survival” analysis 
using the Kaplan-Meier method10 to 
estimate the percentage of patients 
still on therapy at each week of the 
trial. The duration of ketoconazole 
therapy was calculated as the differ­
ence between the date the patient 
first started therapy and the date on 
which he was last confirmed to be 
still on therapy. In many cases this 
was the last recorded visit.
Results
Patients who entered this clinical 
trial were generally debilitated, be­
cause the treatment was considered 
as salvage therapy. The laboratory 
values were quite variable and often 
far outside the normal range. Many 
patients were too ill either to attend 
every required visit or to have labo­
ratory work done. Thus, the data 
for laboratory values were not nec­
essarily complete for every sched­
uled patient visit over the course of 
the study.
Twenty-seven patients demon­
strated persistent (more than 8 
weeks or three visits) improvement 
in serum prostatic acid phosphatase 
and alkaline phosphatase levels dur­
ing therapy, with decreases of more
than 75%. No statistically signifi­
cant changes, however, were noted 
for these two values in the group as 
a whole, although the values during 
treatment were generally lower than 
those before. This lack of signifi­
cance may be attributed to the 
extremely wide variance in these 
levels before treatment. No signifi­
cant changes were noted in markers 
of hepatic function or in serum 
cortisol levels. In one patient the 
bone scan became normal and mul­
tiple “hot” areas were eliminated 
and two patients had marked im­
provement in their bone scans.
The performance ratings showed 
little change. The majority of the 
patients maintained scores in the 1 
and 2 range for the first 12 weeks: 
76.7%, 75.7%, 81.2%, 84.8%,
79.3% and 71.4% for weeks 0, 1, 2, 
4, 8 and 12 respectively. Beyond 
week 12 the data became less relia­
ble because of the small number of 
patients (11 [25%] or fewer from 
week 16 onward). Performance 
scores in the range of 1 and 2 
remained stable.
Pain scores, on the other hand, 
demonstrated a strong decrease 
with therapy. The percentage of 
patients with scores of 1 or less 
increased from 18.5% at the begin­
ning of the study to 76.2% by week 
12 (Fig. 1), with a corresponding 
decrease in analgesic consumption.
On entering this trial, all patients 
had progressive disease. During 
their treatment with ketoconazole, 
25 (57%) patients were recatego­
rized as having stable disease. Thir­
teen patients showed no benefit
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E strogen (d ie th y ls t ib e s tro l 3  m g /d ) 10
L h rh  ana logues (L u p ro n  1 m g /d ) 4
O rch ie c to m y  o r  Lh rh  a n a lo g u es  +  a n tia n d ro g e n s * 14
L h rh  =  lu te in iz in g  h o rm o n e -re le a s in g  h o rm on e .
‘ F lu tam ide  2 5 0  m g  t id  o r A na n d ro n  100  m g tid .
T h e  se rum  te s to s te ro n e  leve l o f  a ll p a tie n ts  w as in  th e  ca s tra te  range 
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from ketoconazole, 1 had complete 
regression and 5 partial regression. 
The mean time of benefit on thera­
py was 27.3 weeks (median 12 
weeks). No significant difference in 
duration of response could be found 
between the 30 patients who had 
been treated with conventional 
forms of androgen ablation and the 
14 patients in whom total androgen 
ablation failed. The mean time on 
ketoconazole therapy analysed by 
the Kaplan-Meier product limit 
method was 35.5 weeks (mean 22.0 
weeks, range from less than 1 week 
to 96 weeks).
Side-effects were frequent in this 
already debilitated group. Thirty- 
two patients (72.7%) reported at 
least one adverse experience and 29 
(65.9%) of them reported experi­
ences that were possibly drug relat­
ed. There were 23 reports (given by 
19 patients) of nausea, vomiting 
and gastrointestinal upset, of which 
22 were considered possibly drug 
related; there were 9 reports of 
weakness, fatigue and lethargy (7
possibly drug related). In all of 
these patients, the serum cortisol 
level was within normal limits. 
Seven (15.9%) patients were taken 
out of the study because of illness 
(two patients) or adverse experience 
(five patients).
Eighteen patients died of disease- 
related causes. The mean time to 
death was 59.1 weeks (median 73.3 
weeks, range from 2 to 100 weeks).
Discussion
To our knowledge this study rep­
resents the largest series of patients 
treated by high-dose ketoconazole 
after the failure of hormonal thera­
py. The design was that of a single­
armed non-controlled trial. Thus, all 
conclusions must be viewed with 
caution until they can be substanti­
ated in controlled studies. None the 
less, we believe that certain assump­
tions are warranted. The patients 
were all severely ill with progres­
sing disease at the time of entry
into this study, yet a large percent­
age of patients demonstrated a 
marked lessening of pain and stabi­
lization of their disease. Although 
the latter is often difficult to sub­
stantiate because of the variable 
rate at which the disease pro­
gresses, these patients did seem to 
benefit, since their condition ap­
peared to stabilize, if only for a 
short time. The objective responses 
that were seen in some of the 
patients seem to add further sup­
port to the belief that ketoconazole 
provides more than just a placebo 
effect.
Ketoconazole not only interferes 
with testosterone production but 
also greatly decreases adrenal an­
drogen production.58 The patients 
who responded in this study, how­
ever, were similarly divided between 
those who received only conven­
tional testicular androgen ablation 
and those who had been subjected 
to total androgen ablation. These 
data suggest that ketoconazole’s 
mechanism of action may be di­
vorced from androgen activity. Not 
only has the product been shown to 
affect androgen synthesis but it also 
directly impairs the growth of 
human prostatic cancer cells in vi­
tro.11 In these studies the androgen- 
independent human prostatic cancer 
cell lines PC-3 and DU-145, when 
incubated with ketoconazole, 
showed decreased growth from 70% 
to 96% at the clinical concentra­
tions of 1.0 to 10.0 /ug/ml. Other 
agents thought to be of use in this 
clinical situation, such as amino- 
glutethimide, did not demonstrate 
similar cytotoxicity. We believe that 
this direct cytotoxicity of ketocona­
zole may be active in the responses 
of these patients. Indeed, the even­
tual cessation of benefit could be 
predicted by the incomplete inhibi­
tion of growth even at the highest 
ketoconazole concentration (which 
was only intermittently achieved). 
The duration of benefit was difficult
FIG. 1. Changes in pain score of patients treated with high-dose ketoconazole 
during initial 12 weeks of therapy. Values represent percentage of patients with 
pain scores of 0 or 1. Pain was rated from 0 to 5 (0 =  no pain).
►
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to quantify, probably because the 
patients were extremely ill and en­
tered the trial only as a last chance 
at salvage. None the less, the dura­
tion of survival is comparable if not 
superior to that reported from other 
similar trials.12 Historical controls 
are usually misleading, but ketoco- 
nazole may impart a small survival 
advantage. We also believe that the 
decrease in pain is significant and 
markedly improved the quality of 
life for many of the patients. Al­
though side-effects were common, 
they were rarely severe enough to 
limit treatment and were milder 
than those experienced by patients 
in a similar stage of disease when 
treated with estramustine phos­
phate or conventional cytotoxic reg­
imens (Koenyves I: Personal com­
munication, 1987). We believe that 
further trials should be undertaken 
to determine more precisely the role 
of ketoconazole in patients with 
advanced prostatic cancer. Experi­
mental in-vitro data further suggest 
that the cell destruction of certain 
classic cytotoxic agents can be in­
creased appreciably with the con­
comitant administration of ketoco­
nazole.13 If this can be substantiat­
ed, then ketoconazole may not only 
play a role as a palliative agent, but 
also as an important adjunct in the 
treatment of patients with far- 
advanced prostatic cancer.
We thank Drs. Orovan, Stogryn, Keat­
ing, Sales, Lommersee, Hussey and Bry­
son who contributed patients to this 
study and Dr. A. Raoult and Mrs. S. 
Lund of Janssen Pharmaceutica Canada 
for their encouragement for this proj­
ect. Janssen Pharmaceutica Canada do­
nated ketoconazole and provided finan­
cial support.
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Destructive Arthropathy of the Hip 
Following Pelvic Irradiation: Report of 
Four Cases
T.W. Phillips, BASc, MD, FRCSC;* D.R. Rao, MB, BS, MS(Orth)t
The replacement of orthovoltage by megavoltage radiotherapy has facilitated 
selective ablation of cancerous tissue, resulting in less toxicity to bone. However, 
damage to bone still occurs and may be more common than generally appreciated. In 
four women, all treated for adenocarcinoma of the reproductive tract, radiotherapy 
was believed to contribute to acetabular failure and secondary arthritis 2 to 31 years 
after treatment. In one case the condition was bilateral.
Because arthritis of the hip is now common in women, there is a risk that unusual 
and remote factors may not be recognized or fully appreciated. In these cases 
prosthetic joint replacement is likely to fail. Special techniques, including bone 
grafting, peripheral support rings, well-fixed and optimally placed sockets and 
gradual rehabilitation, are mandatory.
En radiotherapie, le remplacement de i’orthovoltage par le megavoltage a facilite 
l'ablation selective des tissus cancereux, reduisant ainsi la toxicite osseuse. 
Neanmoins, des dommages osseux surviennent encore, et ils sont possiblement plus 
frequents qu’on ne le pense generalement. On croit que, chez quatre femmes qui 
avaient ete traitees pour des adenocarcinomes des organes reproducteurs, la 
radiotherapie a contribue a un affaissement acetabulaire et a une arthrite secondaire 
apparue de 2 a 31 ans apres le traitement. Dans un cas, l’atteinte etait bilaterale.
Parce que l’arthrite de la hanche est devenue commune chez la femme, il y a 
risque que des facteurs inhabituels ou lointains ne soient pas reconnus ou apprecies 
a leur juste valeur. Dans ces cas, les arthroplasties sont susceptibles d’etre vouees a 
l’echec. Des techniques speciales telles que greffes osseuses, anneaux de soutien 
peripherique, cavites articulaires solidement fixees en position optimale et readapta­
tion graduelle sont obligatoires.
O steoradionecrosis is a well- recognized entity, affecting 
most areas of the skeleton. The 
femoral neck has been one of the
Accepted for publication May 15, 1989
most common locations for second­
ary fracture.1 Acetabular failure and 
protrusio have been described in 
eight patients.2-4 In only one recent
report2 have the pitfalls of recon­
structive arthroplasty been dis­
cussed.
In this paper we describe four 
patients in whom the condition at 
first appeared to be standard arthri­
tis of the hip. However, radiologi- 
cally the arthropathy appeared 
more destructive than usual. It was 
discovered that all patients had un­
dergone radiotherapy. All had also 
had recurrent problems from radia­
tion cystitis, urethritis or proctitis.
Case Reports
Case 1
In 1977, at the age of 68 years, 
this woman underwent a total hys­
terectomy and bilateral salpingo- 
oophorectomy for adenocarcinoma 
of the uterus. Postoperatively, she 
received external pelvic irradiation 
(50 Gy in 20 fractions over 5 
weeks) using 33 mev x-rays, 50% of 
the total dose from the anterior 
field and 25% from each of the 
lateral fields. A scout film obtained 
at the cancer clinic before radiother­
apy showed that both hips were 
normal (Fig. 1).
In 1983 this woman was seen 
complaining of a painful right hip. 
A fracture of the medial wall and 
secondary arthritis were found (Fig. 
2). A right hip replacement arthro­
plasty was performed. The medial 
acetabular wall was found to be
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fractured, eroded and chalk-like, 
and was poorly vascularized. A fem­
oral head autograft was used to 
augment the medial wall. A cement­
less Moore-type femoral stem with a 
Bateman bipolar head was implant­
ed. Seven months later the right 
side was asymptomatic but she had 
severe pain in the left hip due to a 
fracture of the medial acetabulum 
with protrusio acetabuli (Fig. 3). 
This hip was also reconstructed 
using a cementless bipolar prosthe­
sis with medial bone grafting. She 
did well until June 1985 when she 
again began to suffer pain in the 
left hip. X-ray films showed protru­
sion of the prosthetic head into the 
pelvis with a lack of consolidation 
of the medial acetabular fracture 
(Fig. 4). The bipolar head was re­
moved and the medial wall further 
grafted, this time with an iliac crest 
autograft from outside the radiation 
field. An Eichler peripheral support 
ring was positioned over the graft 
and fixed to the rim of the acetabu­
lum with cancellous bone screws. A 
polyethylene prosthetic socket was 
cemented inside this. In March
FIG. 1. Case 1. Taken before radio­
therapy, x-ray with marking grid 
shows acetabular walls inside radiation 
field. Iliac bone-graft donor sites are 
outside field.
1986, a complete transverse frac­
ture of the pelvis was noted on 
follow-up x-ray films (Fig. 5). This 
was also revised with medial bone 
grafting and a cemented socket in­
side a peripheral support ring. Two 
years after this she was doing well 
(Fig. 6), but in late 1988 her condi­
tion deteriorated with recurrence of 
right hip pain and progressive loos­
ening of the prosthesis.
Case 2
In 1981, this 71-year-old woman 
underwent a total hysterectomy and 
bilateral salpingo-oophorectomy for 
adenocarcinoma of the uterus. Post- 
operatively, she received 50 Gy in 
20 fractions over 4 weeks on 6 mev 
Therac — four fields with equal 
weighting. In January 1984, she 
presented with a very painful right 
hip. X-ray films showed a fracture 
of the acetabulum and arthritis
FIG. 2. Case 1. Medial acetabular frac­
ture, protrusio and early degenerative 
changes of right hip. Left hip appears 
normal.
FIG. 3. Case 1. Medial acetabular frac­
ture on left side similar to right 7 
months before. Right bipolar replace­
ment doing well.
(Fig. 7). Roentgenograms obtained 
2 months earlier had revealed a 
fracture of the medial wall of the 
acetabulum but a normal joint 
space. A right hip replacement was 
performed using a cementless bipo-
FIG. 4. Case 1. Left bipolar head has 
migrated into pelvis 2 years after sur­
gery.
FIG. 5. Case 1. Nine months after 
revision of left arthroplasty with exten­
sive medial grafting, peripheral sup­
port ring and cemented components. 
Acetabulum on right side shows com­
plete transverse fracture of medial wall 
(arrow).
FIG. 6. Case 1. After revision on both 
sides, 2 years on right side and 3 years 
on left.
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lar prosthesis and grafting with 
autogenous femoral head exactly as 
in case 1. Examination of the re­
trieved acetabular fragments re­
vealed several areas of grey-brown 
discolouration and pitting in the 
articular cartilage, and a weakened, 
chalk-like bone structure. On mi­
croscopic examination there were 
irregular areas of thickened trabec­
ulae, loss of osteocytes and evi­
dence of bone necrosis. At recent 
4-year follow-up the patient walks 
well, shops and continues living
FIG. 7. Case 2. Preoperative x-ray film 
showing fracture of medial acetabular 
wall (arrow). Joint space was present 2 
months before when fracture was first 
detected.
independently in her apartment. 
X-ray films show no migration or 
protrusio of the acetabular cup, and 
the acetabular fracture has united.
Case 3
In 1976, at 39 years of age, this 
woman underwent a total hysterec­
tomy and bilateral salpingo- 
oophorectomy for adenocarcinoma 
of the uterus. Preoperatively, she 
received intracavitary radium, 45 
mg intrauterine and 20 mg in- 
travaginal, for 72 hours for an 
estimated total dose of 50 Gy to the 
uterus. An estimated 15 Gy was 
delivered to each hip joint. Four 
years earlier, she had also received 
radiotherapy for stage III Hodgkin’s 
disease. The subdiaphragmatic por­
tion of this was in the form of 35 
Gy in 20 fractions over 4 weeks 
using cobalt-60 and an inverted Y 
field with central pelvic shielding 
but with both hip joints in the field. 
The total cumulative dose of all 
previous exposures to the acetabu­
lum had been estimated by the 
cancer clinic as 50 Gy.
She presented in 1985 with an 
exceedingly painful and destructive
FIG. 8. Case 3. Preoperative x-ray film showing marked erosion of acetabulum and 
superior migration of femoral head.
arthropathy of her right hip (Fig. 
8). A cementless porous-surfaced 
femoral stem with a Bateman bipo­
lar head was implanted, after graft­
ing the superior acetabular deficien­
cy with bone from the resected 
femoral head and medializing the 
acetabular socket. Intraoperatively, 
the acetabulum and femoral head 
were found to be dystrophic and 
fragmented with areas of avasculari- 
ty and necrosis. Three weeks later 
the head of the prosthesis broke 
through the acetabulum. A cement­
ed polyethylene acetabular compo­
nent was inserted and reinforced by 
tricortical bone graft harvested 
from the ipsilateral iliac crest. The 
graft was fixed solidly over the 
polyethylene socket with cancellous 
bone screws. At 3-year follow-up 
the patient was doing well, was 
walking extensively, had no pain 
and had a good hip as shown 
radiologically (Fig. 9).
Case 4
In 1955, at the age of 51 years, 
this woman received irradiation for 
adenocarcinoma of the cervix. The 
therapy included 80 hours of radi­
um (50 mg intrauterine and 20 mg 
intravaginal) followed by 60 hours 
of radium (40 mg vaginally) for a 
total of 4000 mg-h to both uterine 
cavity and vagina. This was fol­
lowed by external pelvic radiothera­
py with cobalt-60 to a dose of 27.4 
Gy in 15 fractions over 3.5 weeks 
with anteroposterior and posteroan- 
terior split fields with central shield­
ing. In 1954 she had also received 
external radiotherapy to establish 
an artificial menopause because of 
irregular vaginal bleeding. Radia­
tion was in the form of 14 Gy using 
200 kV x-rays. In 1984 a barium 
enema examination revealed stric­
tures of the lower colon but the hip 
joints appeared normal. The total 
dose to the hips has been estimated 
as 51.4 Gy.
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She presented in 1986, at the age 
of 82 years, with a painful left hip, 
and x-ray films showed protrusio 
and arthritis (Fig. 10). The pro­
trusio was unusual in that its 
course was rapid and there was no 
reactive periosteal bone inside the 
pelvis. The medial wall of the ace­
tabulum was almost nonexistent, 
with only a pale dystrophic mem­
brane at the base; it was reinforced 
with an ipsilateral iliac crest graft. 
An Eichler peripheral support ring 
was fixed to the acetabular rim and 
a polyethylene socket cemented in­
side it. At follow-up 2 years later 
this woman had an excellent result 
— she had no pain, walked well 
with a cane and radiologically had a 
good hip (Fig. 11).
Discussion
It is essential to review the gyne­
cologic history of women who have 
a rapid course of hip pain and 
disability to determine if therapeutic 
radiation has ever been given. If 
this is so, a radiation oncologist 
should be consulted to determine if 
the acetabulum was included in the 
field and what dosage of radiation it 
received. Symptoms of urethritis, 
cystitis and proctitis suggest that 
substantial amounts of radiation 
have been delivered to the pelvis.5
In the hips of all our patients the 
destructive arthropathy appeared to 
have been triggered by severe pro­
trusio or fracture through the 
weakened bone of the medial ace­
tabular wall. The variability of the 
interval from the time of radiothera­
py to acetabular fracture suggests 
that all unilateral cases may eventu­
ally become bilateral.
The dosage of radiation required 
to cause damage to bone has been 
stated as 30 Gy for the threshold of 
cell change and 50 Gy for cell 
death.6 Although less frequent, 
atrophic changes and fractures do
occur with the megavoltage tech­
niques in use today. Cases of ace­
tabular failure reported elsewhere 
have had similar doses and types of 
radiation at 35 to 70 Gy.2-4
The chronologic, radiologic, 
gross and microscopic changes in 
our four cases provide convincing
evidence that radiation was an im­
portant factor contributing to the 
destructive arthropathy. None of 
the patients in the present series 
had chemotherapy, steroids or pre­
vious surgery on the hip. There was 
an inverse correlation between age 
at the time of radiotherapy, and the
FIG. 9. Case 3. Three years postoperatively, position of prosthesis and fixation of 
cup, with incorporation of graft, are good.
FIG. 10. Case 4. Preoperative x-ray film shows fragmentation of medial acetabular 
wall, protrusio and degenerative changes of joint.
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interval before arthropathy. The de­
gree of osteoporosis at the time of 
radiotherapy, as assessed radiologi- 
cally, had a bearing on the time 
interval from irradiation to fracture. 
All patients had osteoporotic hips at 
the time of presentation with frac­
ture. That men treated with similar 
doses of radiation to the pelvis for 
prostatic cancer rarely developed 
secondary fractures7 probably re­
lates to the lower incidence of os­
teoporosis in men.
The microscopic characteristics 
of irradiation-induced bone necrosis 
have varied. In the late stages when 
there is mechanical bone failure and 
fragmentation, signs are obscured 
by a nonspecific mixture of necrosis 
and secondary inflammation. 
Whether frank necrosis occurs is 
debatable. Goodman and Sherman,1 
from analysis of femoral head mate­
rial obtained after radiation-induced 
neck fractures, found that total ne­
crosis did not occur. They believed 
that the osteocyte was damaged and 
unable to perform its metabolic 
functions in bone maintenance, but 
microscopically could look normal.
Radiation-induced fractures can 
heal with time and protection from 
loading.1 However, the prolonged 
morbidity this would entail in ace­
tabular fractures necessitates an op­
erative approach. Reconstruction in 
these cases in which the bone stock 
is poor is difficult and demands 
techniques often used in revision 
hip surgery, such as the use of 
protrusio rings and extensive bone 
grafting. Ideally, autograft har­
vested from the ipsilateral iliac crest 
outside the original radiation field 
should be used. The need for subse­
quent surgery on many of these 
hips makes the use of cementless 
components attractive, but the 
probability of failure of such com­
ponents in these cases is high as
demonstrated by our case 1. The 
use of acrylic bone cement and 
peripheral support rings is preferred 
in these cases to maximize the area 
and magnitude of immediate fixa­
tion.
Based on the improvement in 
four of our five hips over a 5-year 
period, it is our opinion that radia­
tion necrosis of the acetabulum is 
not an absolute contraindication to 
prosthetic joint replacement. How­
ever, it is necessary to recognize 
the condition and be aware of the 
potential problems.
We thank Drs. Alan Y.C. Cheung and 
Peter Corbett of the London Regional 
Cancer Clinic for providing details of 
the radiotherapy and proofreading the 
manuscript.
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inDiagnosis of Acute Appendicitis 
Pregnancy
Christine Richards, MD; Salim Daya, MB, MSc*
Although the clinical diagnosis of appendicitis in pregnancy seems to be 
complicated by the physiologic changes of pregnancy, evidence from controlled 
studies is lacking. The aims of this study were to determine whether there are any 
features of appendicitis in pregnant women that would help to establish the 
diagnosis and whether any difference exists between the presentation of appendicitis 
in pregnant and nonpregnant women. Twenty-eight pregnant women with a clinical 
diagnosis of appendicitis were compared with an equal number of nonpregnant 
patients matched for age and randomly selected from a group of patients who had 
appendicitis. No differences were observed in the presenting symptoms, physical 
signs and laboratory tests. The false-positive rates were identical. The results 
indicated that the diagnosis of appendicitis is no more difficult in the pregnant state 
than in the nonpregnant state.
Bien que le diagnostic clinique de l’appendicite en cours de grossesse semble etre 
complique par les changements physiologiques de la grossesse, il y a absence de 
preuves a cet effet, issues d’etudes controlees. Les objectifs de cette etude etaient de 
determiner s’il existe des caracteristiques de l’appendicite chez la femme enceinte 
pouvant aider a etablir le diagnostic, et s’il y a des differences dans le tableau 
clinique des femmes enceintes atteintes d’appendicite, par rapport a celles qui ne 
sont pas enceintes. Vingt-huit femmes enceintes ayant un diagnostic clinique 
d’appendicite ont ete companies a un nombre egal de patientes non enceintes 
appariees pour Page et choisies au hasard parmi un groupe de patientes souffrant 
d’appendicite. Aucune difference n’a ete observee dans les symptomes, les signes 
physiques ou les epreuves de laboratoire. Les taux de faux positifs etaient 
identiques. Ces resultats indiquent que le diagnostic d’appendicite n’est pas plus 
difficile a etablir chez la femme enceinte que chez celle qui ne Test pas.
A cute appendicitis is the most common nonobstetric condi­
tion requiring operative intervention 
during pregnancy.1-5 It is not a 
frequent complication, occurring 
only once in every 1500 deliveries.6 
Thus, in most obstetrical units it is
encountered approximately twice a 
year.
The clinical presentation varies, 
often making the diagnosis difficult, 
especially later in pregnancy. The 
progressive displacement and rota­
tion of the tip of the appendix has
been one factor responsible for this 
difficulty. Also, the physiologic 
changes of pregnancy may con­
found the interpretation of laborato­
ry tests. The resulting delay in 
diagnosis and operation is a major 
factor contributing to the higher 
maternal mortality associated with 
this disorder. It is generally believed 
that if appendicitis is suspected in a 
pregnant woman, immediate surgi­
cal intervention is indicated. But 
often the surgeon is reluctant to 
perform exploratory laparotomy 
since there is a risk of precipitating 
spontaneous abortion or premature 
labour. Consequently, better diag­
nostic criteria are required to enable 
the diagnosis to be made with more 
confidence. The purpose of this 
study was to compare the presenta­
tion of appendicitis in pregnant 
women with that in nonpregnant 
women to determine whether there 
is a specific pattern of presentation 
in pregnancy that would aid in its 
diagnosis.
Patients and Methods
A chart review was carried out of 
28 pregnant patients admitted with 
abdominal pain to Chedoke-McMas- 
ter Hospital or St. Joseph’s Hospital 
in Hamilton, Ont. between Jan. 1, 
1981 and Sept. 30, 1986 and who 
underwent appendectomy because 
of a preoperative diagnosis of ap­
pendicitis. The charts from a con­
trol group of 28 nonpregnant 
women in the same age range and
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with a diagnosis of appendicitis ad­
mitted during this period were ran­
domly selected for comparison. In­
formation on presenting symptoms 
(vomiting, nausea, diarrhea and 
anorexia), physical signs (rebound 
tenderness, abdominal guarding, 
Rovsing’s sign, psoas irritation and 
pyrexia) and results of laboratory
tests (leukocyte count in blood and 
urine) were extracted from the hos­
pital charts. Histologic findings 
were also obtained for each patient 
and the two groups compared. The 
time from presentation in the hospi­
tal to surgery was also recorded and 
compared.
The two groups were compared
using x2> Fisher’s exact and Wil- 
coxon rank sum tests where appro­
priate and significance was tested at 
the 5% level.
Results
The average age of the women in 
the pregnant group was 26.2 years, 
compared with 25.4 years for those 
in the nonpregnant group. There 
were no differences between the 
two groups with respect to symp­
toms and physical signs (Table I) or 
in the duration from presentation in 
the hospital to surgery. The most 
consistent symptom present in 
these patients was abdominal pain. 
Two-thirds of the pregnant patients 
presented with nausea and had ab­
dominal guarding, rebound tender­
ness and demonstrated a positive 
Rovsing’s sign. Anorexia and diar­
rhea were infrequent and the elicita­
tion of psoas irritation was not a 
reliable sign. Both groups had simi­
lar proportions of patients with 
white blood cells in the urine and 
elevated blood leukocyte counts. 
However, the difference between 
the mean levels (pregnant women 
14.9 X 109/L , nonpregnant women 
16.0 X 109/L ) was not statistically 
significant. When the two groups 
were compared after selecting only 
those who had histologically proven 
appendicitis (Table II), again, no 
significant differences were found 
with respect to symptoms, signs or 
laboratory test results. Perforation 
of the appendix was observed with 
the same frequency (11%) in each 
group. The overall false-positive 
rate (i.e., histologically normal ap­
pendix) was identical in the two 
groups (18%). However, there was a 
significant (p =  0.041) trend toward 
more false-positive cases in the 
third trimester (Table III). Also, 
50% of the true-positive cases in the 
third trimester were complicated by 
appendiceal perforation.
Table 1. Clinical Presentation in Pregnant and Nonpregnant Patients Presenting With Abdominal
Pain*
Variable Pregnant Nonpregnant
Age, yr 25.4 ± 0.8 26.2 ±  1.9
Time from presentation to operation, h 25.1 ± 4 .3 10.2 ±  1.7
Temperature, °C 
Leukocyte count, x  109/L
37.1 ± 0.1 37.3 ±  0.1
Blood 14.9 ±  0.6 16.0 ± 0 .9
Urine 1.7 ± 0.5 3.0 ±  1.2
Vomiting 50 46
Nausea 71 93
Diarrhea 21 21
Anorexia 39 39
Rebound tenderness 68 64
Positive Rovsing's sign 46 18
Psoas irritation 14 11
Abdominal guarding 64 75
Histologically proven appendicitis 82 82
'Values are either mean ± SEM or %.
Table II. Clinical Presentation in Pregnant and Nonpregnant Patients With Histologically
Confirmed Appendicitis*
Variable Pregnant Nonpregnant
Age, yr 25.3 ± 0.9 25.9 ±  2.0
Time from presentation to operation, h 11.4 ± 1 .9 10.7 ±  1.9
Temperature, °C 37.1 ± 0.1 37.3 ± 0.1
Leukocyte count, x  109/L
Blood 15.3 ± 0 .7 16.6 ± 0 .9
Urine 1.6 ± 0 .5 2.1 ± 0 .7
Vomiting 57 52
Nausea 78 100
Diarrhea 24 23
Anorexia 36 67
Rebound tenderness 65 65
Positive Rovsing’s sign 61 57
Psoas irritation 12 40
Abdominal guarding 61 83
'Values are either mean ± SEM or %.
Table III. Prevalence of Appendicitis in Each Trimester
Trimester of pregnancy
Appendicitis 1st 2nd 3rd Totals
Positive 6 13 4 23
Negative 0 2 3 5
Totals 6 15 7 28
x 2 with 2 df =  4.50, p =  0.106.
x 2 due to linearity with 1 df =  4.19, p =  0.041.
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Discussion
The false-positive rate (18%) in 
this study is similar to that (21%) 
reported in a review of 545 preg­
nant patients with a preoperative 
diagnosis of appendicitis.7 This sug­
gests that, in general, the diagnosis 
of appendicitis in pregnancy is no 
more difficult than in the nonpreg­
nant state. However, significantly 
more normal appendices were re­
moved in the third trimester than in 
the other two. It is known that as 
pregnancy advances, the abdominal 
pain associated with appendicitis be­
comes less characteristic, and the 
localizing signs may be in the right 
upper quadrant or in the right 
flank. This is further complicated 
by the uterus pushing the abdomi­
nal wall away from the appendix. 
Thus, better diagnostic tests are 
required so that unnecessary opera­
tive intervention and the risk of 
precipitating premature labour are 
avoided.
The value of leukocytosis in sup­
porting the diagnosis has been 
thought to be limited since a physi­
ologic leukocytosis (up to 12.5 X 
109/L ) occurs in pregnancy. The 
mean leukocyte count in pregnant 
women with histologically proven 
appendicitis in this study was 15.3 
X 109/L  and 80% of women in the 
study had a count greater than 12.5 
X 109/L . Using this cut-off level, 
the sensitivity of this diagnostic test 
was 82%, indicating that very few 
patients with histologic appendicitis 
would be misdiagnosed. However, 
the specificity was only 20%, indi­
cating that a very high proportion 
of false-positive diagnoses would 
occur.
Other diagnostic measures have 
been reported. For example, lapa­
roscopy was used to confirm the 
diagnosis in one woman.8 Laparos­
copy may be useful in the first 
trimester when the uterus is still in 
the pelvis, but it becomes technical­
ly more difficult to perform as preg­
nancy progresses. Furthermore, 
none of the patients in our study 
had a false-positive diagnosis in the 
first trimester, indicating that the 
diagnosis can usually be made pre- 
operatively on clinical and laborato­
ry assessment alone, without the 
need for laparoscopy. Culdocentesis 
confirmed the need for surgery in 
one patient in whom purulent mate­
rial was aspirated from the pelvic 
cul-de-sac.7 Such a procedure is not 
without risk in view of the presence 
of the soft, very vascular and en­
larged uterus in the pelvis. Also, its 
accuracy depends upon the pres­
ence of pus in the cul-de-sac, result­
ing from perforation of the appen­
dix. Such a situation was present in 
only 11% of the patients in this 
study, further limiting its useful­
ness.
Ultrasonography has been de­
scribed as a quick, noninvasive and 
reliable tool for diagnosing appen­
dicitis.9-11 With graded compression 
a high degree of diagnostic accura­
cy was achieved, leading to appro­
priate clinical management.11 Also, 
in patients having disease other 
than appendicitis, the correct diag­
nosis was made. Such a technique 
may potentially be of use in preg­
nancy to complement the clinical 
evaluation, thereby avoiding any 
delay in operative intervention. 
However, its sensitivity in the pres­
ence of perforation is low, so its 
value in the presence of this compli­
cation is limited.
The mortality and serious mor­
bidity associated with appendicitis
in pregnancy are the result of fail­
ure to recognize or suspect the 
condition when it presents with 
atypical features.12 The key to man­
agement lies in earlier diagnosis and 
prompt operative intervention. Pa­
tients who present in pregnancy 
with abdominal pain and have a 
leukocyte count greater than 12.5 
X 109/L  should be suspected of 
having appendicitis, especially if 
they also complain of nausea and 
have abdominal guarding.
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N eoadjuvant Treatment in Conservative 
Surgery of Peripheral Sarcomas
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Twenty-five patients with soft-tissue and bony sarcomas of the head and neck and 
limbs were treated by local neoadjuvant therapy. It consisted of 90 mg of Adriamycin 
infused intra-arterially over 3 days into a vessel feeding the involved area and 30 Gy 
of radiotherapy given over 10 days; this was followed by a complete resection of the 
sarcoma 4 to 6 weeks later. All the tumours were associated with a high risk of local 
recurrence; eight were locally recurrent and the remainder were stage II to stage IV 
tumours. Serious local complications were seen in 4% of the patients. This rate 
compares well with other higher dose neoadjuvant regimens (35 Gy over 10 days), 
which are associated with a 35% local complication rate. Follow-up at a mean of 30 
months demonstrated no local recurrence. All limbs were spared. Long-term 
morbidity was negligible. No effect on systemic control is suggested; only 63% of 
the patients were free of systemic disease. This report substantiates other similar 
experiences supporting neoadjuvant therapy followed by resection as the treatment 
of choice for local control of sarcomas.
Vingt-cinq patients souffrant de sarcomes des tissus mous et des os de la tete, du 
cou et des membres ont re?u une therapie neoadjuvante locale. Celle-ci consistait en 
90 mg d’Adriamycine perfusee sur une periode de 3 jours par voie intra-arterielle 
dans un vaisseau qui alimentait la region atteinte, et de 30 Gy de radiotherapie 
administree sur 10 jours; on procedait a une resection complete du sarcome 4 a 6 
semaines plus tard. Toutes les tumeurs etaient liees a un risque eleve de recidive 
locale; dans huit cas, il s’agissait de recidives locales, alors que les autres etaient des 
tumeurs de stades II a IV. Des complications locales serieuses ont ete vues chez 4% 
des malades. Ce taux se compare avantageusement avec des doses plus elevees de 
therapie neoadjuvante (35 Gy sur 10 jours), lesquelles etaient reliees a un taux de 
complication locale de 35%. Les examens de controle effectuees apres 30 mois en 
moyenne, n’ont devoile aucune recidive. Tous les membres ont pu etre sauvegardes. 
La morbidity a long terme a ete negligeable. Aucun controle systemique n’est 
suggere; seulement 63% des patients etaient exempts d’atteinte systemique. Cette 
etude corrobore des experiences similaires qui ont demontre que la therapie 
neoadjuvante suivie d’une resection constitue le traitement de premier choix quand 
il s’agit du controle local des sarcomes.
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L ocal control of soft-tissue and bony sarcomas continues to 
challenge the oncologist. In recent 
years, the effective use of radiother­
apy with limb-salvage surgery has 
successfully reduced both local re­
currence and limb loss. However, 
the local recurrence rate remains 
approximately 15% to 20%.1-6 In 
the last 5 years, neoadjuvant thera­
py of intra-arterially infused 
Adriamycin and medium-dose radio­
therapy before surgery has provided 
further improvement, both in 
shrinking many large lesions and 
thereby reducing the extent of sur­
gery, and in providing long-term 
local control in the range of 95%.7 
In this report we document our 
experience with this regimen in sar­
comas of the limbs and head and 
neck.
Methods
A prospective study was initiated 
in 1984 into which all patients with 
newly diagnosed or recurrent limb 
or head and neck sarcoma needing 
further treatment were entered. The 
only exclusions were patients with 
metastases whose sarcoma could 
not be resected for cure, patients 
with superficial and small lesions in 
which a wide excision would suffice 
and patients who refused the proto­
col. Before entering the study, all 
patients underwent a complete his­
tory-taking and physical examina­
tion, pulmonary tomography and
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computed tomography of the lesion 
to document the extent of disease. 
All lesions were reviewed by a team 
of three pathologists.
The protocol was started with 72 
hours of continuous intra-arterial 
Adriamycin infusion totalling 90 
mg (30 mg/d). The catheter was 
placed in a large proximal vessel 
feeding the area and was never 
placed beyond the common femoral 
or axillary artery. Intravenous che­
motherapy was used for a head and 
neck lesion and a shoulder lesion 
with multiple feeding vessels when 
single-artery catheterization would 
not entirely infuse the lesion. Cath­
eter access was usually through the 
femoral artery. The patient was 
kept on bed rest for the 3 days, and 
therapeutic anticoagulation was 
provided with heparin, keeping the 
partial thromboplastin time well 
over 80 seconds. After completion 
of the Adriamycin infusion, radio­
therapy was given at a rate of 3.0 
Gy/d for 10 days. In the hand or 
foot, it was divided into 1.65 Gy 
twice daily for 10 days in an at­
tempt to improve normal tissue tol­
erance at these difficult sites. The 
field extended 10 cm on either side 
of the lesion and encompassed a 
maximum of two-thirds of the limb 
circumference. Four to 6 weeks 
later, the patient underwent surgi­
cal removal of the tumour.
The planned excision included 2 
cm of the skin and scar around the 
previous biopsy and a 2-cm margin 
in all directions around the residual 
tumour. When the tumour was ad­
jacent to a vessel or nerve, a mar­
ginal excision was accepted as long 
as biopsy of the margin showed 
that there were no malignant cells 
present. The defect was closed pri­
marily when possible. When a bone 
was resected, an allograft was 
placed. When there was massive 
soft-tissue resection including skin, 
a myocutaneous axial or free flap 
was used for cover. All patients
were followed up in the sarcoma 
clinic on a 4- to 6-month basis by 
physical examination and routine 
chest x-ray films to document re­
currence of disease.
Findings
Twenty-five patients were entered 
into this study. One patient had a 
lesion of the face above the zygoma 
and the remainder had lesions of 
the limb or limb girdles (Table I). 
Fifteen patients had a biopsy before 
neoadjuvant treatment. The remain­
ing patients presented with “total 
excisions” of the lesions which 
were considered inadequate on re­
view of the submitted surgical or 
pathology report. Eight patients 
had locally recurrent lesions with a 
history of one to five previous fail­
ures of surgery. Three patients had 
pulmonary metastases which were 
deemed resectable as a second stage 
of treatment. Two patients had os­
teosarcoma of the bone, one in the 
upper humerus and one in the distal 
femur.
The sarcomas were of varied his­
tologic type (Table II). All were 
staged according to the American 
Joint Committee for Cancer Staging 
and End-Results Reporting (Table 
III). Involvement of surrounding 
structures such as muscle, nerve, 
artery or bone was clinically impor­
tant in all but one patient. Mean 
follow-up for the entire group is 
now 2.5 years, ranging from 1 to 5 
years.
The morbidity of treatment in­
cluded various problems with the 
infusion. Nausea was minimal; only 
one patient requested and was given 
Gravol intramuscularly. Two pa­
tients had thrombosis of the infused 
artery and required treatment to 
reconstitute the lumen. This was a 
direct result of the partial thrombo­
plastin times being less than 60 
seconds. This is no longer a prob­
lem because the partial thrombo­
plastin time is now kept over 80 
seconds. One patient had a catheter 
dislodge from the axillary artery 
into the vertebral artery, producing 
temporary confusion and occipital 
blindness for 12 hours. Another 
patient had pectoral muscle inflam-
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mation secondary to streaming of 
the infusion from the main axillary 
artery catheter; the condition re­
solved over 2 months.
There were no important compli­
cations of radiotherapy. Only one 
patient had delayed healing in spite 
of a myocutaneous flap placed to 
cover the defect resulting from 
groin, pubic bone and testicular 
resection. No patient had a radia­
tion-induced bone fracture and only 
one patient had moderate fibrosis of 
the treated area that resolved within 
1 year. In the two patients who had
FIG. 1. Large grade 2 liposarcoma 
(stage IIB) of thigh, measuring 25 X 
15 cm was clinically palpable in but­
tock.
bone resection and replacement, 
there were no fractures of the allo­
graft; the patient with a replaced 
femur has been followed up for over 
2 years.
Dramatic shrinkage of the lesions 
was seen in over 50% of the pa­
tients (Table IV) (Figs. 1 to 5). 
Shrinkage often began immediately 
after the Adriamycin infusion before 
radiotherapy and continued up to 
the time of surgery. In two patients, 
there was a complete histologic 
response. Patients often experi­
enced a marked decrease in pain 
during the therapy, and it preceded 
a clinically measured reduction in 
size. The only patient with a tu­
mour that grew during treatment 
had a soft-tissue osteosarcoma.
Local control was seen in all 
treated sites of disease. One patient 
with a facial sarcoma had regional 
failure outside the treatment field. 
This was subsequently controlled 
with a cranial facial resection. The 
patient is alive and free of local and 
systemic disease at 2-year follow­
up.
During follow-up, unresectable 
systemic disease developed in nine 
patients. The disease stage and tu­
FIG. 2. Computed tomogram demonstrated lesion of left thigh compressing sciatic 
nerve.
mour type are shown in Tables V 
and VI. The overall survival rate of 
the 25 patients at 30 months was 
76% with a disease-free survival of 
64% (Fig. 6).
All but one of the patients who 
underwent nonosseous limb surgery 
returned to normal activity within 
weeks of operation. One patient 
who had thrombosis of an arterial 
replacement graft was partially dis­
abled with ischemic pain for 3 
years. The patient with an allograft 
replacement of the distal segment 
of a femur is fully mobile using an 
external brace.
Discussion
Our results of neoadjuvant thera­
py with intra-arterial Adriamycin 
and preoperative radiotherapy are 
equal to those of other reports 
using a similar regimen and superi­
or to treatments consisting of sur­
gery and pre- or postoperative radi­
otherapy.2_5'7_9 In other series, local 
recurrence of high-grade sarcoma 
after treatment has been noted clini­
cally in 95% of those whose tu­
mours recur within 2 years of initial 
treatment. Since our mean follow­
up is now more than 2.5 years, we 
believe that the absence of local 
recurrence in our patients is strong­
ly supportive of this approach.10
Although in this group of sarco­
ma patients the tumours were at 
varied sites, and of varied patholog­
ic features and stages, all patients 
were at high risk for local recur­
rence with standard therapy. There­
fore, this diversity does not take 
away from the results of this study. 
The value of this approach is also 
emphasized by the dramatic shrink­
age of even large lesions before 
surgery, an effect that is very un­
usual with radiotherapy alone. In 
many cases, preservation of major 
nerves, arteries and veins, which 
normally would have been resected
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to obtain a clear margin, became 
possible.
This experience is also important 
in that most tumours were large 
and many of the patients had recur­
rent tumours after multiple previ­
ous surgical procedures. It is inter­
esting that systemic disease devel­
oped in only four of the nine pa­
tients on whom we reoperated for 
local recurrence. This emphasizes 
the fact that one should be as 
aggressive in obtaining local control 
of recurrent disease as one is for a 
patient presenting with a primary 
sarcoma. It is also encouraging that 
even after previous surgery, limb 
salvage is still possible using this 
approach.
Anticoagulation with heparin pre­
sented difficulties. Since patients 
had an intra-arterial catheter and 
were fully heparinized, they were 
kept in an intensive care setting. As
some of these tumours would 
shrink and presumably release large 
amounts of procoagulants from 
dying cells, the partial thromboplas­
tin time would sometimes rapidly 
and unexpectedly become sub- 
therapeutic.11 After two experiences 
with intra-arterial thrombosis, the 
problem was prevented by maintain­
ing the partial thromboplastin time 
over 80 seconds. We noticed some 
unusual streaming effects of the 
Adriamycin, not only to areas of the 
skin in a few patients, but in one 
patient to a muscle. This was asso­
ciated with pain or tenderness in 
the area involved. When streaming 
effects were noted during infusion, 
the catheters were retracted a few 
centimetres.
Other local complications includ­
ed failure of a myocutaneous flap 
placed to cover a groin lesion; the 
wound healed by secondary inten­
tion. One patient had excessive 
post-treatment fibrosis which re­
solved slowly. No patient had radia­
tion-induced fractures. This con­
trasts markedly to Eilber’s experi­
ence7'8 in which 17% had a second 
operation to treat failure of healing 
and 11% had a radiation-induced 
fracture. The lower morbidity of 
our protocol may be a result of
FIG. 4. Lesion was resected with mi­
croscopically clear margin without sac­
rifice of sciatic nerve.
FIG. 5. At 5 years’ follow-up, patient 
remains free of local and systemic 
disease.
FIG. 6. Recurrence-free survival of 25 
patients treated by neoadjuvant chemo­
therapy and radiotherapy.
FIG. 3. By end of radiotherapy and 2 weeks after initiation of treatment, lesion had 
shrunk to 10 X 8 cm. Change is shown by comparing amount of soft tissue lateral 
to greater trochanter on initial simulation film with lead wire on skin (left) and 
follow-up simulation film (right).
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using a radiotherapy dose of only 
3.0 Gy/d compared with 3.5 Gy/d 
as reported by Eilber.
Conclusions
We believe that neoadjuvant ther­
apy as described in this paper 
should be considered for all sarco­
mas that cannot be treated by sur­
gery alone. The preoperative treat­
ment appears to add substantially to 
the microscopic sterilization of sar­
comas in the periphery of the le­
sion, but does not seem to have any 
measurable effect on overall control 
of systemic disease. When design­
ing adjuvant trials to control sys­
temic disease, this protocol should 
be considered to minimize local re­
currence. Although the debate over 
whether local control contributes to 
overall survival continues,1213 this 
factor cannot be ignored in the 
analysis of future adjuvant therapy 
trials.
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Medial Epicondylitis Caused by Injury to 
the Medial Antebrachial Cutaneous Nerve: 
a Case Report
Robin R. Richards, MD, FRCSC; William D. Regan, MD, FRCSC
A 35-year-old man who had chronic elbow pain due to medial epicondylitis received a 
steroid injection into the medial epicondyle. This was followed immediately by 
increased pain and symptoms of dysesthesia in the distribution of the medial 
antebrachial cutaneous nerve. On surgical exploration 9 months later, the nerve was 
found to lie directly over the medial epicondyle and appeared to have sustained an 
injection injury. This report draws attention to the fact that because the posterior 
division of the medial antebrachial cutaneous nerve may lie directly over the medial 
epicondyle, it may be at risk of direct injury if injections are given into the 
epicondyle.
Un homme de 35 ans qui souffrait d’une douleur chronique au coude due a une 
epicondylite moyenne a re?u une injection de steroide dans l’epitrochlee. Ceci fut 
suivi d’une exacerbation immediate de la douleur et de symptomes de dysesthesie 
dans l’aire de distribution du nerf brachial cutane interne. A la chirurgie 
exploratrice pratiquee 9 mois plus tard, on decouvrit que le nerf chevauchait 
l’epicondyle moyen et semblait avoir subi une lesion par piqure. Cet article veut 
attirer l’attention sur le fait que puisque la division posterieure du nerf brachial 
cutane interne peut chevaucher l’epicondyle moyen, celui-ci peut etre blesse lors 
d’une injection dans l’epicondyle.
Epicondylitis is a common cause of elbow pain. Previous publi­
cations have not specifically dis­
cussed the treatment of medial epi­
condylitis (tenderness over the me­
dial epicondyle), although it has 
been considered in articles dealing 
with lateral epicondylitis, constitut­
ing 10% to 20% of such series.1-3 
According to Hirschl,4 the patho­
logic cause of medial epicondylitis
is “angiofibroblastic hyperplasia” , 
occurring at the insertion of the 
origins of the common flexor- 
pronator muscles. Other causes of 
the clinical syndrome of medial epi­
condylitis have not been proposed. 
We describe a patient with medial 
elbow pain refractory to conserva­
tive management. Exploration of 
the elbow revealed that the posteri­
or division of the medial antebrachi­
al cutaneous nerve was inflamed 
and enlarged, probably because of a 
steroid injection injury. Although 
this cause of medial epicondylitis 
has never been reported, the prima­
ry reason for presenting this case is 
to draw attention to the danger of 
injury to the medial antebrachial 
cutaneous nerve if injections are 
administered in the area of the 
medial epicondyle.
Case Report
A 35-year-old right-handed man 
was referred for the management of 
chronic pain in the region of the 
right medial elbow. The pain had 
begun 15 years earlier as the result 
of a fall directly onto the medial 
aspect of the elbow during a base­
ball game. After the fall, the area of 
the medial epicondyle was tender 
for 3 to 4 weeks. The patient 
continued to play baseball but com­
plained of recurrent swelling and 
pain while throwing. Over the years 
he had been treated with nonsteroi­
dal anti-inflammatory agents, ice 
and ultrasonography.
In an attempt to alleviate the 
pain, the patient was given a steroid 
injection directly into the medial 
epicondyle. The injection was fol­
lowed immediately by a burning 
pain over the medial epicondyle; the 
pain continued for 1 month. A
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MEDIAL EPICONDYLITIS
dysesthetic pain radiating over the 
posteromedial forearm distal to the 
elbow then developed. For the 9 
months before presentation, he ex­
perienced constant pain and sensi­
tivity to direct palpation of the 
medial epicondyle associated with 
dysesthesia over the posteromedial 
forearm.
On examination, there was in­
creased warmth over the medial 
epicondyle and marked tenderness 
on palpation. The range of elbow 
motion was normal. Resisted fore­
arm pronation produced epicondylar 
discomfort. There was no Tinel’s 
sign and no neurologic deficit apart 
from hypoesthesia in the distribu­
tion of the posterior division of the 
medial antebrachial cutaneous 
nerve. X-ray views of the elbow, 
including oblique views, appeared 
normal. Results of nerve conduction 
studies of the ulnar nerve across 
the cubital tunnel were normal, as 
were those of electromyography of 
the ulnar innervated musculature of 
the hand.
The patient was admitted to hos­
pital and the elbow was explored 
through a posteromedial incision, 
centred over the medial epicondyle. 
An enlarged and inflamed posterior 
division of the medial antebrachial 
cutaneous nerve was found lying 
directly over the medial epicondyle 
(Fig. 1). The location of the nerve 
corresponded to the area of preop­
erative tenderness. The underlying 
medial epicondyle appeared in­
flamed. A neurolysis of the posteri­
or branch of the medial antebrachial 
cutaneous nerve was performed, 
and a portion of the medial epicon­
dyle was resected. Postoperatively, 
the medial epicondyle was support­
ed in a posterior slab for 2 weeks. 
Two months postoperatively the pa­
tient had a full range of elbow 
motion with complete resolution of 
pain over the medial epicondyle. 
One year later sensation continued 
to be decreased in the distribution
of the posterior division of the 
medial antebrachial cutaneous 
nerve. The patient was able to re­
turn to sports activity.
Discussion
The medial antebrachial cutane­
ous nerve originates from the 
eighth cervical root and emerges 
from the medial cord of the brachial 
plexus to pierce the deep fascia in 
the mid-brachium.5' 7 The nerve, 
now in a subcutaneous location, 
divides into an anterior branch, 
coursing anterior to the medial epi­
condyle and a posterior branch. The 
posterior branch has been noted by 
Dellon and MacKinnon5 to vary in 
location, crossing from the anterior 
mid-brachium to the posterior fore­
arm from 6 cm proximal to 6 cm 
distal to the medial epicondyle. The 
posterior division of the medial an­
tebrachial cutaneous nerve provides 
sensation to the posteromedial fore­
arm. Its subcutaneous location 
makes it prone to injury.
Our patient had pain directly over
the medial epicondyle with posterior 
and volar radiation. Initially, his 
symptoms were characteristic of 
medial epicondylitis. However, after 
the cortisone injection, the quality 
of the pain changed. An injection 
injury to the posterior division of 
the medial antebrachial cutaneous 
nerve likely occurred at that time.8 
This is supported by the following 
findings: (a) the nerve lay directly 
over the medial epicondyle, (b) 
symptoms of numbness developed 
in the distribution of the nerve after 
the injection and (c) the nerve ap­
peared inflamed at the time of ex­
ploration.
Leffert9 and Dellon and MacKin­
non5 have advised careful dissection 
of the cubital tunnel region to avoid 
injury to the posterior branch of the 
medial antebrachial cutaneous 
nerve. The latter authors reported 
injury to the posterior branch in 23 
of 25 patients who had recurrent 
ulnar nerve entrapment and were 
referred for re-exploration. The sur­
geon must be aware of the nerve’s 
course when exposing the medial 
epicondyle. Since the physician has
FIG. 1. Posterior division of medial antebrachial cutaneous nerve crossing directly 
over medial epicondyle. Nerve was enlarged and inflamed. Underlying medial 
epicondyle was inflamed. Medial epicondylectomy and external neurolysis of nerve 
were carried out.
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ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycin C, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the 7a position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES 
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia 
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fec tions caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b il ity  of the causative o rgan ism (s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available. 
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and 
non-producing strains)
Escherichia coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria. 
MEFOXIN® is not active against Pseudomonas 
spp., most strains of enterococci, many strains 
of Enterobacter cloacae, and methicillin- 
re s is ta n t s ta p h y lo c o c c i and L is te r ia  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post- 
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal surgery 
when there is a significant risk of postoperative 
infection or where the occurrence of post­
operative infection is considered to be especially 
serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
®Trademark Merck & Co., Inc./ 
Merck Frosst Canada Inc., R.U.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally 
reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate treatment may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cepha­
losporins, penicillinsorotherdrugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of partial cross-allergenicity between cepha- 
mycins and the other beta-lactam antibiotics, 
penicillins and cephalosporins. Severe reactions 
(including anaphylaxis) have been reported 
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported 
w ith  v ir tu a lly  a ll a n t ib io tic s  in c lu d in g  
MEFOXIN®. This colitis can range from mild to 
life threatening in severity. Antibiotics should 
therefore be prescribed with caution in indi­
viduals with a history of gastrointestinal disease, 
particularly colitis. It is important to consider a 
diagnosis of pseudomembranous colitis in 
patients who develop diarrhea in association 
with antibiotic use. While studies indicate that a 
toxin produced by Clostridium difficile is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling’s solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100yug/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration. 
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing concom itan t adm in is tra tion  of 
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient’s condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should be taken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
Use in Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pru ritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on A D M IN ISTR ATIO N  and 
RECONSTITUTION.)
Intravenous Administration 
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as malnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending. 
TREATMENT DOSAGE 
Adults
The usual adu lt dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by 
severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
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Usual Adult Dosage RICHARDS & REGAN
Type of Daily Frequency
infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher 
dosage (e.g. gas 
gangrene)
•Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min
DOSE FREQUENCY
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment 29-10 1-2 g every 12-24 h
Severe
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In patients undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete
monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
At present there  is in s u ffic ie n t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations for adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g administered intramuscularly or in tra ­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and third 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2 g doses 
should be given intravenously or intramus­
cularly four hours and eight hours after the first 
dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt 
Storage
MEFOXIN® in the dry state should be stored 
below 30°C. The dry material as well as 
solutions tends to darken, depending on storage 
conditions; product potency, however, is not 
adversely affected.
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no way of knowing the location of 
the nerve in any one patient, injec­
tion of the medial epicondyle is 
probably best avoided. Medial epi­
condylitis can be caused and aggra­
vated by injury to the posterior 
division of the medial antebrachial 
cutaneous nerve.
References
1. Baumcard SH, Schwartz DR: Percutane­
ous release of the epicondylar muscles for 
humeral epicondylitis. Am J Sports Med 
1982; 10: 233-236
2. Meine J, Eicher E: [Results of a denervat- 
ing operation in radial and ulnar humeral 
epicondylitis.] Handchirurgie 1981; 13: 
254-259
3. Spencer G E jr, Herndon CH: Surgical 
treatment of epicondylitis. J Bone Joint 
Surg [Am] 1953; 35: 421-424
1127a
N/1EMBER
| PAAB ]  tp ~ » c |
M SP
MERCK
DOHME
C A N A D A
P.O. BOX 1005, POINTE-CLAIRE 
DORVAL, QUEBEC H9R 4P8
4. Hirschl RP: Muscle and tendon trauma: 
tennis elbow. In Morrey BF (ed): The 
Elbow and Its Disorders, Saunders, Phila­
delphia, 1985:492-495
5. Dellon AL, MacKinnon SE: Injury to the 
medial antebrachial cutaneous nerve dur­
ing cubital tunnel surgery. J Hand Surg 
[B r] 1985; 10: 33-36
6. Izzo KL. Aravabhumi S, Jafri A, et al: 
Medial and lateral antebrachial cutaneous 
nerves: standardization of technique, reli­
ability and age effect on healthy subjects. 
Arch Phys Med Rehabil 1985; 66: 592- 
597
7. Pribyl R, You SB, Jantra P: Sensory 
nerve conduction velocity of the medial 
antebrachial cutaneous nerve. Elec- 
tromyogr Clin Neurophysiol 1979; 19: 
41-46
8. Mackinnon SE. Hudson AR, Gentili F, et 
al: Peripheral nerve injection injury with 
steroid agents. Plast Reconstr Surg  1982; 
69:482-490
9. Leffert RD: Anterior submuscular trans­
position of the ulnar nerves by the Lear- 
month technique. J Hand Surg [Am] 
1982; 7: 147-155
CJS, VOL. 32, NO. 5, SEPTEMBER 1989 369
ORIGINAL ARTICLES
Perforated Diverticulitis After Surgery
Andrus J. Voitk, MD, MSc, FRCSC;* Robert A. Mustard, MD, FRCSCt
The authors report on three patients who had a perforated sigmoid diverticulum 
after unrelated surgery. If the preceding operation is remote in time from the 
perforation, detection is relatively easy, but if the perforation occurs shortly after 
major abdominal surgery, its presentation may be totally masked by the 
postoperative state. Awareness of this possibility may help alert the clinician to the 
presence of perforation of a sigmoid diverticulum in unexplained postoperative 
collapse. Although discovery of these three cases suggests that diverticular 
perforation is not uncommon after surgery, a causal relationship is not known, and 
the authors could not find any previous reports of such a relationship.
Les auteurs signalent trois patients qui ont subi une perforation d’un diverticule 
sigmoidien apres une intervention chirurgicale totalement independante. Quand 
l’operation precede de beaucoup la perforation, la detection est relativement simple 
mais, quand la perforation survient tot apres une chirurgie abdominale majeure, le 
tableau clinique peut se confondre avec l’etat postoperatoire. En gardant a l’esprit 
cette possibility, le clinicien pourra soupconner la presence d’une perforation d’un 
diverticule sigmoidien face a un affaissement postoperatoire inexplique. Alors que la 
decouverte de ces trois cas indique que les perforations diverticulaires ne sont pas 
rares apres la chirurgie, on ne connait pas de rapport de cause a effet et les auteurs 
n’ont pu retracer aucun rapport prealable d'un tel lien.
About 50% of North Americans over the age of 50 years have 
diverticulosis, and diverticulitis will 
develop in 20% of these. Although 
it is usually self-limiting, diverticuli­
tis rarely presents with acute perfo­
ration without significant pro­
dromes. Diverticular perforation is a 
catastrophe, needing prompt recog­
nition and treatment to prevent 
death. Attempts to identify patients 
with such complications postopera- 
tively by quantitative assessment of
the acute-phase response have not 
been successful. The diagnosis of 
these complications remains entirely 
clinical, yet the signs and symptoms 
of diverticular perforation after 
major abdominal surgery may be 
totally obscured by the postopera­
tive state. One may also speculate 
on a possible causal relationship 
between surgery and diverticular 
perforation, unrecognized to date.
Our experience, reported in this 
paper, with three patients who suf­
fered acute diverticular perforation 
after surgery suggested that this 
association is not rare, yet we were 
unable to find published reports of 
it.
Case Reports
Case 1
An obese 67-year-old diabetic 
woman presented with an insidious 
3-year history of passing feces 
through the vagina. There was no 
heralding episode of fever or ab­
dominal pain. Contrast studies dem­
onstrated diverticulosis of the sig­
moid colon and a fistula from the 
sigmoid to the vagina. The cause 
was assumed to be diverticular and 
not related to a hysterectomy per­
formed 26 years earlier. The fistula 
was cannulated vaginally and ex­
cised transabdominally. As the sig­
moid colon looked healthy, a Z- 
stitch was used to close the fresh­
ened edges of the small hole left by 
the excised fistula. The vagina was 
repaired similarly and omentum 
placed between. Cefazolin, 1 g, was 
given intravenously 2 hours preop- 
eratively and every 6 hours postop- 
eratively for 24 hours. Her postop­
erative course was uncomplicated, 
with no fever and early return of 
bowel function. She was scheduled 
for discharge on postoperative day 
6, ambulatory, with bowel move­
ments and eating a full diet. That 
morning she reported sudden ab­
dominal pain. On examination she 
appeared pale and sweating, her 
pulse was 110 beats/min, her body 
temperature 38.7°C and she had
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abdominal guarding and rebound 
tenderness. The leukocyte count 
was 12.0 X 109/L . A leak of the 
closed fistula was suspected, so oral 
feedings were stopped. When she 
did not improve after 48 hours of 
intravenous fluids and antibiotics, a 
laparotomy was done. Fibropuru- 
lent peritonitis and a pelvic abscess 
were found, with a perforated diver­
ticulum in an area of acutely in­
flamed sigmoid colon about 20 cm 
proximal to the intact site of the 
fistula repair. Abscess drainage, 
peritoneal toilet and a Hartmann 
resection were followed by satisfac­
tory recovery.
Case 2
A 67-year-old woman complained 
of sudden acute lower abdominal 
pain with sweating and numbness 
of the right leg, 3 days after a total 
replacement of the right hip. Rup­
ture of an abdominal aneurysm was 
suspected, so she was referred to a 
tertiary care hospital. On arrival 
there her body temperature was 
38.7°C and she was in acute dis­
tress with abdominal guarding and 
rebound tenderness. The vascular 
consultant thought she had perito­
nitis, and computed tomography ex­
cluded an aneurysm. Free air was 
seen on abdominal films, and a 
diagnosis of perforated diverticulo- 
sis made. At laparotomy, sigmoid 
diverticulitis was found with perfo­
ration and free purulent material in 
the peritoneal cavity. Peritoneal toi­
let was carried out and a Hart­
mann’s resection performed. Her 
recovery was smooth.
Case 3
A 63-year-old woman underwent 
uncomplicated truncal vagotomy 
and Nissen fundoplication for recur­
rent ulcers and esophageal reflux. 
Adhesions from previous operations 
precluded laparotomy beyond the
hiatal area. The morning after oper­
ation she was unexpectedly found 
cyanotic and sweating, with a blood 
pressure of 80/60 mm Hg, a pulse 
rate of 68 beats/min and body 
temperature of 36.7°C. The abdo­
men was not distended but was 
tender, and bowel sounds were ab­
sent, in keeping with her postopera­
tive state. The hemoglobin concen­
tration and leukocyte count were 
normal, with normal differential and 
no shift. No air was seen in the 
mediastinum or abdomen on x-ray 
films. A roentgenogram after a di­
lute barium swallow failed to dem­
onstrate a leak at the hiatus; never­
theless the working diagnosis re­
mained iatrogenic esophageal perfo­
ration. Morphine overdose, hypo­
thyroidism, hypoadrenalism, diabet­
ic acidosis, pulmonary edema, pul­
monary embolism, pneumonia, myo­
cardial infarction and acute blood 
loss were all excluded by appropri­
ate examinations, tests or therapeu­
tic maneuvers. She was transferred 
to the intensive care unit where 
treatment with broad-spectrum anti­
biotics, intravenous fluids, steroids 
and dopamine was started. Within 
48 hours Klebsiella pneumoniae 
was cultured from the blood. Fol­
lowing initial recovery from shock 
there was no further improvement 
and after 8 days she was transferred 
to a tertiary care hospital. After 
another 2 weeks of intensive care, 
pelvic abscesses became evident. 
Laparotomy was done and abscess­
es were drained. A perforated sig­
moid diverticulum was found as the 
source. A transverse colostomy was 
done and eventually she recovered.
Discussion
When an association between an 
operation and subsequent complica­
tion is known, diagnosis of the 
complication is likely. Even when 
no association is known, if the
second event is dramatic, the cor­
rect diagnosis is made in time. 
However, if there is no known asso­
ciation and the presentation is 
masked by the first operation, the 
correct diagnosis may be beyond 
reach. Our patients illustrate this 
spectrum of diverticular perforation 
after surgery. In the first patient, 
the possibility of perforation was 
anticipated because primary suture 
repair is known to carry this risk. 
The acute deterioration after initial 
satisfactory recovery led to early 
diagnosis and reoperation. The only 
unexpected finding was the new site 
of perforation with healing of the 
original repair. In the second pa­
tient, the first operation was extra­
abdominal, proving that postopera­
tive diverticular perforation is a 
spontaneous event, needing no di­
rect physical contribution from the 
preceding operation. The peritonitis 
of free diverticular perforation is so 
dramatic that the seriousness is 
obvious to a physician of any spe­
cialty and a referral process quickly 
narrows down the possibilities, lead­
ing to the appropriate diagnosis.
In the first two patients, suffi­
cient time elapsed between the oper­
ation and the perforation to detect a 
dramatic change easily. The third 
patient illustrates the worst circum­
stances in which postoperative di­
verticular perforation can occur. 
The condition was entirely unex­
pected, there being no known asso­
ciation between the primary surgery 
and diverticular perforation. Adhe­
sions had prevented examination of 
the colon, which may have shown 
evidence of active inflammation. For 
24 hours after major abdominal 
surgery, the patient expects abdom­
inal pain and is unable to distin­
guish new pain in the same region, 
further dampened by analgesia. 
Pain, tenderness, guarding and lack 
of bowel sounds are all normal 
findings at this stage after abdomi­
nal surgery. Although our patient’s
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collapse was dramatic, cyanosis and 
hypotension herald a wide range of 
conditions, of which diverticular 
perforation is not foremost. The 
initial absence of fever, tachycardia 
and leukocytosis did not point to 
sepsis, although it was considered 
in the differential diagnosis and 
antibiotics were prescribed after 
blood cultures were taken. Growth 
of K. pneumoniae confirmed this 
diagnosis, even though the origin 
remained unknown. Despite inabili­
BOOK REVIEWS
continued from page 330
chapter 2, only references 1 to 4 are 
quoted in the text. If the remainder are 
meant to be general references, they 
should have been so identified.
The educational and practical value 
of this book is not diminished by these 
shortcomings. Confidence based on ex­
tensive experience permeates the text, 
and this should reassure readers who 
are members of a team that cares for 
such patients. Indeed, as the author 
stated, “it is teamwork which saves 
patients with cardiothoracic trauma”.
Ray C-J. Chiu, MD, PhD. FRCSC
Professor o f  Surgery.
McGill University,
The Montreal General Hospital.
1650 Cedar Ave.,
Montreal. PQ 
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ESSENTIAL RADIOLOGY IN HEAD 
INJURY. A Diagnostic Atlas of Skull 
Trauma. D.W.H. Mok and L. Kreel. 
215 pp. Illust. Heinemann Profession­
al Publishing Ltd, Oxford; Butter- 
worths, Stoneham, Mass., 1988. 
$90.00 (US). ISBN 0-433-00041-4.
The stated intent of this book is to 
provide a practical atlas for dealing with 
the radiologic aspects of head injuries. 
It is a small but well-organized book, 
except for the now-commonplace sepa­
ty to demonstrate the leak, the 
working diagnosis remained unrec­
ognized iatrogenic esophageal per­
foration. Administration of antibiot­
ics delayed the appearance of pelvic 
abscesses, which eventually led to 
the correct diagnosis.
Present knowledge suggests that 
the temporal relationship described 
in this paper is not causal and can 
be explained only by chance associ­
ation due to the relative prevalence 
of both surgery and spontaneous
ration of text and illustrations, which 
requires constant flipping back and 
forth.
Although the book’s title promises a 
discussion of “essential” radiology in 
head injury, with the widespread avail­
ability of computed tomography, plain 
films have become much less essential. 
Indeed, the introductory chapter lists a 
number of indications for computed 
tomography after trauma, both subse­
quent to or instead of plain films. 
Generally speaking, these lists could be 
even broader and in many areas plain 
skull films have become an anachro­
nism. However, computed tomography 
is not universally available and, al­
though the clinical utility of plain films 
is frequently questionable, useful infor­
mation is sometimes obtained. This 
book is a reasonably good text on 
plain-film examinations in head injuries, 
and in this respect fulfils its purpose.
The introduction is followed by chap­
ters on projections and anatomy, cal­
cifications, linear fractures, depressed 
fractures, fractures in children, skull- 
base fractures, facial fractures and nor­
mal variants and postoperative appear­
ances. The text of each chapter is brief 
but generally adequate. The illustra­
tions are generally well produced and 
most complement the text reasonably 
well. Some are excellent and depict 
beautifully both common and unusual 
features of the traumatized head. There 
are a few computed tomograms, some
diverticular perforation in the popu­
lation. However, if such anecdotal 
reports become common, then a 
causal relationship may be suspect­
ed, possibly explained by increased 
collagenase activity after surgery, 
with attendant collagen breakdown 
in thin-walled diverticula. Whether 
fortuitous or not, it will serve the 
clinician well to be aware of this 
rare event after surgery, because its 
presence may be totally unrecogniz­
able unless suspected. ■
of which are not particularly well de­
scribed. The chapter on facial injuries is 
well done and here plain films remain 
the procedure of choice.
Although there are no major flaws in 
the book, there are a few unnecessary 
errors. Computed tomography should 
perhaps be more widely used and could 
be better interpreted. The illustrations 
of normal anatomy have too many la­
bels, making them hard to read. An 
illustration of facial fractures fails to 
mention a portion of a dental plate 
displaced into the nasopharynx, per­
haps by the endotracheal tube insertion. 
This would be a vital feature of these 
films in terms of immediate patient 
management.
Overall, this is a reasonably good 
introductory text on the radiologic as­
pects of head injury using plain films. 
There is nothing new here compared 
with many much older texts, but the 
information is gathered together in one 
book which is easy to read and well 
illustrated. It is certainly of historical 
value and would be of some value to 
senior medical students or junior house 
officers, keeping in mind that the clini­
cal efficacy of plain skull films is fre­
quently questionable, and that plain- 
film findings can even be misleading. 
Certainly computed tomography is the 
essential radiologic procedure in head 
injury, and in most instances probably
continued on page 377
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Isolated Posterior Cruciate Ligament 
Injury in a Child: Literature Review and a 
Case Report
C. Frank, MD, FRCSC;* R. Strother, MDt
The authors describe the sixth reported case of a child with a truly isolated 
posterior cruciate ligament (PCL) injury and the first in which the deficiency was 
not repaired immediately. Review of this case emphasizes a number of points: the 
need for awareness of PCL injuries in children; the inability of x-ray films to detect 
cartilaginous avulsions in such circumstances; and the fact that missed PCL 
avulsions can cause locking and may also result in abnormal ligament length in the 
growing child, preventing reattachment. Finally, it is noteworthy that despite 
ongoing PCL laxity in this child, functional results were excellent at 3.5-year 
follow-up, supporting at least short-term conservative management of such injuries 
in children.
Les auteurs decrivent le sixieme cas signale de dechirure isolee vraie du ligament 
croise posterieur (LCP) chez un enfant et le premier chez qui cette lesion ne fut pas 
reparee immediatement. L’etude de ce cas met en lumiere plusieurs points: la 
necessite de rechercher une dechirure du LCP chez l’enfant; l’inutilite de la 
radiographie pour deceler les avulsions cartilagineuses dans de telles circonstances; 
et le fait que l’incapacite de reconnaltre des avulsions de LCP peut entrainer un 
blocage et aussi resulter, chez l’enfant en croissance, en un ligament de longueur 
anormale pouvant empecher le rattachement. Finalement, il faut souligner que 
malgre une hyperlaxite du LCP chez cet enfant, les resultats fonctionnels sont 
excellents apres 3.5 ans, ce qui suggere de s'en tenir a un traitement conservateur, 
du moins a court terme, dans ce genre de blessure chez l’enfant.
Knee ligament injuries in skele- tally immature children are 
rare,1 fewer than 100 cases having 
been reported.1' 18 Of these, about 
40 have involved the posterior cru­
ciate ligament (PCL) in patients 
under the age of 18 years. l 2 A ~ 
6,9.11,12.14-17 Only five were definitely 
isolated PCL injuries. Three of 
those were avulsions from the 
femur in boys under the age of 8 
years and all three were repaired.1'17
The fourth and fifth were in a 
14-year-old boy and a 16-year-old 
girl with tibial avulsion; they also 
were repaired.216 Four of these five 
children had residual stiffness and 
instability.
In this report we describe a sixth 
case of an isolated PCL injury, in a 
7-year-old boy. The condition was 
diagnosed late and has, with the 
exception of an arthroscopic proce­
dure, been treated conservatively
with good functional results over 
3.5 years of follow-up.
Case Report
A 7-year-old boy suffered an inju­
ry to his right knee while skiing. 
The exact mechanism was not re­
called. X-ray films taken at the time 
of injury were reported as normal. 
No diagnosis was made and no 
specific treatment was instituted.
Approximately 1 year later, the 
boy noted the sudden onset of lock­
ing of his knee. On repeat physical 
examination a posterior sag was 
evident, with positive passive and 
active posterior drawer tests. All 
other tests gave normal results. The 
clinical diagnosis of posterior cruci­
ate ligament (PCL) insufficiency 
was established. Repeat x-ray films 
now showed a small bony fragment 
in the intercondylar notch, but no 
other abnormalities.
Arthroscopy revealed a rounded 
femoral osteochondral fragment at­
tached to an avulsed, shortened 
PCL. There was no other abnormal­
ity in the knee. Since this fragment 
was responsible for the locking of 
this patient’s knee and since it 
could not be approximated to its 
original insertion site, it was 
trimmed. After quadriceps therapy, 
the boy returned to a fully active 
life-style and has remained that way 
for the past 2.5 years (3.5 years 
post-injury). He plays soccer, partic­
ipates in karate and is asymptomat­
ic. He had one episode of pain
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during a karate kick but this re­
solved quickly without swelling. 
Present examination of his knee 
reveals a significant posterior sag 
but no other abnormality. X-ray 
films remain normal.
Discussion
This case illustrates a number of 
important points concerning PCL 
injuries in children. First, as noted 
elsewhere,1 there must be an aware­
ness of PCL injuries for patients of 
all ages. While rare, isolated PCL 
injuries can occur in children. Sec­
ond, avulsion of the femoral attach­
ment of the PCL could not be seen 
on the original x-ray films in our 
patient, probably because the inser­
tion site had not yet ossified. Subse­
quent x-ray films showed the ossify­
ing fragment. While it is possible 
that fragment displacement was a 
late event, it seems more likely that, 
as reported by Sanders and col­
leagues17 and Frankl and Wasilew- 
ski10 it was simply not visible on 
original plain x-ray films. Arthro­
scopic examination of our patient’s 
knee at the time of the original 
injury would have been the only 
means of confirming the site of the 
PCL lesion and should likely be 
considered in all suspicious lesions 
in children, as in adults. Third, over 
the year that the avulsed PCL was 
missed, the ligament either short­
ened, as noted in a case described 
by Meyers,14 or failed to grow in 
proportion to the joint, causing it 
to be too short to reattach. Rather 
than attaching the rounded-off frag­
ment to an abnormal location on 
the femur,14 we trimmed it. This 
cured the symptom of locking 
which clearly had been due to the 
impingement of this avulsed inser­
tion; this is an interesting and previ­
ously unsuspected potential cause 
of locking.
The last important point in this 
case revolves around the treatment
controversy, which is based on con­
flicts or deficiencies in the litera­
ture. Even acutely repaired avul­
sions121617 of ligaments in children 
have not had perfect subjective and 
objective results at 2-year follow­
up. A PCL reconstruction, the only 
other surgical option, is without 
documented precedent in a child. 
The most successful PCL recon­
structions in adults use bony tun­
nels,5 which would not be appropri­
ate in children. Other options for 
PCL reconstruction111219 20 similarly 
cannot guarantee a safe and reliable 
method for treating a child’s knee.
The 3.5-year follow-up of this 
patient suggests that, as with the 
adult,2'6-915 the pediatric PCL-defi- 
cient knee is subjectively very satis­
factory in the short term, despite 
being objectively lax. This does not 
mean, however, that our patient will 
not experience symptoms in the 
future.5-614 If his knee does not 
deteriorate, however, as seen in the 
short-term follow-up of other series 
of adult PCL deficiencies,9'15'21 then 
long-term conservative management 
of pediatric PCL deficiencies may 
suffice. From our experience with 
short-term follow-up, conservative 
management of PCL deficiencies in 
children, for at least a few years, 
may be justified.
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Lymphoma Pancreatitis: a Real Entity
C.A. Kotwall, MD, MSc, FRCSC; J.R. Brow, MD, FRCPC; R.G. Keith, MD, FRCS, FRCSC
Pancreatitis induced by malignant disease is uncommon. A case of lymphoma 
presenting as acute pancreatitis and subsequent pancreatic abscess is reported; this 
led to the patient’s death, 6 weeks after the initial attack of pancreatitis. Five other 
reports are reviewed. The pancreatitis always preceded the diagnosis of lymphoma 
and the preoperative diagnosis was always difficult.
Lymphoma pancreatitis should, therefore, be considered in the etiology of acute 
pancreatitis, especially if the more likely causes have been ruled out.
Les pancreatites provoquees par les cancers sont peu frequentes. On decrit un cas de 
lymphome qui prit les apparences d’une pancreatite aigue, puis, subsequemment, 
d’un abces pancreatique; le patient deceda 6 semaines apres Faeces de pancreatite 
initial. Cinq autres cas sont passes en revue. Chaque fois, la pancreatite preceda le 
diagnostic de lymphome et celui-ci fut toujours difficile a etablir en preoperatoire.
La pancreatite d’origine lymphomateuse devrait done etre envisagee dans 
l’etiologie de la pancreatite aigue, surtout si les causes les plus probables ont deja 
ete eliminees.
A mong the various causes of pancreatitis, that which is tu­
mour induced is unusual. Pancreati­
tis associated with primary adeno­
carcinoma of the pancreas is well 
known,1 but that induced by lym­
phoma is rare. We report a case of 
abdominal lymphoma presenting as 
severe acute pancreatitis and pan­
creatic abscess.
Case Report
A 31-year-old man had a 3-day 
history of epigastric pain radiating 
to the back. He had previously felt 
well and was only an occasional 
social drinker. On abdominal exami­
nation, he had marked localized 
tenderness in the epigastrium and 
left upper quadrant. The leukocyte 
count, hemoglobin and serum calci­
um levels and results of liver func­
tion tests were normal; the serum 
amylase value was 340 U/L (nor­
mal 25 to 115 U/L). Ultrasonogra­
phy revealed enlargement of the 
neck, body and tail of the pancreas. 
The pain resolved with conservative 
management and he was dis­
charged.
He was readmitted 1 week later 
with recurrent severe epigastric 
stabbing pain and nausea. He had 
acute epigastric tenderness but no 
peritoneal signs. The serum amy­
lase level on admission was 222
U/L. He became progressively ic­
teric with a serum bilirubin level of 
115 jim ol/L  (normal < 17
jumol/L), a serum aspartate amino­
transferase level of 175 U /L (nor­
mal 25 to 41 U/L) and a serum 
alkaline phosphatase level of 608 
U/L (normal 25 to 96 U/L). Com­
puted tomography revealed consid­
erable thickening of the pancreas, 
consistent with acute pancreatitis. 
The patient’s pain subsided, but 
because of progressive jaundice and 
abdominal distension he was trans­
ferred to our hospital.
He appeared ill and had gross 
ascites, right upper quadrant ten­
derness and diffuse guarding. Ab­
dominal paracentesis was performed 
and 1350 ml of thick fluid was 
obtained, culture of which grew 
Staphylococcus aureus and Strepto­
coccus faecalis. Computed tomogra­
phy revealed a 9-cm phlegmonous 
mass in the head of the pancreas, a 
fluid collection in the lesser sac, 
and free intraperitoneal fluid (Fig. 
1). Nine days after admission he 
became febrile (leukocyte count of 
20 X 109/L ) and antibiotics were 
prescribed. The serum bilirubin 
level was 236 txmo\/L, serum as­
partate aminotransferase 133 U/L, 
alkaline phosphatase 535 U /L and 
serum lactic dehydrogenase 3160 
U/L (normal < 150 U/L). The 
sepsis did not resolve and, because 
of progressive respiratory and renal 
insufficiency, surgery was per­
formed 13 days after transfer, the 
preoperative diagnosis being pan­
creatic abscess.
At laparotomy, the patient’s pan­
creas was grossly enlarged and in-
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durated; the process involved most­
ly the head but also included the 
body and tail of the pancreas. There 
was an infected lesser sac pseudo­
cyst with surrounding retroperito­
neal inflammation and friability of 
all blood vessels. Th. greater omen­
tum was preinfarctive. Liver and 
gallbladder appeared normal. The 
lesser sac was drained of fluid and 
necrotic debris; the retroduodenal 
space and right paracolic gutter 
were explored, but no collection 
was found. Greater omentectomy 
was performed. There was an ex­
traordinary amount of retroperito­
neal bleeding that required packing. 
Intraoperatively, the patient re­
quired 16 units of packed cells and 
considerable inotropic support. He 
was returned to the intensive care 
unit in irreversible shock and died 
the following day, 6 weeks after the 
illness began. Pathological exami­
nation of the greater omentum dis­
closed poorly differentiated lympho­
cytic lymphoma extensively infil­
trating adipose tissue. The patient’s 
family would not give permission 
for an autopsy.
Discussion
There is no doubt that epithelial 
cancers, both primary and metastat­
ic to the pancreas, can induce acute 
pancreatitis. In the Mayo Clinic se­
ries1 of 255 consecutive patients 
with pancreatic and ampullary ade­
nocarcinoma, acute pancreatitis was 
present and preceded the diagnosis 
of carcinoma in 26 (10.2%). Meta­
static tumours invading the pancre­
as and causing acute pancreatitis 
are much less common. There are 
isolated reports in the literature 
with primary sites in the stomach,2 
lung (squamous cell and small cell 
cancer)3-5 and tonsil.2 In McLatchie 
and Imrie’s prospective study2 of 
360 patients with acute pancreati­
tis, 7 (1.9%) were found to have
disease metastatic to the pancreas. 
In six of these seven patients, acute 
pancreatitis preceded the diagnosis 
of carcinoma.
Malignant lymphoma can also in­
volve the pancreas. In the series of 
Erlich and colleagues6 of 323 pa­
tients with lymphoma, in all of 
whom autopsy was done, the pan­
creas was the most common gas­
trointestinal organ to be invaded by 
tumour. This occurred in 86 pa­
tients (26.6%); however, there was 
no mention of acute pancreatitis 
secondary to the lymphoma. Pres­
ently, the incidence of “lymphoma 
pancreatitis” is unknown.
Five reports in the literature doc­
ument a total of six patients with 
lymphoma pancreatitis.7-11 Five of 
them had non-Hodgkin’s lympho­
ma, and one had Hodgkin’s lym­
phoma and pancreatitis. In all six 
patients plus our patient, acute pan­
creatitis was the presenting mani­
festation and occurred an average 
of 5 weeks before the definitive 
diagnosis of lymphoma was made. 
Two of the patients presented with 
acute pancreatitis and pancreatic 
abscess. Obtaining tissue for histo­
logic confirmation of a pancreas 
suspected of harbouring lymphoma 
is important, because two of the 
five patients with known follow-up 
who received chemotherapy and ra­
diotherapy survived 1 year from the 
time of diagnosis. At present, how­
ever, we can offer no criteria for the 
diagnosis of lymphoma pancreatitis, 
aside from any suspicious findings 
at the time of laparotomy.
The pathophysiology of tumour 
pancreatitis is still speculative. Pro­
posed mechanisms include ductal 
obstruction,5 ductal obstruction and 
rupture with direct parenchymal tu­
mour invasion34 and ischemia sec-
FIG. 1. Computed tomogram at level of head of pancreas, showing 9-cm 
phlegmonous mass in head (2), fluid collection in anterior lesser sac (1) and free 
intraperitoneal fluid (3).
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ondary to vascular occlusion  by 
tum our.3
The entity o f  tum our or lym pho­
ma pancreatitis is not to be co n ­
fused w ith tum our lysis pancreati­
tis.12 T he latter process refers to  a 
tum our o f  the pancreas, such as a 
lym phom a, that is exquisitely sensi­
tive to chem otherapy. Chem othera­
py induces a rapid tum our lysis in 
the pancreas leading to  an extensive 
inflammatory response subsequent­
ly inciting acute pancreatitis.
In summ ary, lymphoma pan­
creatitis is a very real disease entity, 
although rare, and almost always 
precedes the diagnosis o f  lym pho­
ma. If the cause o f  acute pancreati­
tis is unclear, and the usual causes 
(gallstones, alcohol, metabolic fac­
tors, drugs and various toxins) have
BOOK REVIEW S
continued from page 372
an introductory text in computed to­
mography would be more useful.
W.L. Gordon, MD, FRCPC
Department o f  Radiology,
Health Sciences Centre,
820 Sherbrook St.,
Winnipeg. Man.
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SURGERY OF THE STOMACH. Indi­
cations, Methods, Complications. Edit­
ed by H.D. Becker, Ch. Herfarth, W. 
Lierse and H.W. Schreiber. 374 pp. 
Illust. Springer-Verlag New York, 
Inc., Secaucus, NJ, 1988. $240.00 
(US). ISBN 0-387-17116-9.
This multiauthored text deals primarily 
with operative techniques for treating 
gastric and duodenal diseases and is 
aimed at the practising gastric surgeon. 
Although most o f the contributors are 
from West Germany, some are from 
France, the US and the UK (notably
been ruled out, lym phom a or other 
tum ours must be considered as a 
cause for the pancreatitis.
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PERSPECTIVES IN VASCULAR 
SURGERY. Edited by Jerry Goldstone. 
162 pp. Illust. Quality Medical Pub­
lishing, Inc., St. Louis, 1988. Price 
not stated. ISSN 0894-8046.
This book, the first issue o f a semi­
annual publication produced by Vascu­
lar Surgery Outlook, is intended as a 
new concept in vascular surgery publi­
cation, filling the gap between scientifi­
cally oriented journals and textbooks.
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Femoral Appendicitis: An Unusual Case
E.M. Guirguis, MD, CCFP; G.A. Taylor, MD, FRCSC; C.D.J. Chadwick, MD, FRCSC
The presentation of acute appendicitis in a strangulated femoral hernia is rare. The 
authors describe what they believe is the first reported case of necrotizing fasciitis 
as a consequence of a gangrenous appendix in this situation. An 80-year-old woman 
presented with crepitant cellulitis of her right thigh with fever and leukocytosis, 
leading to a preoperative diagnosis of necrotizing fasciitis. Intraoperatively, an 
unsuspected gangrenous appendix was found in an incarcerated femoral hernia. A 
knowledge of the existence of this rare and serious condition will avoid delay in its 
recognition and management.
II est rare de decouvrir une appendicite aigue dans un cas de hernie femorale 
etranglee. Les auteurs decrivent ce qu’ils croient etre le premier cas de fasciite 
necrosante en resultat d’appendice gangreneux a survenir dans une telle situation. 
Une femme de 80 ans presentait une cellulite crepitante a la cuisse gauche, avec 
pyrexie et leucocytose, le tout compatible avec un diagnostic preoperatoire de 
fasciite necrosante. A l’operation, on decouvrit un appendice gangreneux enclave 
dans une hernie femorale. On pourra eviter des delais de diagnostic et de traitement 
en gardant a l’esprit l’existence de cette affection rare mais serieuse.
A lthough rare, the finding of acute appendicitis in an incar­
cerated femoral hernia has been 
reported previously.1' 10 The signs 
and symptoms usually relate to the 
gastrointestinal tract and the skin 
overlying the hernia.16-8 We en­
countered a patient with gangre­
nous appendicitis in an incarcerated 
femoral hernia, presenting with nec­
rotizing fasciitis of the right thigh, 
without gastrointestinal or abdomi­
nal signs and symptoms. To our 
knowledge, such a presentation has 
not previously been reported.
Case Report
An 80-year-old diabetic woman 
presented with a 5-day history of
increasing pain, swelling and red­
ness of the right medial thigh, with 
intermittent fever.
Her medical history included atri­
al fibrillation, hypertension and 
non-insulin-dependent diabetes. She 
was taking digoxin, furosemide, 
glyburide and acetaminophen.
On examination, her temperature 
was 37.8°C, blood pressure 
110/70 mm Hg, pulse rate 128 
beats/min (irregularly irregular) 
and respiratory rate 20/min. She 
appeared ill and distressed and com­
plained of pain in the right thigh. 
An area of cellulitis over the middle 
portion of the medial thigh mea­
sured approximately 12 cm in diam­
eter. The affected area was notably 
crepitant on palpation. The abdomi­
nal examination revealed normal
bowel sounds and a soft, nontender 
abdomen, with no palpable or­
ganomegaly or masses.
The patient’s hemoglobin level 
was 155 g /L  and the leukocyte 
count was 11.0 X 109/L  (normal 
differential). Her blood glucose level 
was 35.1 mmol/L. X-ray films of 
the right thigh showed soft-tissue 
edema and extensive gas within the 
soft tissues (Fig. 1). Three-view 
films of her abdomen appeared nor­
mal.
A clinical diagnosis of necrotizing 
fasciitis of the right thigh was 
made, and the patient was taken to 
the operating room for drainage 
and debridement. Using a longitudi­
nal incision over the erythematous 
area, we initially encountered ede-
FIG. 1. Preoperative x-ray film of right 
thigh with soft-tissue penetration 
shows extensive soft-tissue gas in 
upper medial thigh extending down 
great saphenous vein.
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matous inflammatory tissue but no 
sign of suppuration or tissue necro­
sis; however, on dissecting upward 
toward the inguinal ligament, we 
found a large, foul-smelling cavity 
containing pus and necrotic tissue. 
It was then apparent that the septic 
process originated in the femoral 
canal. Exploration of the femoral 
canal through an oblique inguinal 
incision revealed an incarcerated 
femoral hernia containing a gangre­
nous perforated appendix. A culture 
swab, taken from the right thigh 
intraoperatively, grew diphtheroids, 
Bacteroides oralis, and group B 
(8-hemolytic streptococci.
Comment
In their review of the literature, 
Jackson and Bell11 categorized gan­
grenous and necrotic soft-tissue in­
fections. Necrotizing fasciitis is 
characterized by an acute inflamma­
tory process, involving the subcuta­
neous tissue and the deep fascia, 
and toxemia. Two different sets of 
organisms have been isolated from 
patients with necrotizing fasciitis. 
One set (isolated from 81.2% of 
subjects) consists of aerobes and 
anaerobes: the aerobes include a 
variety of streptococci and en­
terobacteria and the anaerobes in­
clude Bacteroides sp and peptos- 
treptococci. The other set of organ­
isms (18.8%) consists of group A 
streptococci (Streptococcus pyo­
genes), either alone or with a few 
staphylococci (Staphylococcus au­
reus or Staphylococcus epidermi-
dis).n M Culture of material from 
this patient’s thigh resulted in isola­
tion of the organisms more fre­
quently associated with necrotizing 
fasciitis.
Necrotizing fasciitis is most fre­
quently found in debilitated patients 
such as those suffering from alco­
holism, severe diabetes, malnutri­
tion, advanced age, ulcerative coli­
tis, Crohn’s disease, an im­
munocompromised state and severe 
arteriosclerosis of large or medium­
sized vessels. Our patient’s age and 
diabetic state were likely contribut­
ing factors in the development of 
her necrotizing fasciitis.
Although the finding of acute 
appendicitis in a femoral hernia has 
been well documented,1-10 the pre­
sentation of necrotizing fasciitis due 
to the condition has not previously 
been reported. Although the fre­
quency of acute appendicitis in fem­
oral hernias is unknown,1 an esti­
mated 0.13% of cases of acute 
appendicitis occur in various exter­
nal hernial sacs.4 9
Gangrenous appendicitis in a 
strangulated femoral hernia is 
thought to be caused by constric­
tion of the lumen of the appendix 
by the neck of the hernial sac,5 
leading to inflammation and subse­
quent gangrene of the appendix.1 In 
this case the infection spread into 
the right medial thigh, resulting in 
the development of a fulminant nec­
rotizing fasciitis. This complication 
was the major presenting feature 
and overshadowed the signs and 
symptoms of the underlying abdom­
inal condition.
In approaching patients with 
crepitant cellulitis of the thigh, a 
knowledge of the existence of this 
extremely rare but serious condition 
will avoid delay in its recognition 
and management.
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Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in­
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram­
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin­
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the 
infections listed below when caused by susceptible strains of the designated 
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ­
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; 
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains); 
Staphylococcus aureus (including penicillinase-producing but excluding 
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epider­
midis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia 
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to 
Pseudomonas infections of the urinary tract, a good clinical response accompanied 
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus 
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides 
sp. (including 8 .  fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. 
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains); 
Escherichia coli; Bacteroides sp. (including 8 . fragilis); Klebsiella sp.; and Serratia 
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli; 
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci 
but including Group A B-hemolytic Streptococcus pyogenes); Proteus mirabilis; 
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including 8. fragilis); Peptococcus 
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto­
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to 
identify the causative organisms and to determine their susceptibilities to cefti­
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility 
studies are known. However, modification of the treatment may be required once 
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have 
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group 
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hyper­
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM 
should be given cautiously to penicillin-sensitive patients. Antibiotics, including 
CefizoxTMi should be administered with caution to any patient who has demon­
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi­
zoxTM occurs, its administration should be discontinued. Serious acute hyper­
sensitivity reactions may require epinephrine and other emergency measures. 
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other 
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis­
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may 
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium 
difficile  is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte and protein supplementation as 
indicated. When the colitis is not relieved by drug discontinuance or when it is 
severe, consideration may be given to the administration of oral vancomycin or 
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in 
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti­
zoxime sodium) has produced alterations in renal function. Renal status should be 
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible 
organisms including species originally sensitive to the drug. Careful observation of 
the patient is essential. If superinfection occurs during therapy, appropriate 
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of 
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, 
patients with impaired renal function (i.e., creatinine clearance <1.32 mL/s or 
<79 mL/min) should be placed on a special dosage schedule recommended under 
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to 
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and 
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM 
concomitantly with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The 
use of CefizoxTM in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus. The pharmacokinetics 
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies 
performed in rats and rabbits have revealed no evidence of impaired fertility or harm 
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not 
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and 
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations 
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi­
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to 
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM in infants less than 6 months of age 
has not been established. In children six months of age and older, treatment with 
CefizoxTM has been associated w ith transient elevated levels of eosinophils, 
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related 
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age- 
dependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction
Incidence
<1%
Incidence 
>1%  but <5%
Hypersensitivity: Rash
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no 
specific information available on symptoms or treatment. In cases of suspected 
overdosage, supportive therapy should be instituted according to symptoms. Serum 
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly 
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the 
patient, severity of the infection and susceptibility of the causative organism(s). The 
intravenous route may be preferable for patients with bacterial septicemia, or other 
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at 
least 48 hours after evidence of bacterial eradication has been obtained. For 
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is 
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams admin­
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500 mg q12h, IV or IM
Other Sites 2-3 1 g q8h or q12h, IV or IM
Severe or 
Refractory
3-6 1 g q8h, IV or IM, to 
2gq8h orq12h, IV orIM*
Life-Threatening 9-12 3o r4 g  q8h IV
*When administering 2 g intramuscularly, the dose should be divided and injected 
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas 
aeruginosa and because many strains are only moderately susceptible to CefizoxTM, 
higher dosage may be appropriate when urinary tract infections are caused by 
these organisms. Other therapy should be instituted if the response is not prompt.
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Adults with Impaired Renal Function: In patients in whom the creatinine clearance 
is  1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Fo llow ­
ing an in itia l loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing 
schedule presented in Table 2 should be followed in patients with reduced renal 
function.
TABLE 2
Renal
Function
Creatinine 
Clearance 
mL/s mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to 
severe impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hem odialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to l.Og 
q48h or 500 mg 
q24h
*ln patients undergoing hem odialysis no additional supplemental dosing is 
required. DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT 
RECEIVES THE DOSE AT THE END OF THE DIALYSIS. When started 24 hours after 
adm inistration of 1 g o f CefizoxTM, hemodialysis has been shown to reduce serum 
levels by 50%.
When only the serum creatinine level is available, creatinine clearance may be 
calcu lated from the follow ing formulae (for patients 18 years and over only). The 
serum creatinine level should represent renal function at the steady state.
Males:
Creatin ine Clearance Weight (kg)x(140-age)
(mL/min) 72 x serum creatinine (mg/100 mL)
Creatin ine Clearance 
(ml_/s)
Weight (kg) x 140 - age)
49 x serum creatinine ( /xmol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.),
and 50mg/kg IVorIM q6h orq8h, IV or IM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious 
infections.
ADMINISTRATION
Intramuscular: The reconstituted solution of CefizoxTM should be injected well 
w ithin the body of a relatively large muscle, such as the gluteus. When adm inister­
ing 2 g IM doses, the dose should be divided equally and then injected into different 
large m usc le  masses.
Intravenous: Injection (bolus): The reconstituted so lution of CefizoxTM should be 
injected s low ly  over 3 to 5 minutes, directly or through the tubing system by which 
the patient is  receiving another com patib le intravenous solution. During adm inistra­
tion of the so lution containing CefizoxTM, it is desirab le to temporarily discontinue 
adm inistration of the other solution.
Intermittent or continuous infusion: The further diluted reconstituted so lution of 
CefizoxTM should be administered over a 20 to 30 m inute period.
NOTE: CefizoxTM so lutions should not be physica lly m ixed with any other drug. 
There is a known incompatib ility with am inoglycoside antib iotics. Therefore, they 
should not be physically mixed with CefizoxTM so lu tions nor administered at the 
same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium (6R-[6°», 76(Z)]]-7 -[[(2 ,3 -d ihydro -2-im ino-4-th iazo ly l) 
(m ethoxy im ino)ace ty l]am ino]-8 -oxo-5-th ia -1 -azab ilcyc lo  [4.2.0] o c t -2 -e n e -2 -  
carboxylate
Structural Formula:
COON,
Molecular Formula: C 1 3 H i 2 N 5 0 5 S 2 Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow  crysta lline powder.
Composition: CefizoxTM via ls contain ceftizoxime sodium  (expressed in terms 
of^  free acid). The sodium content o f each gram of CefizoxTM is  approximately
mg (2.6 mEq sodium ion).
So lu tions o f CefizoxTM range from colourless to pale yellow, depending upon the 
diluent and volume used. The so lution should be d iscarded if it becomes cloudy. 
The pH of freshly reconstituted so lutions usually ranges from 6.0 to 8.0.
A so lution o f 1 g CefizoxTM jn 13 mL Sterile Water for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 GRAM and2GR^S)
For Intramuscular Injection: Reconstute w it h  S te r ile  Water for Injection or Bac­
teriostatic Water for Injection.
Reconstitution Table fcS ta n d a rd  Vials - I.M. Injection
Vial
Size
D iluent to be 
Added to Vial
A p p r o x im a te
A v a i la b le
V o lu m e
Approximate
Average
Concentration
ig 3.0 mL 3 .7  m L 270mg/mL
2g 6.0 m L 7 .4  m L 270 mg/mL
Shake well until d isso lved.
For Intravenous Injection: Reconstitus o n ly  w ith  Sterile  Water for Injection.
Reconstitution Table fv S ta n d a rd  Vials - I.V. Injection
A p p ro x im a te Approximate
Vial D iluent to be A v a i la b le Average
Size Added to Vial V o lu m e Concentration
1 g 10 m L 1 0 .7  m L 95 mg/mL
2g 20 m L 2 1 .4  m L 95 mg/mL
Shake well until d isso lved.
For Intravenous Infusion: Reconstitute a s  fo r  intravenous injection. Further 
dilute the reconstituted so lution to 50 to  100  m L  with one of the “So lutions for 
Intravenous Infusion” (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection 
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% S o d iu m  C h lo r id e  Injection
Ringer’s Injection
Lactated Ringer’s  Injection
10% Invert Sugar in Sterile  Water for Injection
5% Sodium Bicarbonate in  Sterile Water fo r In je c tio n
5% Dextrose in Lacta ted Ringer’s In je c tio n  O N LY  when reconstituted with 
4% Sodium Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: A ll reconstituted solutions and  th o s e  further diluted shou ld  be used 
within 24 hours if stored at room tem perature  o r w ithin 48 hours if refrigerated. 
These storage lim its are from  the time o f the  in it ia l reconstitution.
Incompatibility: CefizoxTM should not be added  to blood products, protein 
hydrolysates or am ino a c id s . CefizoxTM sh o u ld  not be m ixed together with an 
aminoglycoside.
DOSAGE FORMS
Availability: CefizoxTM jS available a s  a  s te r i le  powder in Standard V ia ls of 
1 gram or 2 grams, con ta in ing  ceftizoxime a s  so d iu m  salt.
Storage: CefizoxTM  powder for injection sh o u ld  be stored at room temperature 
(15°-30°C).
FOOTNOTES
’As indicated in the manufacturer's product monograph. Cefizox, Sm ith  Kline & French Canada Ltd ., 1988.
2As indicated in the manufacturer's p roduct monograph cefoxitin, M e rck  Sharp & Dohme Canada, 1985.
3LouM.A. etal.: 14th International Congr. Chemother., Kyoto, Japan. June  1985, pp 2378-2379.
4Neu H.C., Chin N .X .: The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. 
Chemioterapia 1985;4:271-277.
5Fu K.P, Neu H.C.: Antibacterial activ ity o f ceftizoxime, a B-lactamase-stable cephalosporin Antim icrob Aaents 
Chemother. 1980;12:583-590.
6Thornsberry C.: Review of in vitro activ ity  of third-generation cephalosporins and other newer beta-lactam antibiotics 
against clinically important bacteria. Am . J. Med 1985;/y (Suppl. 2A): 15-20.
7DrulakM.W., Chow A.W .: Comparitive in vitro activity of ceftizoxime cefoperazone and cefoxitin against anaerobic 
bacteria. Antimicrob. Agents Chemother. 1981;20:683-685.
8Aldridge K.E. et a l.: Comparision of the activities of penicillin 6  and new B-lactam antibiotics against clin ical isolates of 
Bacteroides species. Antimicrob. Agents Chemother 1984;26(3):410-413.
9Adapted from Parker D.D.: Abstr. Annu. Meet. Am, Soc. M icrobiol..Atlanta, GA, March 1987, Abstract no. A-107, p. 18. 
10Kitzmann R. Cost analysis of the ecom om ic effect of replacement of cefoxitin with ceftizoxime. Presented at the 45th 
Annual Meeting, American Society of Hospital Pharmacists. San Francisco, California.
’ ’ Guastell C. Cost savings realized from  interchanging ceftizoxime for cefoxitin Am  J  Hosd Pharm 1988 
Nov;45:2376-2377.
12Wikler M.A. et al.: Efficacy of ceftizoxime administered twice daily fo r the treatment of serious in fections in hospitalized 
patients. Infect. Med. 1986;(Suppl.):9-12.
,3Data on file. Sm ith Kline & French Canada Ltd.
14Sanford J . P : Guide to Antim icrobial Therapy. West Bethesda, MD:Antim icrobial Therapy Inc. 1988:50.
,5RichardsDM. Heel RC. Ceftizoxime: A  review of its antibacterial activity, pharmacokinetic properties and therapeutic 
use. Drugs 1985:29:281-329. K
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Carcinoids of the Kidney: Case Report and 
Literature Review
Saad Juma, MD;* J. Curtis Nickel, MD, FRCSC;* Iain Young, MD, FRCPCt
Primary carcinoids of the kidney are very rare, only 10 cases having been reported 
in the literature. The authors report a case of primary renal carcinoid in a 
50-year-old woman. A radical nephrectomy with lymphadenectomy was successfully 
performed and there was no residual or recurrent tumour at 2-year follow-up. A 
review of the reported cases revealed a variable, nonspecific presentation. Most 
laboratory tests were non-contributory except for urinalysis. When a renal carcinoid 
is diagnosed, a search should be made for a possible primary elsewhere. Primary 
renal carcinoid does exhibit malignant behaviour. It should be managed by radical 
nephrectomy with retroperitoneal lymphadenectomy.
Les carcino'ides renaux primitifs sont tres rares. Seulement 10 cas ont ete decrits 
dans la presse medicale. Les auteurs en signalent un cas chez une femme de 50 ans. 
Une nephrectomie radicale avec lymphadenectomie fut pratiquee avec succes; il n’y 
avait ni tumeur residuelle, ni recidive, a l’examen de controle, 2 ans plus tard. 
L’etude des cas signales revele un tableau clinique variable et non specifique. A part 
le test d’urine, la plupart des examens de laboratoire ne sont d’aucun apport au 
diagnostic. Quand un carcinoide renal est diagnostique, une autre tumeur primitive 
devrait etre recherchee. Les carcino'ides renaux primitifs mainfestent un comporte- 
ment malin. Le traitement consiste a pratiquer une nephrectomie radicale avec 
lymphadenectomie retroperitoneale.
P rimary renal carcinoids are very rare tumours that arise from 
cells of neuroendocrine origin (Kul­
chitsky cells). The presence of these 
cells in the kidney, however, has 
been a source of controversy since 
they are not known to be a compo­
nent of the normal kidney. Several 
theories have been proposed to ex­
plain their presence, including neu­
roendocrine cell ectopia or seque­
stration,1 neuroendocrine metapla­
sia of mesodermal tissue2 3 and neu-
Accepted for publication Mar. 15, 1989
roendocrine differentiation of cells 
regardless of their embryonic ori­
gin.4
We report a case of primary renal 
carcinoid with regional nodal metas­
tasis.
Case Report
A 50-year-old woman was re­
ferred to our unit for further evalu­
ation of a left renal mass discovered
by ultrasonography, which was 
done to find the cause of her epi­
gastric pain and weight loss. She 
had undergone appendectomy, hys­
terectomy and cholecystectomy and 
was allergic to intravenous contrast 
dye. Her medical history was other­
wise unremarkable, and findings on 
physical examination were within 
normal limits.
Results of laboratory investiga­
tions, which included complete 
blood count and measurement of 
serum electrolytes, creatinine and 
amylase, blood urea nitrogen and 
liver function, were normal. Urinaly­
sis revealed traces of blood and 
protein. The chest x-ray film ap­
peared normal. Ultrasonography of 
the abdomen revealed a left renal 
mass and a computed tomogram 
confirmed the presence of a 3 X 5 
cm solid bilobed mass with focal 
calcification in the lower pole of the 
left kidney (Fig. 1). The inferior 
vena cava, liver, spleen and other 
intra-abdominal viscera appeared 
normal.
FIG. 1. Unenhanced computed tomo­
gram shows bilobed mass with calcifi­
cation in lower pole of kidney.
From the ’"Department o f Urology and tDepartment o f  Pathology, Queen’s University, Kingston, 
Ont.
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At laparotomy, a solid mass con­
fined to the left kidney was found, 
with no evidence of extrarenal ex­
tension. Grossly, the remaining in­
tra-abdominal structures were nor­
mal. A left radical nephrectomy 
with lymphadenectomy was done. 
Postoperative recovery was uncom­
plicated.
Gross examination revealed a 
solid yellow tumour measuring 5.5 
X 3 X 2 cm, which was confined to 
the lower pole of the kidney. There 
was no capsular, pelvic or vascular 
invasion. On light microscopy, the 
tumour was composed of interlac­
ing cords of uniform cells contain­
ing central oval nuclei (Fig. 2). The 
Fontana stain was negative, but the 
Grimelius stain showed numerous 
argyrophilic granules. Immunoper- 
oxidase stains for neuron-specific 
enolase were positive and electron 
microscopy demonstrated abundant 
neurosecretory granules (Fig. 3). 
These findings are characteristic 
of a carcinoid. Three of 11 peri­
aortic lymph nodes contained meta- 
stases. Immunoperoxidase tech­
niques identified no insulin, glu­
cagon, somatostatin or calcitonin 
within tumour cells.
In view of these findings, further 
investigations were done, includ­
ing bone scanning, upper gastro­
intestinal endoscopy, colonoscopy, 
barium enema examination and ur­
inary 5-hydroxyindoleacetic acid
FIG. 2. Tumour is composed of cords 
of uniform cells with ovoid nuclei 
(hematoxylin-phloxine-saffron stain, 
original magnification X 400).
(5-HIAA). All results were normal. 
Follow-up 2 years postoperatively 
showed no residual or recurrent 
tumour.
Discussion
Twelve cases of renal carcinoid 
have been reported;1-10 however, we 
noticed two instances of duplicate 
case reporting.3 7-9 Of the remaining 
cases, only eight were adequately 
documented.1-10 The average age at 
the time of presentation was 46.8 
years and no sex tendency was 
observed. The tumour was unilater­
al in all cases with no predilection 
for either kidney. No familial ten­
dency was noted.
Clinical presentation was variable 
and nonspecific. The most common 
presenting symptoms and signs 
were abdominal pain (30%) and 
gross hematuria (20%). Patients 
were asymptomatic in 20% of the 
cases. The most consistent physical 
finding was an abdominal or flank 
mass, in 60% of the cases.1-3 6-9
Laboratory tests, including com­
plete blood count and measurement 
of serum electrolytes, blood urea 
nitrogen and creatinine levels and 
liver function test results were not 
contributory; urinalysis may reveal 
hematuria, proteinuria, glycosuria 
or pyuria. Urinary excretion of 
5-HIAA was measured in three
FIG. 3. Electron photomicrograph 
demonstrates abundant neurosecretory 
granules in cytoplasm of tumour cells 
(original magnification X 8000).
cases and was normal.47 Ul­
trasonography may demonstrate a 
renal mass and intravenous pyelog­
raphy may show a mass, dilated 
pelvis and calyces, or non-visualiza­
tion of the affected kidney, with or 
without calcification. Computed to­
mography in our case and two 
previously reported cases10 demon­
strated a bilobed renal mass with 
focal calcification. Renal angiogra­
phy was done in two cases and 
demonstrated a hypovascular or 
avascular mass.8'10 Chest x-ray films 
reported in four cases were normal. 
Bone scanning was negative in 
three cases4 5 and showed increased 
activity in another two; however, 
skeletal survey in both of these 
showed no evidence of metastatic 
deposits.27 When a renal carcinoid 
is diagnosed, a search for a possible 
primary elsewhere should include a 
small-bowel follow-through and 
barium enema.
The pathological findings in 
these cases have been more consis­
tent. The tumour was solid in six 
cases and had a cystic component in 
another three. One case was report­
ed in a benign cystic teratoma,6 and 
another in a horseshoe kidney with 
renal dysplasia.9
Microscopically, these tumours 
were composed of uniform cells 
with central oval nuclei and few 
mitotic figures (Fig. 2). Grimelius or 
Bodian stains demonstrated argyro­
philic granules in eight cases,1-7 
and the Fontana stain for argentaf- 
fian granules was positive in two 
cases and negative in six.1-7 No 
special stains were reported in three 
cases. Electron microscopy, when 
employed, consistently showed neu­
rosecretory granules in the cysto- 
plasm (Fig. 3). Immunoperoxidase 
studies were used in three cases and 
were positive for glucagon in one 
case5 and for serotonin, glucagon 
and somatostatin in another,3 and 
were negative in the third.
The association of renal carcinoid
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with the carcinoid syndrome was 
reported in one case in which the 
tumour was secreting glucagon.5 
This case does not allow for accu­
rate conclusions to be drawn, and in 
view of the scarcity of available 
information, we believe that car­
cinoid syndrome in association with 
a primary renal carcinoid should be 
treated similarly to carcinoid syn­
drome associated with a primary 
tumour outside the kidney.
Primary renal carcinoid does ex­
hibit malignant behaviour; however, 
its prognosis remains uncertain. In 
the reported cases, the tumour was 
confined to the kidney in five ca­
ses,1-36 extended through the renal 
capsule in one,5 was found at the 
resection margin in one,4 and in 
regional lymph nodes in four 
cases.5 7'8 A positive bone scan was 
reported in two cases, but neither 
patient had evidence of bone in­
volvement on skeletal survey.2'7
BOOK REVIEWS
continued from page 377
Recognized vascular surgeons review 
controversial subjects in the manage­
ment of patients with arterial insuffi­
ciency. The articles are followed by a 
critical appraisal of the review by the 
editor, to which the authors have an 
opportunity to respond. This format is 
further strengthened by a round-table 
discussion with a moderator and panel­
ists, a section focusing specifically on 
vascular techniques and a discussion of 
a case for which a second opinion is 
being sought from an established vascu­
lar surgeon.
In this first edition the role of lasers 
in vascular surgery is discussed, the 
management of patients with abdominal 
aortic aneurysms and coronary artery 
disease assessed, and a fiery defence, by 
John Porter, of the reversed saphenous 
vein graft in preference to the in-situ 
vein bypass presented. The focus on 
reconstructive techniques for venous 
obstruction and valvar incompetence is 
timely and well carried out, and many 
vascular surgeons will be interested in
Seven patients were alive after an 
average follow-up of 3.7 years and 
no deaths were reported. Treatment 
of primary renal carcinoid should be 
radical nephrectomy with retroperi­
toneal lymphadenectomy when pos­
sible. The lymphadenectomy will 
allow proper staging of the tumour, 
but the therapeutic value of the 
procedure is still unconfirmed.
We thank Dr. Paul Mozarowski for his 
help with the ultrastructural study and 
acknowledge the editorial assistance of 
Dimitra Baxter.
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opposing views in controversial areas of 
vascular surgery. The book is easy to 
read and, in general, the articles make 
their point without being verbose. The 
print is clear, the headings make the 
text easy to follow, and the diagrams 
are, on the whole, easy to read, al­
though the transverse sections of the 
thigh in Veith’s account of exposure of 
the middle and distal portion of the 
profunda femoris leave a little to be 
desired. At $191, some may find this 
book overpriced, and I suspect that this 
series will have a short life. One can 
only go so far with controversy, and 
this one volume seems to have dealt 
with most issues already, so it will be 
interesting to see what else is to come.
John L. Provan, MS, FRCS,
FRCSC, FACS
Ste. 418,
E.K. Jones Building,
160 Wellesley St. E.
Toronto, Ont.
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Persistent Ectopic Syndrome
J.D. Cairns, BM, FRCSC; D. Xuereb, MD, FRCSC
Persistent ectopic syndrome is a complication of conservative surgery for tubal 
pregnancy. This study is directed toward the escalating conservatism in the 
treatment of tubal ectopic pregnancy and its possible sequelae. Residual trophoblast 
propagation after initial surgery is becoming more frequent. Two cases are reported. 
The first woman was admitted with an acute abdomen; salpingectomy was performed 
to control hemorrhage from tubal rupture at the site of the previous salpingostomy. 
The second woman was treated by fimbrial expression. Because of the recurrence of 
pain, the beta human chorionic gonadotropin (BHCG) levels were measured; they 
indicated fresh trophoblastic activity. She was treated with methotrexate orally, 10 
m g/d for 5 days. The need for BHCG surveillance of conservatively managed tubal 
ectopic pregnancy is stressed. The value of using methotrexate when tubal integrity 
persists is discussed in the light of its traditional role against trophoblastic 
tumours.
La persistance d’un syndrome ectopique est une complication des chirurgies 
conservatrices lors des grossesses tubaires. Cette etude s’adresse a la montee du 
conservatisme dans le traitement des grossesses tubaires ectopiques et a ses 
sequelles possibles. Apres la chirurgie initiale, une propagation trophoblastique 
residuelle devient plus frequente. On en signale deux cas. La premiere femme fut 
hospitalisee en abdomen aigu; une salpingectomie fut pratiquee en vue de juguler 
une hemorragie causee par la rupture de la trompe au point de salpingostomie. La 
deuxieme femme fut traitee par extraction de la frange. A cause d’une recidive de la 
douleur, on mesura les taux de beta-gonadotrophines chorioniques humaines 
(BHCG); ils indiquaient une activite trophoblastique recente. La patiente fut traitee a 
l’aide de methotrexate par voie orale a raison de 10 m g/j pendant 5 jours. On 
souligne la necessity de surveiller les taux de BHCG dans les cas de grossesses 
tubaires ectopiques traitees de fa?on conservatrice. On commente l’interet d’utiliser 
du methotrexate quand il y a persistance de l’ integrite tubaire, a la lueur de son role 
traditionnelle contre les tumeurs trophoblastiques.
I n 1884, Lawson Tait1 first de­scribed salpingectomy for ectopic 
pregnancy. Treatment initially was 
directed at controlling intraperito- 
neal hemorrhage, but conservative 
surgical treatment before tubal rup­
ture has become more common.23 
The incidence o f ectopic preg­
nancy increased threefold in the 
years 1970 to 1980,4 and, concur­
rently, the diagnosis of unruptured 
ectopic pregnancy was facilitated 
by the use of serum /3-human chori­
onic gonadotropin (BHCG) and pel­
vic ultrasonography. The most solid 
argument for conservative surgery
over traditional resection of the 
affected tube is improved fertility. 
The worst scenario for conservative 
surgery would be an unacceptable 
incidence o f ectopic pregnancy in 
the retained tube or the persistence 
of trophoblastic tissue following an 
incomplete procedure. This report 
is concerned with the second possi­
bility — the so-called persistent 
ectopic syndrome.
Case Reports
Case 1
A 29-year-old woman (G2 PI), 
first seen at 7 weeks’ gestation 
because o f  vaginal spotting and 
abdominal pain, stated that her first 
child had been delivered by cesarean 
section and she had used an intra­
uterine device between pregnancies. 
A qualitative BHCG was positive for 
pregnancy and the uterine cavity 
was empty on pelvic ultrasonogra­
phy, but a right adnexal mass was 
described, measuring 4 x 3  cm. 
Lapafoscopy revealed a fusiform 
swelling in the isthmus o f the right 
fallopan tube. The ectopic pregnan­
cy w« evacuated by a right salpin­
gostomy- F ou r weeks after the pro­
cedure th e  woman came to the 
emerFn c y  department with an 
acute abd om en . Symptoms and 
signs w e r e  characteristic of in- 
trapedoneal hemorrhage. There 
was ) rnarked reduction in the 
hemo/lobin level. At laparotomy, 
the k fliorrhage was estimated at 
one lbT- T h e  bleeding was at the 
site a th e  previous salpingostomy. 
Examination of the resected tube
From the Department o f  Obstetrics and Gynecology, North York General Hospital, Willowdale, 
Ont.
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showed a persistent trophoblast. 
Recovery was complete and the pa­
tient later conceived and was deliv­
ered at term of a live infant.
Case 2
A 27-year-old woman (G1 PO) 
presented with uncertain menstrual 
dates, early symptoms of pregnancy 
and abdominal pain. She had been 
using an intrauterine device for 
contraception. Laboratory findings 
showed a BHCG positive for preg­
nancy (279 U/L) and an empty 
uterine cavity on ultrasonography. 
Laparoscopy showed an ectopic 
pregnancy in the right ampulla with 
blood exiting from the tubal osti­
um. At laparotomy, the distal one- 
third of the tube was “milked” to 
extrude the pregnancy. The patient 
was seen 4 weeks postoperatively, 
when she presented with abdominal 
pain. Her hemoglobin level was 142 
g /L  and BHCG 3520 U/L. Pelvic 
ultrasonography again showed an 
empty uterine cavity. Experience 
with the first case suggested persis­
tent trophoblastic activity at the 
previous ectopic site. In this in­
stance, however, there had been no 
hemorrhage. Methotrexate orally 
was prescribed (10 m g/d for 5 
days). Serial determinations of 
BHCG were recorded for 7 weeks. 
Levels declined from 3080 U/L to 
366 U/L over the initial 12 days. A 
week later the level was 75 U/L 
and the next week 34 U/L. Ten 
weeks after the conclusion of che­
motherapy, the patient had her first 
menstrual period. Since then she 
has been pregnant on two occa­
sions: on the first, she had a miscar­
riage at 6 to 8 weeks and on the 
second, she had a term pregnancy.
Discussion
Persistent ectopic syndrome is 
defined as the persistence of tro­
phoblast at the operative site. The 
incidence of this complication is 
unknown, but it will likely increase 
as the numbers of ectopic pregnan­
cies and conservative procedures 
rise.
It is almost certain that micro­
scopic amounts of trophoblast re­
main following fimbrial expression 
and salpingostomy. Fimbrial expres­
sion is especially likely to leave 
trophoblast behind and is possibly 
contraindicated for that reason. 
Parmley5 pointed out that the major 
propagation in ampullary pregnancy 
is between serosa and muscularis. 
This type of ectopic pregnancy 
should be treated by salpingostomy. 
In the isthmus, propagation occurs 
in the tubal lumen and lends itself 
to salpingostomy or mid-segmental 
resection, with anastomosis at a 
later date.
Morbidity from persistent ectopic 
syndrome is related to in- 
traperitoneal hemorrhage, as exem­
plified in case 1. Initially, there was 
confusion over the appearance of a 
secondary hemorrhage, and this led 
to a delay in diagnosis.
Bell and colleagues6 reviewed 
nine cases of persistent ectopic syn­
drome, including the first reported 
by Kelly and associates7 in 1979. 
The characteristics common to each 
case include a conservative proce­
dure for ectopic pregnancy, fol­
lowed by an acute abdomen caused 
by hemorrhage at the operative site. 
It is important, when conservative 
measures are offered, that an expla­
nation of possible postoperative 
problems should include persistent 
ectopic syndrome.
Management depends on early 
recognition. Johnson and associ­
ates8 and Rivlin and colleagues9 
insist on follow-up of conservative 
procedures by serial measurement 
of BHCG levels, the first of which 
should be performed 14 days after 
the initial surgery. If the level has 
dropped markedly, there is no need
for further surveillance. If, however, 
the levels plateau or rise, persistent 
trophoblastic activity is indicated. 
If, as in our case 1, there is in- 
traperitoneal bleeding, early salpin­
gectomy is necessary. If there is no 
bleeding, laparoscopy should be 
performed to assess the affected 
tube, and depending on these find­
ings, chemotherapy or salpingecto­
my should be recommended. The 
use of methotrexate has been 
adopted as one option in the man­
agement of trophoblastic tumours. 
More recently, this agent has been 
used in some ectopic pregnancies 
associated with unusual surgical 
risks, such as cervical pregnancy,10 
cornual pregnancy,11 abdominal 
pregnancy and pregnancy associat­
ed with hyperstimulation syn­
drome.12 If methotrexate is effective 
in these circumstances, it should 
provide an effective option for some 
patients who have persistent ectopic 
syndrome, diagnosed early and who 
do not have intraperitoneal he­
morrhage.
Higgins and Schwartz13 and 
Cowan and colleagues14 reported 
excellent results following the use 
of methotrexate for persistent ec­
topic syndrome, with no indication 
of a toxic reaction. Each group 
used a different dosage. The mini­
mum effective dose is not known. 
Ichinoe and colleagues15 believe 
that the dose should be tailored to 
the trophoblast activity evidenced 
by quantitative BHCG estimates. To 
date no failures have been reported 
following treatment of residual tro­
phoblast with methotrexate.
Conclusions
Persistent ectopic syndrome is a 
recognized complication of conser­
vative tubal surgery for unruptured 
ectopic pregnancy. Although few 
cases have been reported, the num­
bers will likely increase as the num-
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ber of conservative procedures 
being performed rises. The conse­
quences of persistent ectopic syn­
drome relate to the severity of in- 
traperitoneal hemorrhage. Conser­
vative surgical techniques for un­
ruptured ectopic pregnancy must be 
followed by measurement of BHCG 
levels. If persistent ectopic syn­
drome occurs, consideration should 
be given to chemotherapy using 
methotrexate.
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As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
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CARDIAC SURGERY: ON -  Unique opportu­
nity for several licensed physicians/surgeons 
to assist in operating room for expanding 
cardiac surgery program. Surgical experience 
preferred, but willing to train suitable appli­
cants. Fee for service remuneration. Must 
have, or be eligible for, licence with the 
Ontario College of Physicians and Surgeons, 
and have CMPA insurance. Interested appli­
cants please submit a detailed resume to: 
Victoria Hospital, Division of Cardiovascu­
lar and Thoracic Surgery, 370 South 
Street, Ste. C102, London, ON, Canada 
N6A 4G5. For further information please 
call: (51 9) 672-3300. -S89-31
UNIVERSITY CHAIRMAN, DIVISION OF 
UROLOGY: ON -  The Department of Sur­
gery, University of Toronto, is seeking appli­
cants for the position of University Chairman 
of the Division of Urology. The incumbent is 
responsible for the clinical care, teaching and 
research programs in eight fully affiliated 
teaching hospitals in the University of Toron­
to. The applicant should have demonstrated 
leadership ability as well as an established 
reputation in academic urology, including 
teaching and research. The position of Chief
of Urology at the Toronto Hospital (including 
the Toronto General and Toronto Western 
Divisions) will also be vacant as of July 1, 
1990 and may be offered to the University 
Chairman of Urology. In accordance with Ca­
nadian immigration requirements, this adver­
tisement is directed primarily to Canadian 
citizens or permanent residents. Applicants 
should send a letter and accompanying curric­
ulum vitae to: Dr. B. Langer, R.S. McLaugh­
lin Professor and Chairman, Department of 
Surgery, University of Toronto, The Ban­
ting Institute, 100 College St., Toronto, 
O NM 5G 1L5. -S89-34
GENERAL SURGEON: MB -  Required to 
join a progressive group of twelve general 
practitioners, one obstetrician/gynecologist, 
and one orthopedic and plastic surgeon. 
Guaranteed income provided for first 12 
months, and thereafter, if mutually agreeable, 
partnership would be offered. Early partner­
ship by agreement is available. The clinic 
occupies three floors of a modern, downtown 
medical facility in a university city of 40 000, 
and services a large trading area. A 220-bed 
hospital with a 12-bed, intensive care unit, a 
201-bed geriatric and rehabilitation hospital, a
large regional laboratory, and an ultrasound 
department, is located in the city. Interested 
persons are asked to contact: Mrs. D.J. 
Mistal, Western Medical Clinic, 144 6th 
St., Brandon, MB, R7A 3N2, Tel: (204) 
727-6451. -S89-14
UNIVERSITY HEAD OF THORACIC SUR­
GERY: ON -  The University of Toronto, 
Department of Surgery is seeking a new Head 
of its Division of Thoracic Surgery. The in­
cumbent will be responsible for coordinating 
the clinical teaching and research activities of 
the University Division of Thoracic Surgery. 
This includes two teaching divisions of tho­
racic surgery and individual thoracic surgeons 
in other affiliated teaching hospitals within the 
University of Toronto system. This incumbent 
will be expected to have an established repu­
tation in clinical thoracic surgery, as well as in 
teaching and research. University rank and 
salary are negotiable. Priority will be given to 
Canadian residents, but permission has been 
received to interview Canadians and non- 
Canadians at the same time. Please forward 
replies to: Dr. B. Langer, Chairman, Depart­
ment of Surgery, 100 College St., Room 
311, Toronto, ON M5G 1 L5. -S89-30
Cardiovascular Thoracic Surgery
The Department of Surgery of The University of Calgary 
and the Foothills Hospital invites applications for a 
full-time appointment as Division Chief, Cardiovas­
cular Thoracic Surgery at the Foothills Hospital.
The incumbent will be responsible for the develop­
ment and promotion of research initiatives within the 
Division. Other responsibilities include administra­
tive duties related to the functions of an academic 
division, promotion of excellence in education and 
the promotion of quality assurance in patient care. 
Academic rank and salary commensurate with 
experience and qualifications. The starting date is 
negotiable.
In accordance with Canadian immigration require­
ments, priority will be given to Canadian citizens and 
permanent residents of Canada. The University of 
Calgary has an Employment Equity Program and 
encourages applications from all qualified candi­
dates, including women, aboriginal people, visible 
minorities, and people with disabilities.
Please submit a curriculum vitae and the names of 
three references by September 30, 1989, to:
Dr. R. Y. McMurtry 
Department of Surgery 
The University of Calgary 
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9
Royal Alexandra 
Hospital
Committed to Caring
Edmonton’s Royal Alexandra Hospital, one o f Canada’s leading service and teaching 
hospitals, is a 932 bed city and regional health care facility. The Hospital is 
committed to excellence in health care through its Active Treatment, Women’s and 
Children’s Centres.
Join the Royal Alexandra team as we move in to the future with an exciting new 
direction and redevelopment o f our facility.
C A N A D A
CHIEF
DEPARTMENT OF SURGERY
Applications are invited for a “ Surgeon-in-Chief", Department of Surgery, 
Royal Alexandra Hospital, a 932 - bed, acute care facility, affiliated with the 
University of Alberta. A hosptial/university-based salary is available to 
complement private practice opportunities. Fifty-two (52) Surgeons practise 
within the Department, which has eight Divisions. There are 330 adult 
in-patient beds and 60 pediatric beds within the facility. In excess of 30,000 
surgical procedures are performed each year on an in-patient or ambulatory 
basis. Patient care, education and research opportunities are exciting.
Edmonton, Alberta, Canada - an attractive, dynamic place to work, is the 
heart of Alberta - land of opportunity.
The capital city, affords the best in education, health care, recreation, 
entertainment, shopping and all other amenities. Alberta’s low tax rate and 
inexpensive housing make it less costly to live in Edmonton than in any other 
major Canadian city.
Centrally located on the North Saskatchewan River, Edmonton is within easy 
reach of recreational areas in the Canadian Rockies. Edmonton is the place 
for people, industry, commerce, agriculture and a high quality of life.
Correspondence to:
Dr. Tom Noseworthy
Associate Vice President, Medical Planning 
Royal Alexandra Hospital 
Room 1412, 10240 Kingsway 
Edmonton, AB T5H 3V9 
Phone: (403) 477 - 4107 
FAX: (403) 477 - 4048 —S89-35
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The Cold Lake Regional Hospital is a modern, multi­
level progressive facility with the potential bed capacity 
of 150. We seek an additional
Psychiatrist 
Surgeon 
GP /  Anesthetist 
GP /  Obstetrician / Gynecologist
The Tri-town area in which the hospital is located is, 
approximately 300 kilometers East of Edmonton. Pri­
mary care and specialty referral care is offered to a 
growing population.
The successful candidates must be eligible for licensure 
in Alberta. In accordance with Canadian immigration 
requirements, priority will be given to Canadian citizens 
and permanent residents of Canada.
Please forward your confidential resume, including refer­
ences, to:
The Search Committee 
Cold Lake Regional Hospital 
Postal Service “A”
COLD LAKE, Alberta
TOA 0V0
Tel: (403) 639-3322, Ext. 280. s 8g
Cold Lake Regional Hospital
Academic Appointment in 
General Surgery
The University of Calgary Faculty of Medicine Department of 
Surgery invites applications for a full-time faculty position in 
General Surgery at the Assistant or Associate Professor level.
The successful candidate will be expected to develop an in­
dependent research program in clinical gastrointestinal sur­
gery, in association with other members of the Division and 
the Gastrointestinal Research Group. Conditions of the ap­
pointment include successful application for support to the 
Alberta Heritage Foundation for Medical Research and/or 
the Medical Research Council of Canada.
Applicants will require an MD and a Fellowship in General 
Surgery from the Royal College of Physicians and Surgeons 
of Canada, or equivalent. Successful candidates will have 
75% of their time protected for research. The appointed sur­
geon will be offered privileges in one of the affiliated teach­
ing hospitals.
In accordance with Canadian immigration requirements, pri­
ority will be given to Canadian citizens and permanent resi­
dents of Canada. The University of Calgary has an 
Employment Equity Program and encourages applications 
from all qualified candidates, including women, aboriginal 
people, visible minorities, and people with disabilities.
Interested candidates should submit a curriculum vitae, the 
names of three referees, and a letter stating their goals and 
research interests by September 30, 1989 to:
Dr. W. Temple 
Chief of General Surgery 
Foothills Hospital 
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9
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